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GENERAL REMARKS 
 
1. Melting points were recorded by open capillary method and are uncorrected. 
2. Infrared spectra were recorded on Shimadzu FT IR-8400 (Diffuse reflectance 
attachment) using KBr. Spectra were calibrated against the polystyrene 
absorption at ‘1610 cm-1. 
3. 1H Spectra were recorded on Bruker Avance II 400 spectrometer. Making a 
solution of samples in DMSO d6 and CDCl3 solvents using tetramethylsilane 
(TMS) as the internal standard unless otherwise mentioned, and are given in 
the δ scale. The standard abbreviations s, d, t, q, m, dd, dt, brs refer to singlet 
doublet, triplet, quartet, multiplet, doublet of a doublet, doublet of a triplet, ab 
quartet and broad singlet respectively. 
4. Mass spectra were recorded on Shimadzu GC MS-QP 2010 spectrometer 
operating at 70 eV using direct injection probe technique. 
5. Analytical thin layer chromatography (TLC) was performed on Merck 
precoated silica gel-G F254 aluminium plates. Visulization of the spots on TLC 
plates was achieved either by exposure to iodine vapor or UV light.     
6. The chemicals used for the synthesis of intermediates and end products were 
purchased fro Spectrochem, Sisco Research Laboratories (SRL), Thomas 
baker, Sd fine chemicals, Loba chemie and SU-Lab.  
7. All the reactions were carried out in Samsung MW83Y Microwave Oven 
which was locally modified for carrying out chemical reactions. 
8. All evaporation of solvents was carried out under reduced pressure on 
Heidolph LABOROTA-400-efficient. 
9. % Yield reported are isolated yields of material judged homogeneous by TLC 
and before recrystallization. 
10. The structures and names of all compounds given in the experimental section 
and in physical data table were generated ChemBio Draw Ultra 10.0. 
11. Elemental analysis was carried out on Vario EL Carlo Erba 1108.  
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1.1    INTRODUCTION 
 
Oxadiazoles belong to an important group of heterocyclic compounds having –N=C-
O- linkage. 1,3,4-oxadiazole(1) is a thermally stable aromatic heterocycle and exist in 
two partially reduced forms; 2,3-dihydro-1,3,4-oxadiazole(1,3,4-oxadiazoline)(2) and 
2,5-dihydro-1,3,4-oxadiazole(1,3,4-oxadiazoline)(3) depending on the position of the 
double bond. The completely reduced form of the 1,3,4-oxadiazole is known as 
2,3,4,5-tetrahydro-1,3,4-oxadiazole (1,3,4-oxadiazolidine)(4)[1] 
 
N
O
N N
O
NH N
O
N HN
O
NH
1 2 3 4
 
1,3,4-Oxadiazole is a heterocyclic molecule with oxygen atom at 1 and two nitrogen 
atoms at 3 and 4 position. They have been known for about 80 years, it is only in the 
last decade that investigations in this field have been intensified. This is because of 
large number of applications of 1,3,4-oxadiazoles in the most diverse areas viz. drug 
synthesis, dye stuff industry, heat resistant materials, heat resistant polymers and scin-
tillators. Reviews of the relevant literature prior to 1965 are available. 
 
 Bactericidal and/or fungicidal activity was reported for oxadiazole (5a), aminoox-
adiazole (5b)[2] and oxadiazolinethiones (6a).[3] The tin derivatives (6b) are an effec-
tive fungicide and antimicrobial activite compound shown by thiones (6c).[4] Antiin-
flammatory, sedative and analgesic properties were reported for aryloxadiazoles 
(5c).[5] Amino-oxadiazoles (5d) show analgesic activity and amino-oxadiazoles (5e) 
exhibit both anti-inflammatory and antiproteolytic properties[6]. Anticonvulsant and 
nervous system depressant activity was reported for amino-oxadiazoles (5f), where R 
is quinazolin-3-yl group.[7] Aminooxadiazole (5g) show local anaesthetic activity.[8] 
The oxadiazolinone (6d) is an orally active antiallergic agent, for example in the 
treatment of asthma and allergy disease and is claimed to be more potent than sodium 
cromoglycate.[9] Examples of the many oxadiazolones for the many herbicidal activity 
(week killers) are (6e,6f) and “oxadiazon”(6g), which is the subject of many regular 
reports in the literature. Insecticidal activity is shown by oxadiazolones (6h, 6i the lat-
er is an aphicide), and oxadiazole (5h) 
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N
O
N
X
R2
R1
6(a-i)  
 
 
 
 
 
 
 
 
 
 
 R1 
Or 
R2 
5a Ar CH2CONHCONHR 
5b AR OCH2 NHCOR 
5c Trimethoxy 3,4-dimethoxyphenyl 
5d 2-pyridyl NR2HCl 
5e 4-biphenylylmethyl NHAr  
5f Ar NHCH2CONHR 
5g Ar NHCO(CH2)nNRR'HCl(n=2or3) 
   
    
 R1 R2 X 
6a heteroarylOCH2 H S 
6b 1-methylcyclopropyl Sn(Ph)3 O 
6c 5-Cl-2-phenylindol-3-ylNH H S 
6d 3-Cl-benzo[b]thiophen-2-yl H O 
6e 4-cyclohexylphenoxy H O 
6f 2,4-diCl-phenoxymethyl Bn O 
6g t-Bu 2,4-diCl--5-isopropoxyphenyl O 
6h OCH3 o-methoxyphenyl O 
6i CH3NH 
2,3-diH-2,2,4-triMebenzofuran-
7-yl 
 
O 
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1.2     PHARMACOLOGY 
 
1,3,4-Oxadiazole derivatives have been tested for various pharmacological 
activities, which have been summarized as under. 
1. Antibacterial[10] 
2. Antiinflammatory[11] 
3. Analgesic[12] 
4. Antiviral and anticancer[13] 
5. Antihypertensive[14] 
6. Anticonvulsant[15] 
7. Antiproliferative[16] 
8. Antifungal[17] 
9. Cardiovascular[18] 
10. Herbicidal[19] 
11. Hypoglycemic[20] 
12. Hypnotic and Sedative[21] 
13. MAO inhibitor[22] 
14. Insecticidal[23] 
 
1,3,4-Oxadiazole is a versatile scaffold and is being consistently used as a building 
block in organic chemistry as well as in medicinal chemistry for the synthesis of dif-
ferent heterocycles. The synthetic versatility of 1,3,4-oxadiazole has led to the exten-
sive use of this compound in organic synthesis.  
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Some new oxadiazole drugs & derivatives under Preclinical/Phase clinical trials. 
 
Sr. No 
 
Chemical structure 
 
 
Activity 
 
 
Phase 
 
 
Originator 
 
1 
Antitussive, 
Bronchodilator 
 
Phase-I 
 
Sanofi-
Synthlabo 
 
2 
Antirhinoviral, 
Antiviral 
 
Phase-III 
 
Viro 
pharma 
 
3 
Antihypertensive, 
Antianginal, 
Antiglaucoma 
agent, 
Beta-adrenoceptor 
antagonist 
 
Phase-II 
 
Center for 
Chemistry 
of Drugs 
 
4 
Antidepressants, 
Anxiolytic, 5-
HT1D Antagonist 
 
Biological 
testing 
 
Smithkline 
Beecham 
 
5 
Antidepressants, 
Anxiolytic, 
5-HT1D Inverse 
agonist 
 
Preclinical 
 
Smithkline 
Beecham 
 
6 
 
Cognition en-
hancing drug, 
GABA(A) recep-
tor modulator, 
GABA(A) B2 site 
inverse 
agonist 
 
Preclinical 
 
Dainoppon 
pharma 
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Some new oxadiazole drugs & derivatives under Preclinical/Phase clinical trials. 
 
Sr. No 
 
Chemical structure 
 
 
Activity 
 
 
Phase 
 
 
Originator 
 
7 Analgesic Preclinical 
Universidade 
federal per-
nambuco 
8 
Antiobesity drug, 
Antidiabetic drug, 
Beta3 adrenoce tor 
agonist 
Preclinical Merck 
9 
OH
NHN
S
O
O
N O
N
OCF3
Antiobesity drug, 
Antidiabetic drug, 
Beta3 adrenoceptor 
agonist 
Preclinical Merck 
10 O
H3CO
O N
N
CH3
CN
Bronchodilator, 
Phosphodiesterase 
Inhibitor 
Preclinical 
Smithkline 
Beecham 
 
11 Antitrypanosomal Preclinical 
Universidad 
de larepubli-
ca 
12 
Antiepileptic 
drug,Neuronal In-
jury Inhibitor, 
AMPA antagon-
ist,Sodium channel 
blocker 
Preclinical Boehringer Ingelaeim 
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1.3  SYNTHETIC ASPECT 
 
There were several routes for the synthesis of 1,3,4-oxadiazoles reported in the litera-
ture among which the most important aspects of synthesis were discussed as under. 
 
2,5-Disubstituted 1,3,4-oxadiazole can be accomplished by cyclodehydration of 1,2-
diacylhydrazine either by using chlorosulphonic acid[24] or phenyl dichorophosphite in 
dimethylformamide. A nonaqueous, nonacedic, route involves treatment of hydrazine 
with hexamethyl disilazane (HMDS) and tetrabutylammoniumfluoride, the last step 
presumably being fluoride catalyzed cyclization of intermediate bis silyl ether. [25-26] 
 
HN NH
O
R2
O
R1
NN
OR1 R2
ClSO3H/Cl2POPh
Diacyl hydrazine
R1, R2 = alkyl, aryl
2,5-disubstituted-1,3,4-oxadiazole
R1, R2 = alkyl, aryl
HMDS (C4H9)4N-F
N N
R2
(H3C)3SiO
R1
OSi(CH3)3
 
In a related reaction, 1,1,2-triacetylhydrazine with trimethylsilylchloride/triethylamine 
gave oxadiazolinyl silylether.[27] Cyclodehydration (PCl5/POCl3) of hydrazinyl diester 
gave the diphenyloxyoxadiazol.[28] 
 
HN N
COCH3
O
R1 R2
O
N
O
N
R2
OSi(CH3)3
R1
O
CH3
HN NH
O
PhO OPh
O
NN
OPhO OPh
(CH3)3SiCl/(Et)3N
1,1,2-triacylhydrazine
R1, R2 = alkyl
Hydrazine diester 2,5-diphenoxy-1,3,4-oxadiazol
POCl3/PCl5
 
The malonate derivative (1) reacted with acylhydrazine (2) to give a mixture of di-
acylhydrazine monoamine (3) and oxadiazole (4). The later was also formed from (3) 
by heating.[29] 
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OEtH2N
COOEt
H2N NH
O
CN (Et)3N, H2N
NHNHCOCH2CN
COOEt
NN
OCH2CN CH2COOEt
1 2 3 4
 
Oxidation of acylhydrazones derived (5) from aldehydes has been developed into a 
useful route to disubstituted oxadiazoles (6). The use of potassium permanganate with 
acetone as solvent was claimed to give better yields than the use of other oxidizing 
agents (e.g.halogens).[30] An improved synthesis of bis-oxadiazolylbenzenes (8) in-
volved oxidation of bishydrazones (7) with lead tetraacetate.[31] Acylhydrazones (9) 
were oxidized by iodosobenzene diacetate to oxadiazolinones (10), with acetates (11) 
also being formed in some cases. A similar oxidation of ethyl esters (9, X=OEt) gave 
oxadiazolyl ethers (11, X=OEt).[32] Oxidative cyclization(FeCl3/AcOH) of semicarba-
zone (12) yielded amino-oxadiazoles (13).[33] 
R1
NNHCOX
NN
OR1 X
CH=NNHCOAr
CH=NNHCOAr
NN
OAr
N
N
O
Ar
N
O
NH
R1 O
N
O
N
R1 OAc
N
O
N
R1 X
R1
NNHCOX
R1
NNHCOX
R1, X = alkyl, aryl
KMnO 4
(m - or p -)
Pb(OAc)4
(m - or p -)
Iodosobenzene diacetate
R1 = alkyl, aryl,    
X=OBut
FeCl3/AcOH
R1 = Ph, X=NHR
5
6 7
8
9
10 11
12 13
 
Important routes to monosubstituted oxadiazoles (14), aminooxadiazoles (15), oxa-
diazolinones (15a) and oxadiazolinethiones (16) involve reaction of hydrazides 
(R1CONHNH2) with triethyl orthoformate, cyanogen bromide, phosgene, or carbon 
disulphide (or CSCl2) respectively.  
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R1
O
HN NH2
N
O
NH
N
O
NH
NN
O
NN
O
O
SR1
R1
R1
R1 NH2
COCl2
C(OC2H5)3
CNBr
CS2/CSCl2
14
1516
15a
 
Reaction of hydrazide (17) with triethylorthoformate, or with CS2/KOH, allowed the 
synthesis of oxadiazolyl methyl ketones (18) and (19), respectively, after hydrolysis 
of the acetal group.[34] 
 
O O
CH3
N
H
O
NH2
NN
O
N
O
NH
S
O
CH3
O
CH3
C(OC2H5)3
CS 2/KOH
17
18
19
 
 
An alternative to cyanogenbromide is phenyl cyanate (PhOCN), which reacted with 
hydrazines (R1CONHNH2) to give aminooxadiazoles (R1= 4,6- dimethyl-2-
pyrimidyl).[35] From oxadiazol-2-carbohydrazides (20) bioxadiazolyls ( 21) and (22) 
were prepared using cyanogen bromide[36] or thiophosgene[37] respectively.  
R1
O
N
H
NH2
NN
OR1
NH2
OCN
N N
O
R1
O
NH
NH2
N
O
N
O
NN
R1
NH2
N
O
N
O
NN
R1
NH2
R1=4,6-dimethyl-2-pyridyl R1=4,6-dimethyl-2-pyridyl
CNBr
CSCl2
20
43
21
22  
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It has been shown that o-aminobenzoylhydrazine reacted with (i) 1,1’-carbonyl- bis-
imidazole(a variation of the use of phosgene) to give oxadiazolinone(23)[38] and (ii) 
1,3 dicyclohexylcarbodiimide and an isothiocyanate RNCS to give aminooxadiazole 
(24).[39] 
HN
O
NH2
NH2 N C N
O
NHN
O
NH2
O
NHN
NHR
NH2
RNCS
1, 1'-ca
rbonyl
bisimid
azole
23
24  
A variation of the oxidative cyclization of acyl-thiosemicarbazides to aminooxadia-
zoles.[40] A variation of the reaction of acylhydrazines and carbon disulfide forming 
oxadiazolinethiones, is the reaction of thiosemicarbazide (RNHCSNHNH2) with car-
bon oxysulfide and benzyl chloride, which yields amino-oxadiazolyl thioeth-
ers(25).[41] 
RHN
S
HN
H2N
N
O
N
NHR
SO=C=S
CH2Cl 25
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1.4  AIM OF CURRENT WORK 
 
The aim of current work is to use green protocol to obtain hybridized molecules with 
less reaction time and high yield. 
 
1.5  REACTION SCHEME 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OH
O
Ethyl bromo acetate
DMF, K2CO3 O
O
O
64 % N2H4
EtOH O
O
NH
H2N
OH
O
R
MW.
POCl3
O O
NN
R
Up to 90 % yield
2 min reaction time
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1.6  PLAUSIBLE REACTION MECHANISM  
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N NH2
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Step-1
O
NH
NH2..
+ Ph
O
HO
O
NH
+H2N
C
O-
Ph
HO
O
NH
H+
N
C
O
Ph
H
OH--
H+-
O
NH
HN
C
O
Ph
Step-2
O
O O
O
Step-3
O
H
NO NH
O
Ph
....
O O
NN
PhO
+
-
H
H..
O O
NN
PhO
H
+
-
H
O O
NN
Ph
H
OH
: -H2O
O O
NN
Ph
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1.7  EXPERIMENTAL 
 Preparation of Ethyl benzofuran-2-carboxylate 
Salicaldehyde (0.01 mole) was charged into 250 ml round bottom flask. 30 ml of 
DMF was added into the flask. Then ethylbromo acetate (0.01 mole) and K2CO3 (0.03 
mole) was added. The reaction mixture was refluxed for 1.5 h at 110 °C on oil bath. 
The progress and the completion of the reaction were checked by TLC using hexane: 
ethyl acetate (9:1) as a mobile phase. After the reaction was completed, reaction mix-
ture was poured into ice water. Then product was extracted using ethyl acetate (50 ml 
× 3), the combined organic layer was washed using brine solution (20 ml × 2). The 
organic layer was dried on anhydrous sodium sulphate and the solvent was removed 
under reduced pressure to acquire the product in a viscous liquid form. Yield - 77 %, 
B.P.- 276 °C.[42] 
 Preparation of Benzofuran-2-carbohydrazides  
Ethyl benzofuran-2-carboxylate (0.01 mole) was charged into 250 ml round bottom 
flask. 15 ml of hydrazine hydrate was added dropwise at 0-5 °C in above flask. The 
progress and the completion of the reaction were checked by silica gel-G F254 thin 
layer chromatography using hexane: ethyl acetate (4: 6) as a mobile phase. After the 
reaction was completed, the mixture was stirred at room temperature to give benzofu-
ran-2-carbohydrazide as a white colored shining product. M.P.-190-194 °C.[43]  
 Preparation of N'-(2-chloroacetyl)benzofuran-2-carbohydrazide 
In a round bottom flask, Benzofuran-2-carbohydrazides (0.01 mole), substituted 
benzoic acid (0.01 mole) and POCl3 (0.015 mole) were  irradiated in domestic 
microwave for 2 minutes at 600 watts. The reaction mix was cooled and poured into 
the ice, stirred for 30 minutes and filtered. The solids obtained were further washed 
with 50 ml 10% solution of sodium bicarbonate and followed by wash with 50 ml DM 
water. The resulting compound was purified by column chromatography by silica gel 
230-400 mesh using ethyl acetate: hexane (4: 6 v/v) as eluent. Yield : 85%. 
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1.8  PHYSICAL DATA  
 PHYSICAL DATA OF 2-(BENZOFURAN-2-YL)-5-(SUBSTITUTED 
PHENYL)-1,3,4-OXADIAZOLES 
 
 
 
 
 
 
 
 
 
Sr.  
No. Code R Mass Formula M.P 
oC Yield % 
1 VNRBF-101 4-Methyl 276.29 C17H12N2O2 145-147 79 
2 VNRBF-102 2-amino 277.28 C16H11N3O2 165-167 85 
3 VNRBF-103 2-chloro, 4-nitro 341.71 C16H8ClN3O4 140
 oC 88 
4 VNRBF-104 4-amino 277.28 C16H11N3O2 >300 oC 77 
5 VNRBF-105 3,5-dihydroxy 294.26 C16H10N2O4 170 oC 84 
6 VNRBF-106 3-methyl 276.29 C17H12N2O2 90 oC 90 
7 VNRBF-107 2-methyl 276.29 C17H12N2O2 94 oC 89 
8 VNRBF-108 2-hydroxy, 3,5-dinitro 368.26 C16H8N4O7 125
 oC 85 
9 VNRBF-109 2,4-dichloro 331.15 C16H8Cl2N2O2 140 oC 78 
10 VNRBF-110 4-chloro 296.71 C16H9ClN2O2 230 oC 87 
11 VNRBF-111 H 262.26 C16H10N2O2 145 oC 92 
O O
NN
R
1
2
3
4
5
6
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1.9  SPECTRAL STUDY 
 
 IR spectra 
Infra Red spectra were taken on Shimadzu FT-IR-8400 spectrometer using KBr 
pellet method. The characteristic aromatic group in 1,3,4-oxadiazol moiety is 
observed at 3010-3090 cm-1. Methyl (-CH3) observed at 1350 cm-1.  
1H NMR spectra 
1H NMR spectra were recorded on a Bruker AC 400 MHz NMR spectrometer using 
TMS (Tetramethyl Silane) as an internal standard and DMSO-d6 & CDCl3 as a 
solvent. In the NMR spectra of 2-(benzofuran-2-yl)-5-(substituted phenyl)-1,3,4-
oxadiazole derivatives various proton values of methylene (-CH2), amine (-NH), 
methyl (-CH3) and aromatic protons (Ar-H) etc. were observed. Individual data are 
given for each compound separately. 
 13C NMR spectra 
13C NMR spectra were recorded on a Bruker AC 400 MHz NMR spectrometer using 
DMSO-d6 & CDCl3 as a solvent. In the 13C NMR spectra of 2-(benzofuran-2-yl)-5-
(substituted phenyl)-1,3,4-oxadiazole derivatives, various carbon values of methylene 
(-CH2), keto (>C=O), methyl (-CH3) and aromatic carbon (Ar-H) etc. were observed. 
 Mass spectra 
The mass spectrum of compounds were recorded by Shimadzu GC-MS-QP-2010  
spectrometer. The mass spectrum of compounds was obtained by positive chemical 
ionization mass spectrometry. The molecular ion peak and the base peak in all 
compounds were clearly obtained in mass spectral study. The molecular ion peak 
(M+) values are in good agreement with molecular formula of all the compounds 
synthesized.  
 Elemental analysis 
Elemental analysis of the synthesized compounds was carried out on Vario EL-III 
Carlo Erba 1108 model at Saurashtra University, Rajkot which showed calculated 
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and found percentage values of Carbon, Hydrogen and Nitrogen in support of the 
structure of synthesized compounds. The elemental analysis data are given for 
individual compounds. 
1.10  SPECTRAL CHARACTERIZATION 
2-(benzofuran-2-yl)-5-p-tolyl-1,3,4-oxadiazole (VNRBF-101) 
Yield: 79%; IR (KBr) cm-1: 1639 (>C=N, str), 1087 (C-O-C), 2852 (>CH2 ,str), 1438 
(>CH2 ,ben), 2868 (>CH3,str), 1390 (>CH3, ben), 3010 (=C-H, str), 3037 (Ar, C-H, 
str), 1564 (Ar, C=C, str). 1H NMR 400 MHz: (CDCl3, δ ppm): 2.45 (s, 2H), 7.31 (m, 
3H), 7.45 (m, 1H), 7.57 (s, 1H), 7.64 (d, 1H), 7.71 (d, 1H), 8.05 (d, 2H). 13C NMR 
400 MHz: (DMSO-d6, δ ppm): 30.6, 39.3, 78.7, 86.2, 100.7, 111.7, 116.4, 117.5, 
119.3, 122.5, 124.1, 130.4, 132.6, 135.8, 154.3, 158.9, 166.2, 195.6; Mass: [m/z 
(%)], M. Wt.: 276. Elemental analysis, Calculated: C, 73.90; H, 4.38; N, 10.14 
Found: C, 73.87; H, 4.85; N, 10.79. 
2-(5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)benzenamine (VNRBF-102) 
Yield: 85%; IR (KBr) cm-1: 1625 (>C=N, str), 1087 (C-O-C), 2872 (>CH2 ,str), 1455 
(>CH2 ,ben), 3015 (=C-H, str), 3042 (Ar, C-H, str), 1513 (Ar, C=C, str), 3450 (>NH2, 
str), 1470 (>NH2, ben). Mass: [m/z (%)], M. Wt.: 277. Elemental analysis, 
Calculated: C, 69.31; H, 4.00; N, 15.15; Found: C, 69.10; H, 4.28; N, 15.65. 
2-(benzofuran-2-yl)-5-(2-chloro-5-nitrophenyl)-1,3,4-oxadiazole (VNRBF-103) 
Yield: 88%; IR (KBr) cm-1: 3496 (-NH), 1616 (>C=N, str), 1077 (C-O-C), 2871 
(>CH2 ,str), 1445 (>CH2 ,ben), 3010 (=C-H, str), 3036 (Ar, C-H, str), 1520 (Ar, C=C, 
str), 1610 (>NO2, str) 952 (C-Cl str.). Mass: [m/z (%)], M. Wt.: 341(M+), 
343(M+2). Elemental analysis, Calculated: C, 56.24; H, 2.36; N, 12.30; Found: C, 
56.23; H, 2.68; N, 12.61. 
4-(5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)benzenamine (VNRBF-104) 
Yield: 77%; IR (KBr) cm-1: 1618 (>C=N, str), 1080 (C-O-C), 2862 (>CH2 ,str), 1455 
(>CH2 ,ben), 3015 (=C-H, str), 3042 (Ar, C-H, str), 1526 (Ar, C=C, str), 3456 (>NH2, 
str), 1484 (>NH2, ben). Mass: [m/z (%)], M. Wt.: 277. Elemental analysis, 
Calculated: C, 69.31; H, 4.00; N, 15.15; Found: C, 69.32; H, 4.16; N, 15.71. 
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5-(5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)benzene-1,3-diol (VNRBF-105) 
Yield: 84%; IR (KBr) cm-1: 1626 (>C=N, str), 1077 (C-O-C), 2878 (>CH2 ,str), 1463 
(>CH2 ,ben), 3026 (=C-H, str), 3047 (Ar, C-H, str), 1533 (Ar, C=C, str), 1374 (-CH3, 
str.), 1180 (>C-O, str), 3550 (>O-H, str). Mass: [m/z (%)], M. Wt.: 294. Elemental 
analysis, Calculated: C, 65.31; H, 3.43; N, 9.52 Found: C, 65.42; H, 3.39; N, 9.88. 
2-(benzofuran-2-yl)-5-m-tolyl-1,3,4-oxadiazole (VNRBF-106) 
Yield: 90%; IR (KBr) cm-1: 1630 (>C=N, str), 1075 (C-O-C), 2885 (>CH2 ,str), 1471 
(>CH2 ,ben), 3025 (=C-H, str), 3052 (Ar, C-H, str), 1545 (Ar, C=C, str), 2872 
(>CH3,str), 1380 (>CH3, ben). 1H NMR 400 MHz: (CDCl3, δ ppm): 2.37 (s, 3H), 
7.32 (m, 4H), 7.55 (d, 1H), 7.62 (d, 1H), 7.87 (m, 2H). 13C NMR 400 MHz: (DMSO-
d6, δ ppm): 109.7, 111.4, 121.6, 122.3, 123.4, 123.6, 126.6, 126.9, 128.6, 132.0, 
132.4, 138.4, 140.0, 154.4, 155.0, 157.0, 164.0, 164.11 Mass: [m/z (%)], M. Wt.: 
276. Elemental analysis, Calculated: C, 73.90; H, 4.38; N, 10.14; Found: C, 73.49; 
H, 4.86; N, 10.90. 
2-(benzofuran-2-yl)-5-o-tolyl-1,3,4-oxadiazole (VNRBF-107) 
Yield: 89%; IR (KBr) cm-1: 1637 (>C=N, str), 1076 (C-O-C), 2882 (>CH2 ,str), 1475 
(>CH2 ,ben), 3023 (=C-H, str), 3056 (Ar, C-H, str), 1547 (Ar, C=C, str), 2885 
(>CH3,str), 1410 (>CH3, ben). 1H NMR 400 MHz: (CDCl3, δ ppm): 2.70 (s, 3H), 
7.28 (m, 3H), 7.35 (m, 2H), 7.49 (d, 2H), 7.56 (m, 1H), 7.62 (d, 1H), 7.96 (m, 1H). 
13C NMR 400 MHz: (DMSO-d6, δ ppm): 109.7, 111.4, 121.6, 122.3, 123.4, 123.6, 
126.6, 126.9, 128.6, 132.0, 132.4, 138.4, 140.0, 154.4, 155.0, 157.0, 164.0, 164.11; 
Mass: [m/z (%)], M. Wt.: 276. Elemental analysis, Calculated: C, 73.90; H, 4.38; 
N, 10.14; Found: C, 73.92; H, 4.65; N, 10.65. 
2-(5-(benzofuran-2-yl)-1,3,4-oxadiazol-2-yl)-4,6-dinitrophenol (VNRBF-108) 
Yield: 85%; IR (KBr) cm-1: 1640 (>C=N, str), 1078 (C-O-C), 2890 (>CH2 ,str), 1463 
(>CH2 ,ben), 3052 (=C-H, str), 3045 (Ar, C-H, str), 1565 (Ar, C=C, str), 1626 (>NO2, 
str), 3590 (>O-H, str) . Mass: [m/z (%)], M. Wt.: 368. Elemental analysis, 
Calculated: C, 52.18; H, 2.19; N, 15.21; Found: C, 52.28; H, 2.55; N, 15.65. 
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2-(benzofuran-2-yl)-5-(2,4-dichlorophenyl)-1,3,4-oxadiazole (VNRBF-109) 
Yield: 78%; IR (KBr) cm-1: 1639 (>C=N, str), 1068 (C-O-C), 2896 (>CH2 ,str), 1455 
(>CH2 ,ben), 3052 (=C-H, str), 3039 (Ar, C-H, str), 1564 (Ar, C=C, str). Mass: [m/z 
(%)], M. Wt.: 331(M+), 333(M+2), 335(M+4).  Elemental analysis, Calculated: C, 
58.03; H, 2.43; N, 8.46;Found: C, 58.22; H, 2.62; N, 8.48. 
2-(benzofuran-2-yl)-5-(4-chlorophenyl)-1,3,4-oxadiazole (VNRBF-110) 
Yield: 87%; IR (KBr) cm-1: 1652 (>C=N, str), 1087 (C-O-C), 2879 (>CH2 ,str), 1462 
(>CH2 ,ben), 3041 (=C-H, str), 3062 (Ar, C-H, str), 1574 (Ar, C=C, str). 1H NMR 400 
MHz: (CDCl3, δ ppm): 1.27 (s, 1H), 7.35 (m, 1H), 7.47 (m, 1H), 7.51 (m, 2H), 7.54 
(s, 1H), 7.63 (d, 1H), 7.72 (d, 1H), 8.10 (m, 2H). 13C NMR 400 MHz: (DMSO-d6, δ 
ppm): 110.0, 111.4, 121.2, 121.9, 123.6, 126.6, 126.7, 127.6, 127.8, 128.9, 129.0, 
137.7, 139.7, 155.1, 157.2, 163.1 Mass: [m/z (%)], M. Wt.: 296(M+), 298(M+2). 
Elemental analysis, Calculated: C, 66.77; H, 6.06; N, 15.44; Found: C, 66.38; H, 
6.35; N, 15.57. 
2-(benzofuran-2-yl)-5-phenyl-1,3,4-oxadiazole (VNRBF-111) 
Yield: 92%; IR (KBr) cm-1: 1651 (>C=N, str), 1089 (C-O-C), 2883 (>CH2 ,str), 1450 
(>CH2 ,ben), 3049 (=C-H, str), 3063 (Ar, C-H, str), 1579 (Ar, C=C, str). Mass: [m/z 
(%)], M. Wt.: 262. Elemental analysis, Calculated: C, 73.27; H, 3.84; N, 10.68; 
Found: C, 73.60; H, 3.38; N, 10.11. 
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1.11  REPRESENTATIVE SPECTRA  
IR spectrum of 2-(benzofuran-2-yl)-5-p-tolyl-1,3,4-oxadiazole (VNRBF-101) 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR spectrum of 2-(benzofuran-2-yl)-5-o-tolyl-1,3,4-oxadiazole (VNRBF-107)  
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Mass spectrum of 2-(benzofuran-2-yl)-5-p-tolyl-1,3,4-oxadiazole (VNRBF-101) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of 2-(benzofuran-2-yl)-5-o-tolyl-1,3,4-oxadiazole (VNRBF-107) 
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1H NMR spectrum of 2-(benzofuran-2-yl)-5-p-tolyl-1,3,4-oxadiazole (VNRBF-101) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expanded 1H NMR spectrum of 2-(benzofuran-2-yl)-5-p-tolyl-1,3,4-oxadiazole 
(VNRBF-101) 
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1H NMR spectrum of 2-(benzofuran-2-yl)-5-o-tolyl-1,3,4-oxadiazole (VNRBF-107) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expanded 1H NMR spectrum of 2-(benzofuran-2-yl)-5-o-tolyl-1,3,4-oxadiazole 
(VNRBF-107) 
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13C NMR spectrum of 2-(benzofuran-2-yl)-5-p-tolyl-1,3,4-oxadiazole (VNRBF-
101) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expanded 13C NMR spectrum of 2-(benzofuran-2-yl)-5-p-tolyl-1,3,4-oxadiazole 
(VNRBF-101) 
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13C NMR spectrum of 2-(benzofuran-2-yl)-5-o-tolyl-1,3,4-oxadiazole (VNRBF-
107) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expanded 13C NMR spectrum of 2-(benzofuran-2-yl)-5-o-tolyl-1,3,4-oxadiazole 
(VNRBF-107) 
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1.12  RESULT AND DISCUSSION 
 
Present work covers the synthesis of some novel oxadiazole compounds clubbed with 
benzofuran moiety. The main significance of the present work is that the reaction is 
carried out under conventional microwave leading to a rapid reaction time, easy work 
up method, excellent yield and high chemical purity of the desired compounds. 
 
1.13  CONCLUSION 
 
Total 11 derivatives of 2-(benzofuran-2-yl)-5-(substituted phenyl)-1,3,4-oxadiazole 
were synthesized. All the newly synthesized compounds were characterized by IR, 1H 
NMR, 13C NMR, Mass spectral data and Elemental Analysis.  
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2.1   INTRODUCTION 
 
Coumarin are the best known aromatic lactones[1].The isolation of coumarin was first 
reported by Vogel[2] in Munich in1820.He associated the pleasant odour of the tonka 
bean from Guiana with that of clover, Melilotous officinalis, which gives rise to the 
characteristic aroma of new –mown hay. Vogel then concluded that the long colorless 
crystals which he discovered on slicing open Tonka beans and which crystallized as 
glistening needles from aqueous alcohol, were identical with similar crystals he 
obtained, albeit in much lower yield, by extracting fresh clover blossoms[3]. The name 
coumarin originated[4] from a Caribbean word ‘coumarou’ for the tonka tree, which 
was known botanically at one time as Coumarouna odorata aubl.Coumarin is now 
well, accepted trivial name. The IUPAC nomenclature of the coumarin fing system is 
2H-1-benzopyran-2-one (I).  
 
 
 
 
 
 
The coumarin ring system has an easy acceptability in the biological system compared 
to its isomeric chromones and flavones nucleus[5] and is widely distributed in nature[6-
9].An excellent account of these naturally occurring coumarin is presented by Murray 
and Brown[10] 
 
Coumarin comprises a group of natural compounds found in a variety of plant 
sources. The very long association of plant coumarin with various animal species and 
other organisms throughout evolution may account for the extraordinary range of 
biochemical and pharmacological activities of these chemicals in mammalian and 
other biological systems. The coumarins that were studied have diverse biological 
properties and various effects on the different cellular systems. A lot of biological 
parameters should be evaluated to increase our understanding of mechanisms by 
which these coumarin act. Coumarin has important effects in plant biochemistry and 
physiology, acting as antioxidants, enzyme inhibitors and precursors of toxic 
O O
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substances. In addition, these compounds are involved in the actions of plant growth 
hormones and growth regulators, the control of respiration, photosynthesis, as well as 
defense against infection. The coumarin have long been recognized to possess anti-
inflammatory, antioxidant, antiallergic, hepatoprotective, antithrombotic, antiviral, 
and anticarcinogenic activities. The hydroxycoumarins are typical phenolic 
compounds and, therefore, act as potent metal chelators and free radical scavengers. 
They are powerful chain-breaking antioxidants. The coumarin display a remarkable 
array of biochemical and pharmacological actions, some of which suggest that certain 
members of this group of compounds may significantly affect the function of various 
mammalian cellular systems. The coumarin are extremely variable in structure, due to 
the various types of substitutions in their basic structure, which can influence their 
biological activity. Vast majority of coumarin, completely innocuous, may be 
beneficial in a variety of human disorders, in spite of some ongoing controversy. 
There has been, in recent years, a major rekindling of interest in pharmacognosy. 
Coumarin turns out to be present in many natural therapeutically utilized products. 
They hold a place apart in view of their cytotoxic activity. It was suggested that 
alterations in the chemical structure of coumarin could change their cytotoxic 
properties[11]. 
 
Coumarin and its hydroxy derivatives have been prominently accepted as natural 
pharmaceuticals[12] world wide, has revealed new biological activities with interesting 
therapeutic applications, besides their traditional employment as anticoagulants(anti-
vitamin K activity)[13], antibiotics(novobiocin and analogues[14]) and anti AID[15]. 
Apart from this, they also possess anti-cancerous[11], antibacte-rial[16], neurotropic[17], 
immunosuppressive[18], anti inflammatory[19], antiulcerous[20], anti PAF(anti platelet 
activating factor)[21] and antimutagenic[22] effects. 
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2.2      PHARMACOLOGY 
Numerous biological activities have been associated with simple coumarin and its 
analogues. Among them, antimicrobial, antiviral, anticancer, enzyme inhibition, anti-
inflammatory, antioxidant, anticoagulant and effect on central nervous system are 
most prominent. Coumarin nucleus possesses diversified biological activities that can 
be briefly summarized as under: 
 
1 Antimicrobial and Molluscicidal [23-45] 
2 Antiviral [46-50] 
3 Anticancer [51-61] 
4 Enzyme Inhibition [62-67] 
5 Antioxidant [68-71] 
6 Anti-inflammatory [72-76] 
7 Anticoagulant and Cardiovascular [77-80] 
8 Effect on Central Nervous System [81-82] 
 
4-hydroxycoumarin is a versatile scaffold and is being consistently used as a building 
block in organic chemistry as well as in heterocyclic chemistry for the synthesis of 
different heterocycles. The synthetic versatility of 4-hydroxycoumarin has led to the 
extensive use of this compound in organic synthesis. 4-hydroxy coumarin shows 
diversified chemical reactivity. 
 
 Anti Cancer activity profile of Benzopyran derivatives 
 
Analysis of scientific literature revealed numerous reports on the antiproliferative and 
antitumor activities of a variety of coumarin compounds, e.g., both coumarin itself 
and 7-hydroxycoumarin have been reported to inhibit the proliferation of a number of 
human malignant cell lines in vitro [83-86] and have demonstrated activity against 
several types of animal tumors [87-91]. These compounds have also been reported in 
clinical trials to demonstrate activity against prostate cancer, malignant melanoma, 
and metastatic renal cell carcinoma [92-94]. 
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O O
O O
O OO O
O O
HO HO
HO
HO
O2N
HO
NO2
O2N NO2
Coumarin 7-Hydroxy coumarin Esculetin
7-Hydroxy-6-nitro coumarin
7-Hydroxy-3,6,8-trinitro coumarin
 
 
For coumarins, generally the in vitro structure-activity relationship studies have 
shown that cytotoxicity is found with derivatives containing ortho dihydroxy 
substituents[85]. Also, the chemical-structure/ biological activity study of the 
coumarins showed that the addition of a cathecolic group to the basic structure 
induces increased cytotoxic activity in tumor cell lines [95]. The different cytotoxic 
values found for the coumarins could be related to presence and the positions of the 
hydroxyls in their structures. The cytotoxicity of 22 natural and semi-synthetic simple 
coumarins was evaluated in GLC4, a human small cell lung carcinoma cell line, and 
in COLO 320, a human colorectal cancer cell line[95]. From the structure cytotoxicity 
relationship, it is conspicuous that all the potentially active natural compounds 
possess at least two phenolic groups in either the 6, 7- or 6, 8-positions. In addition, 
the 5-formyl-6-hydroxy substituted semisynthetic analogue was found to be potent, 
reflecting the importance of at least two polar functions for high cytotoxicity. Several 
hydroxylated and/or methoxylated coumarin derivatives were tested for their relative 
cytotoxicity on four human tumor cell lines (oral squamous cell carcinoma HSC-2, 
HSC-3, melanoma A-375 and promyelocytic HL-60) and three normal human cells 
(gingival fibroblast HGF, periodontal ligament fibroblast HPLF and pulp cell 
HPC)[96]. Tumor cell-specific cytotoxicity was detected in all 6, 7-dihydroxy-
substituted coumarins only. The observations indicated that the tumor-specific 
cytotoxicity of the naturally occurring coumarin esculetin (6, 7- dihydroxycoumarin) 
could be further enhanced by proper substitutions at 3- and/or 4-position(s) of the 
molecule. Agarose gel electrophoresis revealed that esculetin and its derivatives with 
tumor-specific cytotoxicity induce internucleosomal DNA fragmentation in HL-60 
cells. A selected group of natural and synthetic coumarin compounds, including the 
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hydroxylated and nitrated derivatives, were assessed for their cytotoxic potential for 
cellular viability[97]. This study utilized both human skin malignant melanocytes (SK-
MEL-31) and normal human skin fibroblastic cells (HS613.SK), allowing 
identification of those coumarin derivatives that are selectively toxic. Novel synthetic 
nitrated coumarins, 6-nitro-7- hydroxycoumarin and 3, 6, 8-nitro-7-hydroxycoumarin, 
were shown to be significantly more toxic to SK-MEL-31 than HS613.SK cells. In the 
malignant melanocyte skin cell line (SK-MEL-31), the cytotoxic effects of these 
nitroderivatives were shown to be dose and time dependent. Therefore, the cytotoxic 
potential of coumarins appears to be highly dependent on the nature and position of 
the functional group. In addition, nitration of 7- hydroxycoumarin produced 
compounds that were cytotoxic to malignant melanocytes, suggesting that these nitro-
derivatives may have a chemotherapeutic role in future. Protective effects of 
coumarins against cytotoxicity induced by linoleic acid hydroperoxide were examined 
in cultured human umbilical vein endothelial cells28. When the cells were incubated 
in medium supplemented with linoleic acid hydroperoxide and coumarins, esculetin 
(6, 7-dihydroxycoumarin) and 4-methylesculetin protected cells from injury by 
linoleic acid hydroperoxide. 
 
O O O OO OHO HO
H3CO
Coumarin Fraxetin
HO
CH3
4-Methyl Esculetin
 
 
 
Esculetin and 4-methylesculetin provided synergistic protection against cytotoxicity 
induced by linoleic acid hydroperoxide with alpha-tocopherol. Furthermore, the 
radical-scavenging ability of coumarins was examined in electron spin resonance 
spectrometry. Esucletin, 4-methylesculetin, fraxetin, and caffeic acid showed the 
quenching effect on the 1, 1-diphenyl-2- picrylhydrazyl radical. These results indicate 
that the presence of an ortho catechol moiety in the coumarin molecules plays an 
important role in the protective activities against linoleic acid hydroperoixde-induced 
cytotoxicity[98]. 
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An antioxidant auraptene (7-geranyloxycoumarin) isolated from the peel of citrus fruit 
(Citrus natsudaidai Hayata) has been reported to have chemopreventive effects on 
chemically induced carcinogenesis. Dietary administration of auraptene significantly 
increased the activities of detoxification (phase II) enzymes, such as quinone 
reductase and glutathione S-transferase, in the liver and colon of rats. In addition, 
expression of cell proliferation biomarkers, such as ornithine decarboxylase activity 
and polyamine biosynthesis, in the colonic mucosal epithelium was significantly 
inhibited by dietary feeding of auraptene. These biological functions of auraptene may 
contribute to its anti-tumorigenic effect[99]. In addition to this, auraptene have been 
demonstrated its anti-tumor promoting effect in mouse skin and anti-carcinogenesis 
activities in rattongue, esophagus and colon[100]. Murakami A. et al. [100] reported that 
Auraptene suppresses superoxide anion (O2 –) generation from inflammatory 
leukocytes in in vitro experiments. In the study, they investigated the anti-
inflammatory activities of Auraptene and compared them with those of Umbelliferone 
(7- hydroxycoumarin), a structural analog of Auraptene that is virtually inactive 
toward (O2 –) generation inhibition. Double pre-treatments of mouse skin with 
Auraptene, but not Umbelliferone, markedly suppressed edema formation, hydrogen 
peroxide production, leukocyte infiltration, and the rate of proliferating cell nuclear 
antigen-stained cells. These inhibitory effects by Auraptene are attributable to its 
selective blockade of the activation stage. Umbelliferone did not show any inhibitory 
effect. This contrasting activity profile between Auraptene and Umbelliferone was 
rationalized to be a result of their distinct differences in cellular uptake efficiencies, 
i.e. the geranyloxyl group in Auraptene was found to play an essential role in 
incorporation. 
O OO OO HO
Umbelliferon
Auraptene
CH3
H3C
CH3
 
 
The rat hepatic toxicity of coumarin and methyl analogues (3- methylcoumarin, 4-
methylcoumarin and 3, 4-dimethylcoumarin) has been determined in vivo and in 
vitro[101]. Coumarin at a dose of approximately 1 mmol/kg produced clear histological 
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evidence of centrilobular necrosis, while the methyl analogues at an equivalent dose 
were much less toxic. By use of a systematic random sampling protocol and 
quantitative morphometry it was determined that there was a lobar variation in the 
extent of hepatic damage but that this exhibited random inter-animal variation. The 
order of cytotoxicity in vitro was identical to that observed in vivo. 
 
O O O OHO O OHO
CH3 CH3
CH3CH3
3-Methyl Coumarin 4-Methyl 7-hydroxy Coumarin 3,4-Dimethyl 7-hydroxy Coumarin
 
 
Geiparvarin, containing coumarin moiety, is an antiproliferative compound isolated 
from the leaves of Geijera parviflora, and may represent a new drug which targets 
tubulin. To better explore the potential use of this agent, A. Miglieta, et al[102] 
investigated the antimicrotubular and cytotoxic effects of new synthetic aromatic 
derivatives of geiparvarin. These drugs inhibited polymerization of microtubular 
protein, particularly when the assembly was induced by paclitaxel. 
 
 
 
Bocca C. et al.[103] investigated biological activity of ferulenol, a prenylated 4-
hydroxycoumarin from Ferula communis. Ferulenol stimulates tubulin polymerization 
in vitro, and inhibits the binding of radiolabeled colchicines to tubulin. It rearranges 
cellular microtubule network into short fibres, and alters nuclear morphology. 
Remarkably, ferulenol exerts a dose dependent cytotoxic activity against various 
human tumor cell lines. 
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O CH3
CH3
Ferulenol
 
Three new coumarin derivatives along with furanocoumarins and a novel dioxocane 
derivative were isolated from the fern Cyclosorus interruptus (Willd.)H.Ito[104]. Based 
on spectrometric and spectroscopic analysis (FAB or El mass spectrometry as well as 
1D and 2D NMR experiments) their structures were characterised as 5,7- dihydroxy - 
6 - methyl - 4 - phenyl - 8 - ( 3 - phenylpropionyl ) -benzopyran-2-one (1), 5, 7-
dihydroxy-6-methyl-4-phenyl-8- (3-phenyl-trans-acryloyl)-1-benzopyran-2-one (2), 
5,7-dihydroxy - 8 - (2 - hydroxy - 3 - phenylpropionyl) - 6 - methyl – 4 - phenyl-1-
benzopyran-2-one (3). Among which compounds 5,7- dihydroxy - 6 - methyl - 4 - 
phenyl - 8 - (3 - phenylpropionyl) - 1benzopyran-2-one and 5, 7-dihydroxy-6-methyl-
4-phenyl- 8-(3-phenyl-trans-acryloyl)-1-benzopyran-2-one, were cytotoxic to a KB 
cell line 
 
O O
OH
H3C
HO
O
O O
OH
H3C
HO
O
O O
OH
H3C
HO
O
HO
O O
OCH3
H3CO
OH
1 2 3 4
 
A new coumarin, 5-(4-hydroxyphenethenyl)-4, 7-dimethoxycoumarin (4) was isolated 
from the combined ethylacetate extracts of the root bark, root wood and stem bark of 
Monotes engleri, and found to be cytotoxic against two cell lines in a human tumor 
panel [105]. Its structure was determined on the basis of spectroscopic methods. In a 
Chinese herb cytotoxicity screening test, the ethanol extract of Cnidii monnieri 
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Fructus exhibited strong effects on human leukemia (HL-60), cervical carcinoma 
(HeLa) and colorectal carcinoma (CoLo 205) cells. Then, the Cnidii monnieri Fructus 
extract was subjected to silica gel column chromatography and recrystallization to 
give five coumarins:osthol (5), imperatorin (6), bergapten (7), isopimpinellin (8), and 
xanthotoxin (9). Among these compounds, osthol showed the strongest cytotoxic 
activity on tumor cell lines. The structure-activity relationship established from the 
results indicated that the prenyl group has an important role in the cytotoxic effects. 
However, imperatorin showed the highest sensitivity to HL-60 cells and the least 
cytotoxicity to normal PBMCs. Osthol and imperatorin both caused apoptotic bodies, 
DNA fragmentation, and enhanced PARP degradation in HL-60 cells by biochemical 
analysis. These results indicate that osthol and imperatorin can induce apoptosis in 
HL-60 cells. Therefore, osthol and imperatorin are cytotoxic marker substances in the 
fruits of Cnidium monnieri[106]. 
 
O OH3CO
H3C CH3
O O
O
O
CH3
H3C
O OO
OCH3
O OO
OCH3
OCH3
O OO
OCH3
5 6 7
8 9
 
Five coumarins (seselin, 5-methoxyseselin, suberosin, xanthyletin and xanthoxyletin) 
were isolated from the roots of Plumbago zeylanica[107]. All coumarins were not 
previously found in this plant. Cytotoxicity of these compounds to various tumor cells 
lines was evaluated, and they were significantly suppressed growth of Raji, Calu-1, 
HeLa, and Wish tumor cell lines. 
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CH3
H3C
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R
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CH3
H3C
Seselin, R = H
5-methoxyseselin R = OCH3
suberosin
Xanthyletin R = H
Xenthoxyletin R = OCH3
 
 
Fractionation of the methanol extract of Angelica dahurica Benth et Hook resulted in 
the isolation of six furocoumarins, imperatorin, isoimperatorin, (+/-)-byakangelicol, 
(+)-oxypeucedanin, (+)-byakangelicin and (+)-aviprin [108]. Among these, compounds 
imperatorin and (+)-byakangelicin exhibited strong hepatoprotective activities, 
displaying EC50 values of 36.6 +/- 0.98 and 47.9 +/- 4.6 mM, respectively. 
 
O O
O
O
CH3
CH3 O OO
O
O
CH3
CH3
isoimperatorin Oxypeucedanin
 
 
A coumestan derivative, psoralidin was found to be a cytotoxic principle of the seeds 
of Psoralea corylifolia L.(Leguminosae) with the IC50 values of 0.3 and 0.4 mg/mL 
against the HT-29 (colon) and MCF-7 (breast) human cancer cell lines, 
respectively[109]. 
 
O OHO
H3
C
CH3 O
OHpsoralidin
 
 
A series of styrylcoumarin derivatives had been designed by Xu Song et al[110] in 
order to find compounds of antitumor activities by screening in vitro. The title 
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compounds were synthesized by phase-transfer Wittig reaction and screened by 
several antitumor models in vitro.Thirty new compounds of 6- or 7-styrylcoumarin 
were synthesized and their configurations were determined. Seven compounds(10-16) 
showed different inhibitory effects on L-1210, HL-60, HCT-8, KB and Bel-7402 cell 
lines in vitro. The activity data representes as shown in Table-1. Some 6- or 7-
styrylcoumarin derivatives showed antitumor activities and is worth further study. 
 
 
 
In continuation with this, a series of 4-styryl coumarin had been synthesized for in 
vitro antitumor activity study [111]. The titled compounds were synthesized by Phase 
transfer Wittig reaction or Wittig-Horner reaction and screened by several antitumor 
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modeles in vitro. Among a series of 20 compounds, only one had effects on KB cell 
lines in vitro and possesses certain antitumor activities and it was selected for further 
studies. 
 
O O
R
4-Styrylcoumarin derivattives  
 
 Antiviral activity 
The ether soluble fraction of the roots of Ononis vaginalis Vahl. Symb. afforded three 
new compounds: 3-hydroxy-4, 9-dimethoxycoumestan, maginaldehyde [2-(4-
hydroxy-2-methoxyphenyl)-5, 6-dimethoxy-3- benzofurancarboxaldehyde] and 5, 7, 
4'-trihydroxy-4-styrylcoumarin. The styrylcoumarin derivative showed significant 
antiviral activity against Herpes simplex type 1 and weak cytotoxicity. 
 
O O
R
5,7,4'-Trihydroxy-4-Styrylcoumarin
OH
OH
HO
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 Adamantane: 
 
 
Adamantane is a colorless, crystalline chemical compound with a camphor-like 
odor. With a formula C10H16, it is a cycloalkane and also the simplest diamondoid. 
Adamantane molecules consist of three cyclohexane rings arranged in the "armchair" 
configuration. It is unique in that it is both rigid and virtually stress-free. Adamantane 
is the most stable among all the isomers with formula C10H16, which include the 
somewhat similar twistane. The spatial arrangement of carbon atoms is the same in 
adamantane molecule and in the diamond crystal.  
The discovery of adamantane in petroleum in 1933 launched a new chemistry 
field studying the synthesis and properties of polyhedral organic compounds. 
Adamantane derivatives have found practical application as drugs, polymeric 
materials and thermally stable lubricants. 
Drug like compounds having adamantine moiety has many therapeutic value. 
Adafenoxate having Nootropic and Psychostimulant as its therapeutic function, has 
been prepared using 1-Aminoadamantine-2-ethanol, p-Chlorophenoxyacetyl chloride 
and p-Chlorophenoxyacetic acid[179]. 
HN
O
O
O
Cl  
 
  Adamexine having common names Adamexine and Broncostyl is used as a 
mucolytic drug, prepared using 2-Bromomemtyl-4,6-dibromo-N,N,diacetylaniline and 
N-Methyladamantyl[180]. 
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N
NH
OBr
Br
 
Adapalene used as Anti-acne drug is synthesized using 4-Bromophenol and 1-
Adamantanol[181]. 
 
Adatanserin Hydrochloride[115,116] consisting of amide linkage formed by linking [4-
(2-pyrimidinyl)piperazino]ethylamine with Adamantane acid chloride is an anti-
depressant drug[182].  
O N
H
N
N N
N
H Cl
 
 
 Biologically active heterocyclic containing amide linkage 
A number of drugs and drug like compounds have amide linkages. Coumarin 
carboxamide[112] has been prepared from the corresponding coumarin carboxylic acid 
and 2-amino-4-phenylthiazole[113] and tested for anti-fungal and antibacterial 
activity.[114]  
 
O
OCH3
O
C N
HO
S
N
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Adatanserin Hydrochloride[115,116] consisting of amide linkage formed by linking [4-
(2-pyrimidinyl)piperazino]ethylamine with Adamantane acid chloride is an anti-
depressant drug. 
O N
H
N
N N
N
H Cl
 
Aromatic polyamide dendrons HOOC-G1, were synthesized by Ishida et. al.[117] by an 
orthogonal approach, which utilizes the direct condensation reaction and palladium 
catalyzed carbon monoxide insertion reaction in an alternating fashion to form amide 
linkages. 
COCl COOH
H2N NH2
COOH
HN NH
O O
HOOC-G1
 
 
Nevirapine,[118] consisting of amide linkage, is used for inhibition of RT enzyme. 
 
N
HN
N N
H3C
O
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 Planarity of the CONH linkage 
The XC(CO)NHY linkage, under the assumption Y=H called the amide linkage, or 
referred to as the peptide linkage, is generally assumed to have a planar structure.[119]   
 
Conformation and atomic numbering of syn-methyl carbonate 
 
It is shown that formamide, considered prototype for the amide linkage, is not typical 
as it has a planar equilibrium amide linkage corresponding to a single-minimum 
inversion potential around N. In contrast, several molecules containing the CONH 
linkage seem to have pyramidal nitrogen at equilibrium and a double-minimum 
inversion potential with a very small inversion barrier allowing for an effective planar 
ground-state structure.[120] 
Many of the molecules containing the XC(CO)NHY linkage are not planar at 
equilibrium. The simple molecules containing the -C(CO)NH linkage can be divided 
into three groups:  
1) All of the atoms of the molecule lie in a plane, i.e., the point-group symmetry 
of the molecule is Cs.  
2) All of the atoms of the molecule lie in a plane except pairs of hydrogen atoms 
which are situated symmetrically about the plane of symmetry, i.e., the point-
group symmetry of the molecule is Cs. 
      3)  Molecules which do not have a plane of symmetry. 
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 Amide linkage containing analogues: A collection of 
commercial analogues: 
CH3
H
N
O
N COOH
CH3
COOH
 
Lidofenin 
CH3
H
N
O
N
H
Cl
CH3
 
Butanilicain 
H
N
O
CH3
CH3
N
CH3  
Bupivacaine 
CH3
H
N
O
N COOH
COOCH3
COOH  
 
Tylocain 
H
N
O
N
CH3 CH3
 
Aptocaine 
CH3
H
N
O
N CH3
CH3
H3
C
CH3
 
Trimecain 
H
N
O
N
H
CH3
CH3
CH3
 
Prilocaine 
COOCH3
H
N
O
N
H
CH3
CH3
S
H3C
 
Articain 
H
N
O
N
H
N
CH3
CH3  
Pyrrocaine 
CH3
CH3
H
N N
O CH3
 
Mepivacaine 
H
N
O
N
H
CH3
CH3
CH3H3C
 
Quatacaine 
CH3
CH3
H
N
NH2
CH3
O
 
Tocainidin 
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2.3    AIM OF CURRENT WORK 
The literature survey revealed that some extensive work has been done on 4-hydroxy 
coumarin compounds. Also, due to the usefulness of traditional medicines like 
Auraptene, Ferulenol and Fraxetin, the coumarin moiety has been selected for the 
research criteria. 
Browsing through the literature of organomedicinal chemistry the most useful moiety 
found was substituted 3-amino 4-hydroxy coumarin derivatives. Because of the less 
toxicological properties and good to moderate activities, several compounds have 
been synthesized by our team in the laboratory. Though the chemistry of the 
synthesized compounds is unknown, the compounds are reported herein for the first 
time.  
In the current chapter two pharmacophoric moieties, coumarins and adamamtane were 
converted into a hybridized structure by means of amide linkage. 
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2.4    REACTION SCHEME 
 
O O
OH H
N
OR
O O
OH
NH2
R
O
Cl
CHCl3
Triethyl amine
O O
OH
NO2
R
O O
OH
R
Na2S2O4
NaHCO3
HNO3
CH3COOH
 
 
2.5    PLAUSIBLE REACTION MECHANISM 
 
OH ..
+
O
Cl
H+
N
C
O
H
Cl--
H+-
HN
C
O
O O O O
O OO O
NH2
+H2N
C
O-Cl
OH
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2.6    EXPERIMENTAL 
 Preparation of 3-amino 4-hydroxy coumarin 
3-nitro 4-hydroxy coumarin (0.01 mol) was dissolved in 100 ml saturated solution of 
sodium bicarbonate. Reaction mass was taken in a 500 ml beaker with constant 
mechanical stirring under fume hood. To which sodium dithionite 10 g was added in 
portions with constant stirring. As a result, solution colour changes from yellow to sea 
green to clear. Completion of reaction is checked using TLC. Reation mixture was 
then cooled to 0 oC and brought to pH-1 with conc. HCl dropwise. The resulting 
precipitates were filtered u/v, dried at 50 oC for 5-6 hours. Yield : 90%, M.P.: 226-
228.[182] 
 
 Preparation of substituted 3-(1-amido adamantyl) 4-hydroxy coumarins: 
 
To a stirred solution of substituted 3-amino 4-hydroxy coumarin (0.01 mol) in 50 ml 
methylene chloride, adamantane 1-carboxylic acid chloride (0.018 mol) and triethyl 
amine (0.015 mol) were added and stirring was continued overnight at room 
temperature. Reaction mass was washed with H2O, dried over sodium sulphate and 
evaporated under vacuum. Solids obtained were recrystallized using mixture of 
methylene dichloride and hexane. 
 
 
 
Note: Preparation of substituted 4-hydroxy coumarin (VNRINT-101) and 
substituted 3-nitro 4-hydroxy coumarin (VNRINT-103) are described in 
Chapter-7. 
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2.7    PHYSICAL DATA  
 Physical data of substituted 3-(1-amido adamantyl) 4-hydroxy 
coumarins derivatives. 
Sr. 
No Code Structure 
Molecular 
formula 
Molecular 
weight 
M. P. 
(oC) 
% 
Yield
1 VNRAD-101 
O O
OH H
N
O
C20H21NO4 339.39 105oC 68 
2 VNRAD-102 
O O
OH H
N
O
 
C21H23NO4 353.41 221 oC 66 
3 VNRAD-103 
O O
OH H
N
O
C22H25NO4  367.44 170 oC 51 
4 VNRAD-104 
O O
OH H
N
O
C22H25NO4  367.44 185 oC 64 
5 VNRAD-105 
O O
OH H
N
O
C22H25NO4  367.44 238 oC 63 
6 VNRAD-106 
O O
OH H
N
O
C21H23NO4 353.41 166 oC 71 
7 VNRAD-107 
O O
OH H
N
O
F C20H20FNO4 357.38 208 oC 52 
8 VNRAD-108 
O O
OH H
N
O
Cl C20H20ClNO4 373.83 223 oC 55 
9 VNRAD-109 
O O
OH H
N
O
HO
C20H21NO5 355.38 188 oC 77 
10 VNRAD-110 
O O
OH H
N
O
MeO C21H23NO5 369.41 175 oC 75 
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2.8  SPECTRAL STUDY 
 Infra Red spectra 
Infra Red Spectra were taken on SHIMADZU IR-435 Spectrometer using KBr Pellet 
method. The characteristic carbonyl group in coumarin moiety is observed at 1720-
1750 cm-1, while carbonyl value of –CONH- peaks are observed in the range 1630-
1690 cm-1. In some of the compounds, the moisture showed a broad peak between 
3000-3200 cm-1. Secondary amine (> NH) observed a broad peak between 3000-3200 
cm-1.Methylene gp (>CH2) observed at 2850-3000 cm-1. methyl (-CH3) observed at 
1350 cm-1.  
 1H NMR spectra 
1H NMR Spectra were recorded on a Bruker AC 400 MHz FT-NMR Spectrometer 
using TMS (Tetramethyl Silane) as an internal standard and DMSO-d6 & CDCl3 as a 
solvent. In the NMR spectra of derivatives of 3-(1-amido adamantyl) 4-hydroxy 
coumarin various proton values of methylene (-CH2), amine (-NH), methyl (-CH3) 
and aromatic protons (Ar-H) etc. were observed as under. 
The values for methylene (-CH2) proton is observed between δ 2.50-3.55 ppm. In 
some cases, the value of methylene proton differs to δ 4.20 and 4.43 ppm. Aromatic 
protons shows the multiplet between δ 6.01-8.54 δ ppm. The signal due to NH proton 
of amide group (>CONH) was observed at  10.3 δ ppm value.  
 Mass spectra 
The mass spectrum of compounds were recorded by GCMS-QP2010 spectrometer (EI 
method). The mass spectrum of compounds was obtained by positive chemical 
ionization mass spectrometry. The molecular ion peak and the base peak in all 
compounds were clearly obtained in mass spectral study. The molecular ion peak 
(M+) values are in good agreement with molecular formula of all the compounds 
synthesized. 
 Elemental analysis 
Elemental analysis of the synthesized compounds was carried out on Vario EL Carlo 
Erba 1108 model at Saurashtra University, Rajkot which showed calculated and found 
percentage values of Carbon, Hydrogen and Nitrogen in support of the structure of 
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synthesized compounds. The spectral and elemental analysis data are given for 
individual compounds 
2.9  SPECTRAL CHARACTERIZATION 
 
3-(1-amido adamantyl) 4-hydroxy coumarin (VNRAD-101) 
Yield: 68%; IR (cm-1): 3355 (O-H str.), 3412 (N-H str.), 3040 (Ar C=C-H str.), 2980 (Asym 
C-H str. -CH3), 2930 (Asym C-H str. -CH2), 2870 (Sym C-H str. -CH3), 2845 (Sym C-H str. -
CH2), 1735 (C=O str.), 1652 (N-H bend), 1580, 1545, 1500 (Ar C=C str.), 1475 (C-H bend –
CH2), 1365 (C-H bend –CH3), 1340 (C-N sec amine vib), 1180 (C-O str.), 810 (C-H oop def); 
Mass: [m/z (%)], M. Wt.: 339; Elemental analysis, Calculated: C, 70.78; H, 6.24; N, 4.13; 
Found: C, 70.55; H, 6.17; N, 4.23. 
 
8-methyl 3-(1-amido adamantyl) 4-hydroxy coumarin (VNRAD-102) 
Yield: 66%; IR (cm-1): 3360 (O-H str.), 3385(N-H str.), 3040 (Ar C=C-H str.), 2904 (Asym 
C-H str. -CH3), 2948 (Asym C-H str. -CH2), 2850 (Sym C-H str. -CH3), 1730 (C=O str.), 
1602 (N-H bend), 1529, 1634 (Ar C=C str.), 1454 (C-H bend –CH2), 1356 (C-H bend –CH3), 
1332 (C-N sec amine vib), 1195 (C-O str.), 796 (C-H oop def); 1H NMR 400 MHz: (CDCl3, 
δ ppm): 1.73 (m, 6H), 1.97 (s, 6H), 2.41 (s, 3H), 2.54 (m, 3H), 7.25 (t, 1H), 7.43 (d, 1H), 
7.74 (d, 1H), 8.52 (s, 1H), Mass: [m/z (%)], M. Wt.: 353 Elemental analysis, Calculated: 
C, 71.37; H, 6.56; N, 3.96; Found: C, 71.63; H, 6.41; N, 3.27. 
 
7,8- dimethyl 3-(1-amido adamantyl) 4-hydroxy coumarin (VNRAD-103) 
Yield: 51%; %; IR (cm-1): 3402 (O-H str.), 3397 (N-H str.), 3040 (Ar C=C-H str.), 2904 
(Asym C-H str. -CH3), 2903 (Asym C-H str. -CH2), 2850 (Sym C-H str. -CH3), 2845 (Sym C-
H str. -CH2), 1703 (C=O str.), 1639 (N-H bend), 1608, 1545 (Ar C=C str.), 1454 (C-H bend –
CH2), 1356 (C-H bend –CH3), 1319 (C-N sec amine vib), 1176 (C-O str.), 815 (C-H oop def);  
Mass: [m/z (%)], M. Wt.:   367 ; Elemental analysis, Calculated: C, 71.91; H, 6.86; N, 
3.81; Found: C, 71.11; H, 6.42; N, 3.54. 
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5,8- dimethyl 3-(1-amido adamantyl) 4-hydroxy coumarin (VNRAD-104) 
Yield: 64%; IR (cm-1): 3575 (O-H str.), 3362 (N-H str.), 3017 (Ar C=C-H str.), 2908 (Asym 
C-H str. -CH3), 2903 (Asym C-H str. -CH2), 2850 (Sym C-H str. -CH3), 1726 (C=O str.), 
1633 (N-H bend), 1586, 1537, 1504 (Ar C=C str.), 1448 (C-H bend –CH2), 1344 (C-H bend –
CH3), 1317 (C-N sec amine vib), 1232 (C-O str.), 819 (C-H oop def); 1H NMR 400 MHz: 
(CDCl3, δ ppm): 1.75 (m, 8H), 1.92 (s, 6H), 2.07 (m, 7H), 2.37 (t, 3H), 2.5 (s, 3H), 3.32 (s, 
8H), 7.06 (d, 1H), 7.35 (d, 1H), 6.60 (s, 1H). Mass: [m/z (%)], M. Wt.: 367 ; Elemental 
analysis, Calculated: C, 71.91; H, 6.86; N, 3.81; Found: C, 71.33; H, 6.14; N, 3.79. 
 
5,7- dimethyl 3-(1-amido adamantyl) 4-hydroxy coumarin (VNRAD-105) 
Yield: 63%; IR (cm-1): 3578 (O-H str.), 3345 (N-H str.), 3025 (Ar C=C-H str.), 2912 (Asym 
C-H str. -CH3), 2905 (Asym C-H str. -CH2), 2875 (Sym C-H str. -CH3), 1736 (C=O str.), 
1640 (N-H bend), 1582, 1545, 1508 (Ar C=C str.), 1435 (C-H bend –CH2), 1345 (C-H bend –
CH3), 1315 (C-N sec amine vib), 1223 (C-O str.), 815 (C-H oop def);  Mass: [m/z (%)], M. 
Wt.: 367 ; Elemental analysis, Calculated: C, 71.91; H, 6.86; N, 3.81; Found: C, 71.68; H, 
6.19; N, 3.10. 
 
6- methyl 3-(1-amido adamantyl) 4-hydroxy coumarin (VNRAD-106) 
Yield: 71%; IR (cm-1): 3556 (O-H str.), 3345 (N-H str.), 3013 (Ar C=C-H str.), 2905 (Asym 
C-H str. -CH3), 2901 (Asym C-H str. -CH2), 2833 (Sym C-H str. -CH3), 1723 (C=O str.), 
1637 (N-H bend), 1582, 1573, 1506 (Ar C=C str.), 1443 (C-H bend –CH2), 1342 (C-H bend –
CH3), 1314 (C-N sec amine vib), 1239 (C-O str.), 812 (C-H oop def); Mass: [m/z (%)], M. 
Wt.: 353 ; Elemental analysis, Calculated: C, 71.37; H, 6.56; N, 3.96; Found: C, 71.15; H, 
6.65; N, 3.14. 
 
6- fluoro 3-(1-amido adamantyl) 4-hydroxy coumarin (VNRAD-107) 
Yield: 52%; IR (cm-1): 3566 (O-H str.), 3362 (N-H str.), 3021 (Ar C=C-H str.), 2903 (Asym 
C-H str. -CH2), 1735 (C=O str.), 1637 (N-H bend), 1582, 1546, 1510 (Ar C=C str.), 1452 (C-
H bend –CH2), 1338 (C-N sec amine vib), 1227 (C-O str.), 1215 (C-F str.), 817 (C-H oop 
def); Mass: [m/z (%)], M. Wt.: 357 ; Elemental analysis, Calculated:  C, 67.22; H, 5.64; 
N, 3.92; Found: C, 67.26; H, 5.47; N, 3.81. 
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6- chloro 3-(1-amido adamantyl) 4-hydroxy coumarin (VNRAD-108) 
Yield: 55%; IR (cm-1): 3572 (O-H str.), 3365 (N-H str.), 3018 (Ar C=C-H str.), 2905 (Asym 
C-H str. -CH2), 1755 (C=O str.), 1640 (N-H bend), 1586, 1537, 1504 (Ar C=C str.), 1435 (C-
H bend –CH2), 1317 (C-N sec amine vib), 1223 (C-O str.), 946 (C-Cl str.), 809 (C-H oop 
def); Mass: [m/z (%)], M. Wt.:  373(M+), 375(M+2); Elemental analysis, Calculated: C, 
64.26; H, 5.39; N, 3.75; Found: C, 64.32; H, 5.57; N, 3.64. 
 
7- hydroxy 3-(1-amido adamantyl) 4-hydroxy coumarin (VNRAD-109) 
Yield: 77%; IR (cm-1): 3603 (O-H str.), 3370 (N-H str.), 3022 (Ar C=C-H str.), 2912 (Asym 
C-H str. -CH2), 1747 (C=O str.), 1643 (N-H bend), 1582, 1544, 1509 (Ar C=C str.), 1445 (C-
H bend –CH2), 1314 (C-N sec amine vib), 1236 (C-O str.), 810 (C-H oop def); Mass: [m/z 
(%)], M. Wt.: 355 ; Elemental analysis, Calculated:  C, 67.59; H, 5.96; N, 3.94; Found: C, 
67.34; H, 5.85; N, 3.86. 
 
6- methoxy 3-(1-amido adamantyl) 4-hydroxy coumarin (VNRAD-110) 
Yield: 75%; IR (cm-1): 3563 (O-H str.), 3352 (N-H str.), 3019 (Ar C=C-H str.), 2912 (Asym 
C-H str. -CH3), 2907 (Asym C-H str. -CH2), 2857 (Sym C-H str. -CH3), 1706 (C=O str.), 
1629 (N-H bend), 1575, 1533, 1516 (Ar C=C str.), 1457 (C-H bend –CH2), 1350 (C-H bend –
CH3), 1319 (C-N sec amine vib), 1214 (C-O str.), 815 (C-H oop def); Mass: [m/z (%)], M. 
Wt.: 369 ; Elemental analysis, Calculated: C, 68.28; H, 6.28; N, 3.79; Found: C, 68.33; H, 
6.23; N, 3.65. 
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2.10    REPRESENTATIVE SPECTRA 
IR Spectrum of 8-methyl 3-(1-amido adamantyl) 4-hydroxy coumarin (VNRAD-
102) 
 
 
 
 
 
 
 
 
 
 
 
IR Spectrum of 5,8- dimethyl 3-(1-amido adamantyl) 4-hydroxy coumarin 
(VNRAD-104) 
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Mass spectrum of 8-methyl 3-(1-amido adamantyl) 4-hydroxy coumarin 
(VNRAD-102) 
 
 
 
 
 
 
 
 
 
 
 
Mass Spectrum of 5,8- dimethyl 3-(1-amido adamantyl) 4-hydroxy coumarin 
(VNRAD-104) 
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1H NMR Spectrum of 8-methyl 3-(1-amido adamantyl) 4-hydroxy coumarin 
(VNRAD-102) 
 
Expanded 1H NMR Spectrum of 8-methyl 3-(1-amido adamantyl) 4-hydroxy 
coumarin (VNRAD-102) 
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1H NMR Spectrum of 5,8- dimethyl 3-(1-amido adamantyl) 4-hydroxy coumarin 
(VNRAD-104) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expanded 1H NMR Spectrum of 5,8- dimethyl 3-(1-amido adamantyl) 4-
hydroxy coumarin (VNRAD-104) 
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2.11 RESULT AND DISCUSSION 
 
In this Chapter, 10 different substituted 3-amino 4-hydroxy coumarins were prepared, 
preparation method of which is shown in chapter-7. These substituted 3-amino 4-
hydroxy coumarins were linked with adamantane through amide linkage. The main 
significance of present work that the reactions are carried out at room temperature 
under stirring, and desired product is obtained with easy work up method.  
 
2.12 CONCLUSION 
 
Thus, substituted 3-amino 4-hydroxy coumarin are reacted with adamantane acid 
chloride in order to form an amide linkage. By doing so, a new class of coumarin 
derivatives are generated and their potential biological activity will be checked upon. 
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3.1    INTRODUCTION 
 
Schiff Bases: 
Formation of Schiff Bases 
 A Schiff base is nitrogen analog of an aldehyde or ketone in which the C=O 
group is replaced by a C=N-R group. It is usually formed by condensation of an 
aldehyde or ketone with a primary amine according to the following scheme: 
R
NH2 R R
O
N
R
R
R H2O
Primary Amine Aldehyde or Ketone Schiff Base Water
 
Where R may be an alkyl or an aryl group. Schiff bases that contain aryl substituents 
are substantially more stable and more readily synthesized, while those which contain 
alkyl substituents are relatively unstable. Schiff bases of aliphatic aldehydes are 
relatively unstable and readily polymerizable,[1-3] while those of aromatic aldehydes 
having effective conjugation are more stable [4-7]. 
The formation of a Schiff base from an aldehydes or ketones is a reversible reaction 
and generally takes place under acid or base catalysis, or upon heating. 
R H
O
R
NH2 R
OH
NHR
R
R
NR
R
H2O
Aldehyde or Ketone Primary Amine Carbinolamine
N-Substituted Imine Water
 
 The formation is generally driven to the completion by separation of the 
product or removal of water, or both. Many Schiff bases can be hydrolyzed back to 
their aldehydes or ketones and amines by aqueous acid or base. 
 The mechanism of Schiff base formation is another variation on the theme of 
nucleophilic  addition to the carbonyl group. In this case, the neuclophile is the amine. 
In the first part of the mechanism, the amine reacts with the aldehyde or ketone to 
give an unstable addition compound called carbinolamine. 
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 The carbinolamine loses water by either acid or base catalyzed pathways. 
Since the carbinolamine is and alcohol, it undergoes acid catalyzed dehydration. 
N
R'
H
R2C
OH H+
N
R'
H
R2C
OH2
N
R
R H
R' H2O
N
R
R
R' H3O+
(Acid Catalyzed Dehydration)
 
Typically the dehydration of the carbinolamine is the rate-determining step of Schiff 
base formation and this is why the reaction is catalyzed by acids. Yet the acid 
concentration cannot be too high because amines are basic compounds. If the amine is 
protonated and becomes non-nucleophilic, equilibrium is pulled to the left and 
carbinolamine formation cannot occur. Therefore, many Schiff base syntheses are best 
carried out at mildly acidic pH. 
 The dehydration of carbinolamines is also catalyzed by base. This reaction is 
somewhat analogous to the E2 elimination of alkyl halides except that it is not a 
concerted reaction. It proceeds in two steps through an anionic intermediate. 
The Schiff base formation is really a sequence of two types of reactions, i.e. addition 
followed by elimination[8]. 
The utility of Schiff bases lay in their usefulness as synthons in the synthesis of 
bioactive molecules such as 4-thiazolidinines, 2-azetidinones, benzoxazines, 
formazans, etc. Schiff bases are known to have useful biological activity like 
insecticidal [9], antibacterial [10], antituberculosis [11], antimicrobial [12], anticonvulsant 
[13], antifeedant [14] etc. Schiff bases belongs to a widely used group of organic 
intermediates important for production of specially chemicals, e.g. pharmaceutical or 
rubber additives[15], as amino protective groups in organic synthesis[16-19]. They also 
have used as liquid crystals [20], in analytical [21], medical [22] and polymer chemistry 
[23].           
A classical synthesis of these compounds involves the condensation of acetophenones 
and anilines to give Schiff bases [24]. The combination of solvents and   long reaction 
time makes this method environmentally hazardous.   
This provided the stimulus to synthesize new Schiff bases using classical as well as 
grindstone technique [25]. In grindstone technique reaction occur through generation of 
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local heat by grinding of crystals of substrate and reagent by mortar and pestle. 
Reactions are initiated by grinding, with the transfer of very small amount of energy 
through friction. In some cases, a mixture and reagents turns to a glassy material. 
Such reaction are simple to handle, reduce pollution, comparatively cheaper to 
operate and may be regarded as more economical and ecologically favorable 
procedure in chemistry [26].Solid state reaction occur more efficiently and more 
selectively than does the solution reaction, since molecules in the crystal are arranged 
tightly and regularly[27].  
In present work grindstone technique was used for the synthesis of titled compounds. 
This method is superior since it is eco-friendly, high yielding, requires no special 
apparatus, non-hazardous, simple and convenient. A series of some new Schiff bases 
have been prepared. To best our knowledge earlier reports do not exist on the 
synthesis of these Schiff bases.    
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3.2 SYNTHETIC ASPECT 
 
Various methods for the preparation of azomethine derivatives have been cited 
in literature, some of the methods are as under. 
1. General account of the summary of reaction of aldehydes with amine 
(aromatic or aliphatic) has been reviewed by Murray [28]. 
 
R
O
NH2R1 R N
R1
 
 
2. E. C. Creencia and group[29] reported synthesis from ortho substituted aniline 
with 55 % yield in 2 hours in benzene.    
Ar
NH2
O
R
Benzene
Ar
N
R
2h
 
 
3. D. Bleger et al.[30] have synthesized Schiff’s base of aniline and benzaldehyde 
in ethanol with short reaction time of 4 hours and reported E isomer as major 
product.  
 
NH2
O
N
E
EtOH
4h  
 
4.  U. K. Roy and coworkers[31] have reported preparation of Schiff’s base with 
100 % of yield with toluene as a solvent.  
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NH2
O
N
PhMe
24h  
 
5.  L. B. Pierre and coworkers[32] have synthesized (E)-N-phenyl 
methyleneglycineethyl ester by the cyclocondensation of glycine ethyl ester 
hydrochloride, t-butylmethyl ether (TBME), benzaldehyde was added 
followed by anhydrous Na2SO4 and triethylamine. 
 
O
ClHH2N
O
O N O
OEt3N,TBME
Na2SO4  
 
6.  J. G. Amanda et al. [33] have prepared Schiff bases by condensation of 
equimolar quantity of 3,6-diformylcatechol and substituted o-
phenylenediamine. 
 
OH
OH
O
O
NH2
H2N
OR
OR
OH
OH
O
N
NH2
OR
OR
 
 
7.  L. Somogyi[34] reported some azomethine derivatives of phenylhydrazide in 99 
% yield and with short reaction time of 3.5 hours in polar solvent. 
 
Chapter-3                                                                      Solvent less Solid Phase Synthesis of … 
 
73 
 
 
O
H
N
NH2
O
3.5h
O
H
N
N
R
 
 
8.  Schiff’s base of o-phenelene diamine with substituted benzaldehyde was 
reported by M. Zintl and coworkers[35]. 
 
NH2
NH2
Ar O
N
N
Ar
Ar
EtOH
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3.3 GREEN CHEMISTRY APPROACH 
 
Microwave irradiation (MWI) has become an established tool in organic synthesis, 
because of  
the rate enhancements, higher yields, and often, improved selectivity, with respect to 
the  
conventional reaction conditions. 
In recent years, solvent –free reactions using either organic or inorganic solid supports 
have received increasing attention[36]. 
There are several advantages to performing synthesis in dry media: (i) short reaction 
times, (ii) increased safety, (iii) economic advantages due to the absence of solvent. In 
addition, solvent free MWI processes are also clean and efficient[37].  
Owing to environmental restrictions on emissions covered in several legislations 
throughout the world, non-polluting and atom-efficient catalytic technologies are 
much sought after. The use of acid catalysts is very common in the chemical and 
refinery industries, and those technologies employing highly corrosive, hazardous and 
polluting liquid acids are being replaced with solid acids; for instance, acid treated 
clays, zeolites, zeotypes, ion-exchange resins and metal oxides. Of late, a number of 
organic syntheses have been conducted with solid acids like sulfated zirconia, leading 
to better regio- and stereo- selectivity[38].  
The challenge in chemistry to develop practical processes, reaction media, conditions 
and/or utility of materials based on the idea of green chemistry is one of the important 
issues in the scientific community. 
Owing to our interest in solid-state reactions[39-40], we attempted to synthesize Schiff 
bases from reaction of substituted amines of 4-hydroxy coumarin with 3-formyl 4-
hydroxy coumarin using mortar pestle.   
 
 Greener Reactions under solventless conditions  
Due to the growing concern for the influence of the organic solvent on the 
environment as well as on human body, organic reactions without use of conventional 
organic solvents have attracted the attention of synthetic organic chemists. Although a 
number of modern solvents, such as fluorous media, ionic liquids and water have been 
extensively studied recently, not using a solvent at all is definitely the best option. 
Development of solvent-free organic reactions is thus gaining prominence. 
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 Catalyst and solvent-free conditions as an environmentally benign approach 
to 4-aryl-3-cyano-hexahydro-4H-1, 2-benzoxazine-2-oxides 
1,2-Oxazine-2-oxides are generally accessible via a catalyzed formal [4 + 2] 
cycloaddition reactions of nitroalkenes with electron-rich alkenes [41,42]. These 
heterocycles are valuable intermediates to prepare in a regio and stereoselectively 
manner a number of important building blocks or target heterocyclic compounds, such 
as pyrrolidines, β-lactam-N-oxides, pyrrolizidine and indolizidine alkaloids, 
enamines, ketoalcohols, nitroketones, etc. In 2008, Bellachioma et.al [45] reported that 
(E)-2-aryl-1-cyano-1- nitroethenes [43,44] are excellent Michael acceptors in water in 
the reactions with enantiopure alkyl vinyl ethers, allowing the preparation of various 
cyclic nitronates by a completely endo stereoselective [4 + 2] cycloaddition [46] 
(Scheme 1). 
NO2
CN
MeO
OSiMe3 N
O
H
O
CN
OMe
Me3SiO
 
Scheme 1: Michael addition of 1-nitroethene with 1-(trimethylsilyloxy)-cyclohex-1-
ene 
 
Under solvent-free conditions, (E)-2-aryl-1-cyano-1-nitroethenes rapidly react with 1-
(trimethylsilyloxy)-cyclohex-1-ene with a complete regio- and diasteroselectivity and 
leading to the exclusive formation of the cis-fused hexahydro-4H-benzoxazine-2-
oxides, which were isolated without the need for a work-up procedure in excellent 
yields. 
 
 Solid-state regio and stereo-selective benzylic bromination of diquinoline 
compounds using N-bromosuccinimide 
The Wohl–Ziegler reaction, namely allylic or benzylic free radical bromination using 
N-bromosuccinimide (NBS) in a refluxing aprotic solvent, (Scheme 2) is a well-
established synthetic organic procedure [47]. Benzene, chloroform and petrol have 
been employed as solvents, but the traditional choice has been carbon tetrachloride 
which combines optimum properties of solubility, reaction temperature and ease of 
product isolation. The succinimide by-product can be removed simply by filtration of 
the cooled reaction mixture and then evaporation of solvent from the filtrate affords 
the brominated product [48]. In 2005, Rahman et al. [49] synthesised a series of new 
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brominated diquinoline lattice inclusion hosts, some of which have potential in 
separation chemistry due to their selective properties. In each case, the final step 
involved a regio and stereoselective benzylic NBS bromination in refluxing CCl4. 
However, identical products can be obtained by means of solid-state reaction. 
N
N
R
R
R
R
H
H
N
N
R
R
R
R
H
H
Br
Br
 
Scheme 2: Benzylic bromination of diquinoline compounds using N-
bromosuccinimide 
 
 Metal and solvent-free conditions for the acylation reaction catalyzed by 
carbon tetrabromide 
Organocatalysis has attracted much attention as result of both the novelty of the 
concept and more importantly the fact that the efficiency and selectivity of many 
organocatalytic reactions meet the standards of established organic reactions. 
Catalysts of the same class may promote similar reactions or less closely related 
reactions e.g., Carbon tetrabromide (CBr4) is another example of this catalyst class is 
able to mediate an astonishing variety of transformations. Although carbon 
tetrabromide is considered a poisonous, irritating solid (skin contact can cause severe 
irritation; avoid inhalation of fumes; toxicity: irritating to skin, eyes and respiratory 
tract, irritating to mucous membranes, narcotic in high concentrations; possible liver 
and kidney damage;). It has been utilized as a mild Lewis acid imparting high regio 
and chemo-selectivity in various organic transformations [50]. In 2007, Zhang et al. [51] 
reported that an efficient and useful catalyst carbon tetrabromide (CBr4) was 
discovered to be highly effective for the acylation of phenols, alcohols and thiols 
under metal and solvent-free conditions (Scheme 3).  
OH
Ac2O
OAc
CBr4 (5 mol%)
Solvent free
RT, air
24 hr, 91%  
Scheme 3: Acylation reaction catalyzed by carbon tetrabromide 
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 An environmentally benign solvent-free Tishchenko reaction  
 
The conversion of aldehydes to their dimeric esters, better known as the Tishchenko 
reaction has been known for more than a hundred years. This reaction is heavily used 
in industry and it is inherently environmentally benign since it utilizes catalytic 
conditions and is 100% atom economic. Over the years, chemists have looked to 
develop new reagents that are more efficient than the aluminum based catalysts 
traditionally used. Metal catalysts such as alkali metals, alkali metal oxides, 
lanthanides, and many others have been developed towards the improvement of 
Tishchenko chemistry. In 2009, Waddell et al. [52] reported that the solvent-free ball 
milling Tishchenko reaction. Using high speed ball milling and a sodium hydride 
catalyst, the Tishchenko reaction was performed for aryl aldehydes in high yields in 
0.5 hours (Scheme 4). The reaction was not affected by the type of ball bearing used 
and found to be successful in a liquid nitrogen environment. 
2 RCHO
Catalyst
R
O
O R
 
Scheme 4: Tishchenko reaction 
 
 Reformatsky and Luche Reaction in absence of solvent  
 
In 1990, Tanaka et al. [53] reported Reformatsky (scheme 5) and Luche reactions 
(Scheme 6) with Zn provide more economical C-C bond formation methods than 
Grignard reactions with more expensive Mg metal. 
RCHO BrCH2COOEt
Zn
NH4Cl
ArCH(OH)CH2COOEt
 
Scheme 5: Reformatsky Reaction 
RCHO BrCH2CH=CH2
Zn
NH4Cl
RCH(OH)CH2CH=CH2
 
Scheme 6: Luche Reaction 
In addition, it was pointed out that Reformatsky and Luche reactions proceed 
efficiently in the absence of solvent, although Grignard reactions under similar 
conditions are not very efficient and give more reduction product than the normal 
carbonyl addition product. The nonsolvent Reformatsky and Luche reactions can be 
carried out by a very simple procedure and give products in higher yield than with 
solvent. In general, the nonsolvent reaction was carried out by mixing aldehyde or 
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ketone, organic bromo compound and Zn-NH4C1 in an agate mortar and pestle and by 
keeping the mixture at room temperature for several hours. 
 
 Oxidative coupling Reaction of phenols with FeCl3 
Oxidative couplings of phenols are usually carried out by treatment of phenols in 
solution with more than equimolar amount of metal salts such as FeCl3 or manganese 
tris(acetylacetonate), although the latter one is too expensive to use in a large 
quantity. The coupling reactions of phenols with FeCl3, however, sometimes give 
quinones as byproducts.  
OH
FeCl3.6H2O
solid
OH
OH
 
Scheme 7: Oxidative coupling Reaction of phenols with FeCl3 
In 1989, Toda et al. [54] have reported that some oxidative coupling reactions of 
phenols with FeCl3 are faster and more efficient in the solid state than in solution 
(Scheme 7). Some coupling reactions in the solid state were accelerated by irradiation 
with ultrasound. Some coupling reactions are achieved by using a catalytic amount of 
FeCl3 
 
 
 Solvent free synthesis of chalcones  
 
The synthesis of chalcones illustrates the reaction that proceeds with high atom 
economy and is relatively easy to perform in teaching labs. Chalcones are important 
compounds with applications in medicine and physics. 
O
H
O
H3C NaOH
O
R2R2R1 R1
R1= 4-CH3;4-OCH3;3-Cl;4-Cl;-H
R2= 4-CH3;4-Br;4-OCH3;-H  
Scheme 8: Synthesis of chalcones 
In 2004, Palleros et al. [55] found that the reactions proceed rapidly and afford very 
good yields of product. Most of the chalcones can be obtained in a matter of minutes 
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by mixing the corresponding benzaldehyde and acetophenone in the presence of solid 
NaOH in a mortar with pestle (Scheme 8); the yields of crude product were in the 
range 81–94%. 
 
 
 A Practical and Green Approach towards Synthesis of Dihydropyrimidinones 
without Any Solvent or Catalyst  
 
In 2002, Ranu et al. [56] reported a simple, efficient, green and cost-effective 
procedure for the synthesis of dihydropyrimidinones by a solvent-free and catalyst-
free Biginelli’s condensation of 1,3- dicarbonyl compound, aldehyde and urea 
(Scheme 9). This approach of direct reaction in neat without solvent and catalyst 
showed a new direction in green synthesis. 
R1 R2
O O
R3-CHO
H2N NH2
X
N
H
NH
X
R2
O
R1
R3
X=O,S
100-105 oC
1 h
 
Scheme 9: Synthesis of Dihydropyrimidinones 
Dihydropyrimidinone derivatives are of considerable interest in industry as well as in 
academia because of their promising biological activities as calcium channel blockers, 
antihypertensive agents and anticancer drugs. Thus, synthesis of this heterocyclic 
nucleus is of much importance and quite a number of synthetic procedures based on 
the modifications of the century-old Biginelli’s reaction involving acid-catalyzed 
three-component condensation of 1,3- dicarbonyl compound, aldehyde and urea, have 
been developed. Basically these methods are all similar using different Lewis acid 
catalysts such as BF3, FeCl3, InCl3 and 6h in a solvent such as CH3CN, THF. A 
number of procedures under solvent-free conditions using Yb(OTf)3, montmorillonite 
and ionic liquid as catalysts have also been reported. Obviously, many of these 
catalysts and solvents are not at all acceptable in the context of green synthesis. Thus, 
as a part of green synthesis, they have discovered that Biginelli’s reaction proceeds 
very efficiently by stirring a mixture of neat reactants at 100-105°C for an hour, 
requiring no solvent and catalyst, and producing dihydropyrimidinones in high yields. 
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3.4    AIM OF CURRENT WORK 
 
To synthesize Schiff bases under solvent free conditions from 3-formyl 4-hydroxy 
coumarins using different amines including substituted 3-amino 4-hydroxy 
coumarins. 
 
3.5    REACTION SCHEME 
 
 Preparation of 3-((E)-(substited phenylimino)methyl)-4-hydroxy-2H-
chromen-2-one: 
O
OH
O
H
C
O
O O
OH H
C
N
NH2
R'
R'
Solid State
Mortal Pestle
 
 Preparation of 3-((12E)-(substituted 4-hydroxy-2-oxo-2H-chromen-3-
ylimino)methyl)-4-hydroxy-2H-chromen-2-one: 
O
OH
O
H
C
O
O
OH
NH2
O O O
OH H
C
N
O
OH
O
R"
R''
Solid State
Mortal Pestle
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3.6    EXPERIMENTAL 
 
 Preparation of 3-((E)-(substituted phenylimino)methyl)-4-hydroxy-2H-
chromen-2-one: 
 
A mixture of of 3-amino 4-hydroxy coumarin (0.02 mmol) and liquid substituted 
phenyl amines in excess (0.03 mmol) were taken into mortar pestle and grinded for 
about 20 minutes. Completion of reaction was checked over TLC. The mixture was 
then filtered and washed with hot methanol. The filered solids were dried and 
recrystallized from methanol.  
 
 Preparation of 3-((12E)-(substituted 4-hydroxy-2-oxo-2H-chromen-3-
ylimino)methyl)-4-hydroxy-2H-chromen-2-one: 
 
A mixture of substituted 3-amino 4-hydroxy coumarin (0.02 mmol) and 3-formyl 4-
hydroxy coumarin (0.02 mmol) were taken into mortar pestle and grinded for about 
20 minutes. Completion of reaction was checked over TLC. If the reaction was not 
complete complete, drop of acetic acid was added to the mixture and grinded for 5 
more minutes. The mixture was then filtered and washed with hot methanol. The 
filered solids were dried and eluted over silica using Ethyl acetate/Hexane solvent 
mix.  
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3.7    PHYSICAL DATA 
 PHYSICAL DATA TABLE OF 3-((12E)-(SUBSTITUTED 4-HYDROXY-2-
OXO-2H-CHROMEN-3-YLIMINO)METHYL)-4-HYDROXY-2H-
CHROMEN-2-ONE 
Sr. 
No Code Structure 
Molecular 
formula 
Molecular 
weight 
M. P. 
(oC) 
% 
Yield 
1 VNRSc-101 
O O
OH H
C
N
O
OH
O
C19H11NO6 349.29 221-223 64% 
2 VNRSc-102 
O O
OH H
C
N
O
OH
O
C20H13NO6 363.32 252-254 72% 
3 VNRSc-103 
O O
OH H
C
N
O
OH
O
 
C21H15NO6 377.35 231-233 57% 
4 VNRSc-104 
O O
OH H
C
N
O
OH
O
C21H15NO6 377.35 236-238 71% 
5 VNRSc-105 
O O
OH H
C
N
O
OH
O
 
C21H15NO6 377.35 210-212 75% 
6 VNRSc-106 
O O
OH H
C
N
O
OH
O
 
C20H13NO6 363.32 241-243 66% 
7 VNRSc-107 
O O
OH H
C
N
O
OH
O
F
 
C19H10FNO6 367.28 233-235 64% 
8 VNRSc-108 
O O
OH H
C
N
O
OH
O
Cl
 
C19H10ClNO6 383.74 225-227 78% 
9 VNRSc-109 
O O
OH H
C
N
O
OH
O OH
 
C19H11NO7 365.29 214-216 72% 
10 VNRSc-110 
O O
OH H
C
N
O
OH
O
OMe
 
C20H13NO7 379.32 230-232 63% 
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 PHYSICAL DATA TABLE OF 3-((E)-(SUBSTITUTED 
PHENYLIMINO)METHYL)-4-HYDROXY-2H-CHROMEN-2-ONE 
Sr. 
No Code Structure 
Molecular 
formula 
Molecular 
weight 
M. P. 
(oC) 
% 
Yield
1 VNRSc-111 
O O
OH
N
Cl
Cl C16H9Cl2NO3 334.15 165 82% 
2 VNRSc-112 
O O
OH
N
C18H15NO3 293.32 147 85% 
3 VNRSc-113 
O O
OH
N F
F
C16H9F2NO3 301.24 137 75% 
4 VNRSc-114 
O O
OH
N
F
C16H10FNO3 283.25 148 87% 
5 VNRSc-115 
O O
OH
N
F
CF3 C17H9F4NO3 351.25 155 83% 
6 VNRSc-116 
O O
OH
N
Cl
C16H10ClNO3 299.71 132 81% 
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3.8    SPECTRAL STUDY 
 
 Infra Red spectra 
Infra Red Spectra were taken on SHIMADZU IR-435 Spectrometer using KBr Pellet 
method. The characteristic carbonyl group in coumarin moiety is observed at 1720-
1750 cm-1, Methylene gp (>CH2) observed at 2850-3000 cm-1. methyl (-CH3) 
observed at 1350 cm-1.  
 1H NMR spectra 
1H NMR Spectra were recorded on a Bruker AC 400 MHz FT-NMR Spectrometer 
using TMS (Tetramethyl Silane) as an internal standard and DMSO-d6 & CDCl3 as a 
solvent. In the NMR spectra of derivatives of 3-((12E)-(4-hydroxy-(substituted)-2-
oxo-2H-chromen-3-ylimino)methyl)-4-hydroxy-2H-chromen-2-one, various proton 
values of amine (-NH) and aromatic protons (Ar-H) etc. were observed as under. 
The -NH protons of substituted aniline observed at δ 3.95-4.20 ppm. Aromatic 
protons shows the multiplet between δ 6.01-8.54 δ ppm.  
 Mass spectra 
The mass spectrum of compounds were recorded by GCMS-QP2010 spectrometer (EI 
method). The mass spectrum of compounds was obtained by positive chemical 
ionization mass spectrometry. The molecular ion peak and the base peak in all 
compounds were clearly obtained in mass spectral study. The molecular ion peak 
(M+) values are in good agreement with molecular formula of all the compounds 
synthesized. 
 Elemental Analysis 
Elemental analysis of the synthesized compounds was carried out on Vario EL Carlo 
Erba 1108 model at Saurashtra University, Rajkot which showed calculated and found 
percentage values of Carbon, Hydrogen and Nitrogen in support of the structure of 
synthesized compounds. The spectral and elemental analysis data are given for 
individual compounds. 
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3.9    SPECTRAL CHARACTERIZATION 
 
3-((12E)-(4-hydroxy-2-oxo-2H-chromen-3-ylimino)methyl)-4-hydroxy-2H-
chromen-2-one (VNRSC-101) 
Yield: 68%; IR (cm-1): 3545 (O-H str.), 3035 (Ar C=C-H str.), 2982 (Asym C-H str. -
CH3), 2849 (Sym C-H str. -CH3), 2833  (Sym C-H str. -CH2), 1740 (C=O str.), 
1522,1595 ,1506  (Ar C=C str.), 1176 (C-O str.), 740 (C-H oop def); Mass: [m/z 
(%)], M. Wt.: 349; Elemental analysis, Calculated: C, 65.33; H, 3.17; N, 4.01; 
Found: C, 65.43; H, 3.22; N, 4.16. 
 
3-((12E)-(4-hydroxy-8-methyl-2-oxo-2H-chromen-3-ylimino)methyl)-4-hydroxy-
2H-chromen-2-one (VNRSC-102) 
Yield: 66%; IR (cm-1): 3531 (O-H str.), 3032,3256 (Ar C=C-H str.), 2973 (Asym C-H 
str. -CH3), 2855 (Sym C-H str. -CH3), 2836  (Sym C-H str. -CH2), 1756 (C=O str.), 
1587,1502  (Ar C=C str.),1324 (C-H bend –CH3), 1275 (C-O str.), 785 (C-H oop def); 
Mass: [m/z (%)], M. Wt.: 363 Elemental analysis, Calculated: C, 66.12; H, 3.61; 
N, 3.86; Found: C, 66.08; H, 3.67; N, 3.27. 
 
3-((12E)-(4-hydroxy-7,8-dimethyl-2-oxo-2H-chromen-3-ylimino)methyl)-4-
hydroxy-2H-chromen-2-one (VNRSC-103) 
Yield: 51%; %; IR (cm-1): 3508 (O-H str.), 3091, (Ar C=C-H str.), 2983 (Asym C-H 
str. -CH3),2864 (Sym C-H str. -CH3), 2845 (Sym C-H str. -CH2), 1734 (C=O str.), 
1595 ,1506  (Ar C=C str.),1356 (C-H bend –CH3), 1176 (C-O str.), 767 (C-H oop 
def);  Mass: [m/z (%)], M. Wt.:   377 ; Elemental analysis, Calculated: C, 66.84; 
H, 4.01; N, 3.71; Found: C, 66.24; H, 4.45; N, 3.48. 
 
3-((12E)-(4-hydroxy-5,8-dimethyl-2-oxo-2H-chromen-3-ylimino)methyl)-4-
hydroxy-2H-chromen-2-one (VNRSC-104) 
Yield: 64%; IR (cm-1):3612 (O-H str.), 3084, (Ar C=C-H str.), 2976 (Asym C-H str. -
CH3),2854 (Sym C-H str. -CH3), 2825 (Sym C-H str. -CH2), 1731 (C=O str.), 1575 
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,1505  (Ar C=C str.),1346 (C-H bend –CH3), 1076 (C-O str.), 810 (C-H oop def); 
Mass: [m/z (%)], M. Wt.: 377 ; Elemental analysis, Calculated: C, 66.84; H, 4.01; 
N, 3.71; Found: C, 66.65; H, 4.19; N, 3.71. 
 
3-((12E)-(4-hydroxy-5,7-dimethyl-2-oxo-2H-chromen-3-ylimino)methyl)-4-
hydroxy-2H-chromen-2-one (VNRSC-105) 
Yield: 63%;(cm-1):3647,3537(O-H str.), 3097.3066, (Ar C=C-H str.), 3010  (Asym C-
H str. -CH3), (Sym C-H str. -CH3), 1712, 1693 (C=O str.),   1591,1558, 1506  (Ar 
C=C str.)1356 (C-H bend –CH3), 1031,1111 (C-O str.), 785  (C-H oop def);  1H 
NMR 400 MHz: (CDCl3, δ ppm): 2.12 (s, 3H), 2.82 (s, 3H), 6.76 (s, 1H), 6.83 (s, 
1H), 7.25 (m, 2H), 7.53 (m, 1H), 8.04 (m, 1H), 9.80 (d, 1H), 14.24 (d, 1H). Mass: 
[m/z (%)], M. Wt.: 377 ; Elemental analysis, Calculated: C, 66.84; H, 4.01; N, 
3.71; Found: C, 66.48; H, 4.11; N, 3.47. 
 
3-((12E)-(4-hydroxy-6-methyl-2-oxo-2H-chromen-3-ylimino)methyl)-4-hydroxy-
2H-chromen-2-one (VNRSC-106) 
Yield: 71%; IR (cm-1): 3615(O-H str.), 3071, (Ar C=C-H str.), 2973 (Asym C-H str. -
CH3),2861 (Sym C-H str. -CH3), 2843 (Sym C-H str. -CH2), 1724 (C=O str.), 1595 
,1506  (Ar C=C str.),1352 (C-H bend –CH3), 1156 (C-O str.), 741 (C-H oop 
def);Mass: [m/z (%)], M. Wt.: 363 ; Elemental analysis, Calculated: C, 71.47; H, 
6.72; N, 3.16; Found: C, 71.15; H, 6.65; N, 3.14. 
 
3-((12E)-(6-fluoro-4-hydroxy-2-oxo-2H-chromen-3-ylimino)methyl)-4-hydroxy-2H-
chromen-2-one (VNRSC-107) 
Yield: 52%; IR (cm-1): 3655 (O-H str.), 3101, (Ar C=C-H str.), 2993 (Asym C-H str. 
-CH3),2854 (Sym C-H str. -CH3), 2835 (Sym C-H str. -CH2), 1744 (C=O str.), 1585 
,1501  (Ar C=C str.),1354 (C-H bend –CH3), 1176 (C-O str.), 567 (C-F str.) 741 (C-H 
oop def); Mass: [m/z (%)], M. Wt.: 367 ; Elemental analysis, Calculated:  C, 
62.13; H, 2.74; F, 5.17; N, 3.81; Found: C, 62.24; H, 2.52; N, 3.46. 
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3-((12E)-(6-chloro-4-hydroxy-2-oxo-2H-chromen-3-ylimino)methyl)-4-hydroxy-2H-
chromen-2-one (VNRSC-108) 
Yield: 55%; IR (cm-1): 3572 (O-H str.), 3091, (Ar C=C-H str.), 2983 (Asym C-H str. 
-CH3),2874 (Sym C-H str. -CH3), 2845 (Sym C-H str. -CH2), 1724 (C=O str.), 1585 
,1502 (Ar C=C str.),1345 (C-H bend –CH3), 1076 (C-O str.), 967 (C-Cl str.) 780 (C-H 
oop def); Mass: [m/z (%)], M. Wt.:  383 ; Elemental analysis, Calculated: C, 
59.47; H, 2.63; Cl, 9.24; N, 3.65; Found: C, 59.36; H, 2.55; N, 3.87. 
 
3-((12E)-(4,7-dihydroxy-2-oxo-2H-chromen-3-ylimino)methyl)-4-hydroxy-2H-
chromen-2-one (VNRSC-109) 
Yield: 77%; IR (cm-1): 3647 (O-H str.), 3015, (Ar C=C-H str.), 2973 (Asym C-H str. 
-CH3),2857 (Sym C-H str. -CH3), 2845 (Sym C-H str. -CH2), 1724 (C=O str.),   1575 
,1505  (Ar C=C str.),1344 (C-H bend –CH3), 1146 (C-O str.),  745 (C-H oop def); 
Mass: [m/z (%)], M. Wt.: 365 ; Elemental analysis, Calculated:  C, 62.47; H, 3.04; 
N, 3.83; Found: C, 62.58; H, 3.12; N, 3.77. 
 
3-((12E)-(4-hydroxy-6-methoxy-2-oxo-2H-chromen-3-ylimino)methyl)-4-hydroxy-
2H-chromen-2-one (VNRSC-110) 
Yield: 75%; IR (cm-1): 3563 (O-H str.), 3001, (Ar C=C-H str.), 2973 (Asym C-H str. 
-CH3),2854 (Sym C-H str. -CH3), 2835 (Sym C-H str. -CH2), 1735 (C=O str.),   1585 
,1501  (Ar C=C str.),1354 (C-H bend –CH3), 1176 (C-O str.),  745 (C-H oop 
def);Mass: [m/z (%)], M. Wt.: 379 ; Elemental analysis, Calculated: C, 63.33; H, 
3.45; N, 3.69; Found: C, 63.42; H, 3.64; N, 3.57. 
 
3-((E)-(2,3-dichlorophenylimino)methyl)-4-hydroxy-2H-chromen-2-one (VNRSC-
111) 
Yield: 71%; IR (cm-1): 3652 (O-H str.), 3015, (Ar C=C-H str.), 2965 (Asym C-H str. 
-CH3),2874 (Sym C-H str. -CH3), 2855 (Sym C-H str. -CH2), 1732 (C=O str.), 1575 
,1505  (Ar C=C str.),1354 (C-H bend –CH3), 1046 (C-O str.), 965(C-Cl str.), 745 (C-
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H oop def);Mass: [m/z (%)], M. Wt.: 334 ; Elemental analysis, Calculated: C, 
57.51; H, 2.71; N, 4.19; Found: C, 57.15; H, 2.75; N, 4.12. 
 
3-((E)-(3,5-dimethylphenylimino)methyl)-4-hydroxy-2H-chromen-2-one (VNRSC-
112) 
Yield: 52%; IR (cm-1): 3589 (O-H str.), 3088, (Ar C=C-H str.), 2963 (Asym C-H str. 
-CH3),2859 (Sym C-H str. -CH3), 2852 (Sym C-H str. -CH2), 1721(C=O str.), 1575 
,1505  (Ar C=C str.),1374 (C-H bend –CH3), 1185 (C-O str.), 756 (C-H oop def); 
Mass: [m/z (%)], M. Wt.: 293 ; Elemental analysis, Calculated:  C, 73.71; H, 5.15; 
N, 4.78; Found: C, 73.14; H, 5.42; N, 4.51. 
 
3-((E)-(3,4-difluorophenylimino)methyl)-4-hydroxy-2H-chromen-2-one (VNRSC-
113) 
Yield: 55%; IR (cm-1): 3655 (O-H str.), 3017, (Ar C=C-H str.), 2945 (Asym C-H str. 
-CH3),2852 (Sym C-H str. -CH3), 2848 (Sym C-H str. -CH2), 1724 (C=O str.), 1577 
,1535  (Ar C=C str.),1347 (C-H bend –CH3), 1157(C-O str.),587,(C-F str.), 745 (C-H 
oop def); Mass: [m/z (%)], M. Wt.:  301 ; Elemental analysis, Calculated: C, 
63.79; H, 3.01; N, 4.65; Found: C, 63.44; H, 3.21; N, 4.78. 
 
3-((E)-(4-fluorophenylimino)methyl)-4-hydroxy-2H-chromen-2-one (VNRSC-114) 
Yield: 77%; IR (cm-1): 3647 (O-H str.), 3015, (Ar C=C-H str.), 2973 (Asym C-H str. 
-CH3),2857 (Sym C-H str. -CH3), 2845 (Sym C-H str. -CH2), 1724 (C=O str.), 1575 
,1505  (Ar C=C str.),1344 (C-H bend –CH3), 1146 (C-O str.), 586(C-F str.), 745 (C-H 
oop def);Mass: [m/z (%)], M. Wt.: 283 ; Elemental analysis, Calculated:  C, 67.84; 
H, 3.56; N, 4.94; Found: C, 67.49; H, 3.24; N, 4.36. 
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3-((E)-(4-fluoro-3-(trifluoromethyl)phenylimino)methyl)-4-hydroxy-2H-chromen-2-
one (VNRSC-115) 
Yield: 75%; IR (cm-1): 3678 (O-H str.), 3115, (Ar C=C-H str.), 2953 (Asym C-H str. 
-CH3),2878 (Sym C-H str. -CH3), 2845 (Sym C-H str. -CH2), 1724 (C=O str.), 1552 
,1575  (Ar C=C str.),1354 (C-H bend –CH3), 1015 (C-O str.),  755 (C-H oop def) 541 
(C-F );          1H NMR 400 MHz: (CDCl3, δ ppm): 7.34 (m, 2H), 7.51 (m, 1H), 7.66 
(m, 1H), 8.00 (m, 2H), 8.12 (s, 1H), 8.96 (d, 1H). Mass: [m/z (%)], M. Wt.: 351 ; 
Elemental analysis, Calculated: C, 58.13; H, 2.58; N, 3.99; Found: C, 58.12; H, 
2.71; N, 3.85. 
 
3-((E)-(2-chlorophenylimino)methyl)-4-hydroxy-2H-chromen-2-one (VNRSC-116) 
Yield: 75%; IR (cm-1):), 3615 (O-H str.), 3014, (Ar C=C-H str.), 2983 (Asym C-H 
str. -CH3),2857 (Sym C-H str. -CH3), 2855 (Sym C-H str. -CH2), 1734 (C=O str.), 
1575 ,1505  (Ar C=C str.),1354 (C-H bend –CH3), 1046 (C-O str.), 962 (C-Cl str.), 
786 (C-H oop def);Mass: [m/z (%)], M. Wt.: 299 ; Elemental analysis, Calculated: 
C, 64.12; H, 3.36; N, 4.67; Found: C, 64.14; H, 3.42; N, 4.77. 
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3.10    REPRESENTATIVE SPECTRA 
IR Spectrum of 3-((12E)-(4-hydroxy-7,8-dimethyl-2-oxo-2H-chromen-3-
ylimino)methyl)-4-hydroxy-2H-chromen-2-one (VNRSC-103) 
 
IR Spectrum of 3-((12E)-(4-hydroxy-5,7-dimethyl-2-oxo-2H-chromen-3-
ylimino)methyl)-4-hydroxy-2H-chromen-2-one (VNRSC-105) 
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3.11    RESULT & DISCUSSION 
 
Present work covers the synthesis of some novel Azomethine linked 4-hydroxy 
coumarin molecules. The main significance of the present work is that the reaction is 
carried out with help of Mortar and Pestle, leading to  a solvent free facile synthesis 
with rapid reaction time, easy work up method and excellent yield  of the desired 
compounds. 
 
3.12    CONCLUSION 
 
Total 10 derivatives of 3-((12E)-(4-hydroxy-(substituted)-2-oxo-2H-chromen-3-
ylimino)methyl)-4-hydroxy-2H-chromen-2-one were synthesized. All the newly 
synthesized compounds were characterized by IR, 1H NMR, 13C NMR, Mass 
spectral data and Elemental Analysis.  
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4.1    INTRODUCTION 
 
Dihydropyridines (DHPs) are the important class of organic compounds in view of its 
ample of application in the pharmaceuticals.[1,3] Arthur Hantzsch in 1882 [2] first 
reported the classical synthesis of 1,4-dihydropyridines(1,4-DHPs) which involves 
one pot three-component coupling reaction of 1 equivalent of alkyl or aryl aldehyde, 2 
equivalents of β-ketoester and 1 equivalent of ammonia at reflux temperature using 
either acetic acid or ethanol as a solvent. However, the yield of 1,4-DHPs are 
generally low. Hence numerous methodologies with improved reaction conditions 
have been documented.[3] Many of these still suffer some serious drawbacks such as 
unsatisfactory yields, tedious work-up procedure, occurrence of side reactions 
including aromatization, economically non-viable, long reaction rate, high reaction 
temperature etc. 
To overcome these problems, numerous modifications attempted including new Lewis 
acid catalyst, Zn[L-proline] [4] under microwave condition. The catalyst is also 
recycled up to five runs but it appreciably loss the catalytic activity for the next 
successive runs and ultimately yield loss were observed. 1,4-DHPs were also 
synthesized by using water-ethanol solvent[5] system using MWI, but this process fails 
at high microwave power, because reaction mixture is rapidly heated at high 
microwave power leading to solvent evaporation and hence precipitation of the 
reaction mixture were observed. The synthesis of 1,4-DHPs is also reported in room 
temperature ionic liquids[6] but the rate of reaction is sluggish than the microwave 
counterparts. Of all these methodologies, the ionic liquid medium is the sole protocol 
which allows the recycling of the solvent. There is despite the fact that, unlike several 
of ‘neoteric solvent’ like ionic liquids(ILs) where toxicity and environmental burden 
data are for the most part unknown while complete toxicity profiles are available for a 
range of polyethylene glycol(PEG) molecular weights and indeed, many are already 
approved for internal consumption by US-FDA.[7] Moreover, the vapor density for 
low molecular weight PEG is greater than 1 and this is consistent with the industry 
standard for selection of alternative solvents to Volatile Organic Chemicals (VOCs).[8]   
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4.2    BIOLOGICAL PROFILE OF 1,4-DIHYDROPYRIDINE 
 
The DHP skeleton is common to numerous bioactive compounds which include 
various vasodilator, geroprotective, antihypertensive, bronchodilator, 
antiatherosclerotic, hepatoprotective, antitumor, antimutagenic and antidiabetic 
agents[9-14]. 
 
DHPs nucleolus has number of pharmacologically commercial utility as calcium 
channel blockers, as exemplified by therapeutic agents such as Nifedipine[15] 
Nitrendipine[16] and Nimodipine[17]. Second-generation calcium antagonists include 
DHP derivatives with improved bioavailability, tissue selectivity, and/or stability, 
such as the antihypertensive/antianginal drugs like Elgodipine[18], Furnidipine[19,20], 
Darodipine[21], Pranidipine[22], Lemildipine[23], Dexniguldipine[24], Lacidipine[25], and 
Benidipine[26]. Number of DHP calcium agonists has been introduced as potential 
drug candidates for treatment of congestive heart failure[27, 28]. 
 
The key characteristic of calcium channel blockers is their inhibition of entry of 
calcium ions via a subset of channels, thereby leading to impairment of contraction. 
There are three main groups of calcium channel blockers, i.e. dihydropyridines, 
phenylalkylamines and benzothiazepines, classic examples of which are nifedipine, 
verapamil and diltiazem, respectively[29-32]. Each has a specific receptor on the 
calcium channel and a different profile of pharmacological activity. Dihydropyridines 
have a less negative inotropic effect than phenylalkylamines and benzothiazepines but 
can sometimes cause reflex tachycardia. Dihydropyridines are able to reduce 
peripheral resistance, generally without clinically significant cardiodepression. 
 
Among DHPs with other types of bioactivity, Cerebrocrast[33] has been recently 
introduced as a neuroprotectant and cognition enhancer lacking neuronal-specific 
calcium antagonist properties. In addition, a number of DHPs with platelet 
antiaggregatory activity have also been discovered[34]. These recent examples 
highlight the level of ongoing interest toward new DHP derivatives and have 
prompted us to explore this pharmacophoric scaffold to develope a fertile source of 
bioactive molecules. 
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Some representative Ca2+ antagonists of Dihydropyridine class are as shown below: 
 
 
   
 
 
 
 
 
 
 
In particular, DHP-CA (calcium channel antagonist DHP) are extensively used for the 
treatment of hypertension,[35] subarachnoid hemorrhage,[36,37] myocardial infarction[38-
41] and stable[42, 43] and unstable angina[44,45] even though recently their therapeutic 
efficacy in myocardial infarction and angina has been questioned[46]. This class of 
compounds is also under clinical evaluation for the treatment of heart failure[47], 
ischemic brain damage[48] nephropathies, and atherosclerosis[49]. 
 
1,4- DHPs having  different pharmacological activities such as antitumor[50], 
vasodilator[51], coronary vasodilator and cardiopathic[52], antimayocardiac ischemic, 
antiulcer[53], antiallergic[54], antiinflammatory[55] and antiarrhythmic[56], PAF 
antagonist[57], Adenosine A3 receptor antagonist[58] and MDR reversal activity[59,60]. 
 
It is found recently that when the imidazolyl moiety is linked to the phenyl ring by 
means of a C-N bridge, the activity tends to decrease. Finally, the replacement of 
DHP itself by a pyridine ring gives an inactive compound [61]. 
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Cozzi  et al56 have synthesized a series of 4-phenyl-1,4-dihydropyridines bearing 
imidazol-1-yl or pyridine-3-yl moieties on the phenyl ring, with the aim of combining 
Ca2+ antagonism and thermboxane A2(TxA2) synthase inhibition in the same 
molecules. Some of the compounds showed significant combined activity in vitro, 
while other showed single activity. As far as Ca2+ antagonism is concerned, two 
points deserve comment. First, the SAR, in most cases, does not differ substantially 
from that reported for classic DHP-CA, even though the potency is lower than that 
found with the most potent drugs of this class as, for example, reference compound 
nifedipine. In fact, Ca2+ antagonism is dramatically reduced by (a) replacement of 
DHP by a pyridine ring, (b)    substitution of DHP nitrogen N-1 by a methyl group, (c) 
para substitution on the phenyl ring, and (d) replacement of one ester function by a 
ketone or carboxy group. All these variations are also detrimental in classic DHP-
CA.[62] 
 
Hernandez-Gallegos et al[63] have synthesized new 1,4-dihydropyridines and 
evaluated their relaxant ability (rat aorta), antihypertensive activity in spontaneously 
hypertensive rats and their microsomal oxidation rate (MOR) was determined. 
 
 
 
 
 
 
 
R = 3-NO2, 4-F, 3,5-di-F, 3-Br-4-F
R1 = R2 = Me, Et, -CH2-CF3, -CH2CH2-OPh, -(CH2)2-N(CH3)-CH3-Ph  
Christiaans and Timmerman[64] studied new molecules like CV-159 for possible 
variation at 3-position. 
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Carlos et al[65] reported 1,4-DHPs derivatives with a 1,2-benzothiazol-3-one-1-
sulphoxide group, linked through an alkylene bridge to the C3 carboxylate of the DHP 
ring, with both vasoconstricting and vasorelaxant properties were obtained. In 
blocking Ca2+ evoked contractions of K+ depolarized rabbit aortic strips. Many 
compounds were 10 times more potent than nifedipine. Their vascular versus cardiac 
selectivity was very pronounced. 
 
 
 
 
 
 
Schramm and coworker[66] have proved that phenyl carbamoyl moiety in 
dihydorpyridine affords for cardiovascular selective activity. 
 
Reddy and coworkers[67] synthesized 4-aryl hetroaryl-2,6-dimethyl-3,5-bis-N-(2-
methyl / 2-chloro phenyl)carbamoyl-1,4-dihydropyridines through one-pot synthesis 
using appropriate aromatic aldehydes and liquid ammonia. Pharmacological screening 
of the new 1,4-dihyropyridines were also carried out for CNS depresant 
(anticonvulsant and analgesic) and cardiovascular (inotropic and blood pressure) 
activities by standard methods. 
 
 
 
 
 
Similarly Kelvin Cooper (Pfitzer , USA) et al[68] found that DHP can be highly 
selective as platlet activating factor (PAF) antagonist. They found potent compounds 
and prove that platlet aggregating activity (PAF) exhibits a wide spectrum of 
biological activities elicited either directly or via the release of other powerful 
mediator such as Thromboxane A2 or the Leukotrienes. In vitro PAF stimulates the 
movement and aggregation and the release there from of tissue damaging enzymes 
and oxygen radicals. Accordingly compounds like UK-74505, antagonize the action 
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of PAF and consequently also prevent mediator release by PAF, will have clinical 
utilities in the treatment of the variety of the allergic, inflammatory and 
hypersecretory conditions such as asthama, arthritis, rhinitis, bronchitis and utricaria 
in future. [69] 
 
 
 
 
 
 
Neamati and coworkers[70] reported that a 1,4-dihydorpyridine NCS-372643 came out 
with its anti-HIV activity, which has opened up the synthetic as well as 
pharmacological importance in antiviral area also. 
 
 
 
 
 
Sonja[71] and group have synthesized a new series of calcium channel agonists 
structurally related to Bay K8644, containing NO donor furoxans and the related 
furazans unable to release NO. The racemic mixtures were studied for their action on 
L-type Ca2+ channels expressed in cultured rat insulinoma RINm5F cells. All the 
products proved to be potent calcium channel agonists. 
 
 
 
 
 
 
 
2-Heterosubstituted-4-aryl-l,4-dihydro-6-methyl-5-pyrimidinecarboxylic acid esters, 
which lack  the potential C3 symmetry of dihydropyridine calcium channel blockers, 
were  evaluated for biological  activity. Biological assays using potassium-
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depolarized rabbit aorta and radioligand binding techniques showed that some of 
these compounds are potent mimics of dihydropyridine calcium channel blockers. The 
combination of a branched ester (e.g. isopropyl, sec-butyl) and an alkylthio group 
(e.g. SMe) was found to be optimal for biological activity[72].  
 
 
 
 
 
 
 
Labedipinedilol-A, a novel dihydropyridine-type calcium antagonist, has been shown 
to induce hypotension and vasorelaxation. Liouand co-workers have studied to 
investigate the effect of labedipinedilol-A on vascular function of rat aortic rings and 
cultured human umbilical vein endothelial cells (HUVECs). [73] 
Recent reports show that efonidipine, a dihydropyridine Ca2+ antagonist, has blocking 
action on T-type Ca channels, which may produce favorable actions on cardiovascular 
systems. However, the effects of other dihydropyridine Ca antagonists on T-type Ca 
channels have not been investigated yet. Therefore, Furukawa and group[74] have 
examined the effects of dihydropyridine compounds clinically used for treatment of 
hypertension on a T-type Ca channel subtype, alpha1G, expressed in    Xenopus 
oocytes. Twelve DHPs amlodipine, barnidipine, benidipine, cilnidipine, efonidipine, 
felodipine, manidipine, nicardipine, nifedipine, nilvadipine, nimodipine, nitrendipine) 
and mibefradil were tested. Cilnidipine, felodipine, nifedipine, nilvadipine, 
minodipine, and nitrendipine had little effect on the T-type channel. The blocks by 
drugs at 10 muM were less than 10% at a holding potential of -100 mV. The 
remaining 6 drugs had blocking action on the T-type channel comparable to that on 
the L-type channel. These results show that many dihydropyridine Ca2+ antagonists 
have blocking action on the alpha1G channel subtype. 
Joanna Rzeszowska-Wolny et al reported that compounds of the 1,4-dihydropyridine 
(1,4-DHP) series  have been shown to reduce spontaneous, alkylation- and radiation 
induced mutation rates in animal test systems. Studies using AV-153, the 1,4-DHP 
derivative that showed the highestantimutagenic activity in those tests, to examine if it 
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modulates DNA repair in human peripheral blood lymphocytes and in two human 
lymphoblastoid cell lines.[75] 
 
1,4-Dihydropyridines are now established as heterocycles having numerous 
applications and having widened scope for its pronounced drug activity like calcium 
channel antagonism and antihypertensive action. Many other activities are associated 
with such compounds and they can be presented in the structure as 2,6-dimethyl-3,5-
diacetyl or dicarboxylate or dicarbamoyl or many other homoaryl or heteroaryl carbon 
chain having C2 to C8 1,4-dihydropyridines substituted at 4-position.[76-81] 
 
In continuation of earlier work on DHPs, an improved synthetic protocol is used to 
prepare several structurally diverse 1,4-dihydropyridines.  
In short, in viewing the benignity and superiority of PEG as a solvent over ionic 
liquids and other reported protocols for the synthesis of 1,4-DHPs as mentioned 
earlier, herein we disclose our findings by using PEG-400 as a solvent for the rapid 
microwave assisted multi component reaction (MCR). 
  
4.3    1,4-DIHYDROPYRIDINES AND MANNICH REACTION 
The Mannich reaction is an organic reaction which consists of an amino alkylation of 
an acidic proton placed next to a carbonyl functional group with formaldehyde and 
ammonia or any primary or secondary amine. The final product is a β-amino-carbonyl 
compound also known as a ‘Mannich Base’. Mannich bases are of particular in 
interest due to their application as synthetic building blocks and precursors of 
biologically active compounds. The reaction is named after chemist Carl Mannich.[82] 
The Mannich reaction is an example of nucleophilic addition of an amine to a 
carbonyl group followed by dehydration to the schiff base. The schiff base is an 
electrophile which reacts in the second step in an electrophilic addition with a 
compound containing an acidic proton (which is, or had become an enol).[83] The 
Mannich reaction is also considered a condensation reaction. The Mannich Reaction 
is an important carbon-carbon-bond forming reaction that is commonly employed in 
the synthesis of alkaloid natural products and is involved in a number of biosynthetic 
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pathways.[84] Numerous examples of both direct and indirect Mannich reactions have 
been reported in the literature, some of recent are sited in reference. [85-110] 
Few references are found related to Mannich reaction of 1,4-dihydropyridines. Some 
of them are enlisted below. 
 
Jiro Aritomi et al [111-112] reported Mannich reaction of dialkyl 4-aryl-2,6-dimethyl 
1,4-dihydropyridine-3,5-dicarboxylates with secondary amines and found that the 
reaction proceeds on the 2- and 6- methyl carbon. 
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V. V. Dotsenko et al [113,114] reported the reactions of N-methylmorpholinium 6-
amino-3,5-dicyano-1,4-dihydropyridine-2-thiolates with formaldehyde and primary 
aromatic amines produce 3,5,7,11-tetraaza-tricyclo[7.3.1.02,7]tridec-2-ene-1,9-
dicarbonitrile derivatives. 
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K. A. Frolov et al [115] gave synthesis of derivatives of 3,5,7,11-tetraazatricyclo-
[7.3.1.02,7]tridec-2-ene-8-selenone yield by Mannich reaction of N-methyl-
morpholinium 6-amino-3,5-di-cyano-4-(2-methoxy phenyl)-1,4-dihydropyridine-2-
selenolate with primary amines and excess HCHO. 
 
 
 
 
M Vijey Aanandhi et al [116] demonstrated synthesis, characterization and in-vitro 
antioxidant activity of Mannich bases of 1, 4-dihydro pyridines derivatives. 
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B. B. Subudhi et al [117] reported synthesis and anti-ulcer activity study of 1,4-
dihydropyridines and their mannich bases with sulfanilamides. 
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N
H
H3C CH3
COOEtEtOOC
R
NH3C CH3
COOEtEtOOCHCHO/ EtOH
H2N SO2NH2
NH
SO2NH2
R
Where R=-OH, -OCH3, etc
  
 
Mane D. V. et al [118] synthesized 1,3-Bis- [N-substituted dihydropyridine methylc]-
benzimidazoline-2-thiones I (R= Ph, substituted phenyl; R1 = Me, OMe, OEt) from 
benz-imidazoline-2-thione, various dihydropyridines and paraformaldehyde by 
Mannich reaction and screened for their antimicrobial activities. 
 
 
 
Sielemann Dirk et al [119] gave synthesis of novel functionalized bi- and 
oligopyridines. An annelation reaction is presented in which 1,3-cyclohexanedione 
and Mannich bases derived thereof are used for the preparation of functionalized 
bipyridines I (R = H, n = 1; R = H, n = 0; R = CMe3, n = 1) and dihydropyridine 
derivatives II (n = 0, 1). All these products possess a keto group which will allow 
further transformations. The same concept was applied for the synthesis of the S-
shaped terpyridine III. The reaction of a Mannich base derived from 1,2,3,4,5,6,7,8-
octahydro-4,5-acridinedione with 1,3-cyclohexanedione yielded a heptacyclic 
terpyridine, which is a key intermediate for the synthesis of torands and other 
tridentate clefts. Ketone I (R = H, n = 1) was used for the synthesis of a 
quaterpyridine. 
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Apart from these, Michael et al [120] prepared antihypertensive and coronary 
vasodilator Mannich type N-substituted -1,4-dihydropyridine. 
 
 
 
 
Hung et al [121] were successful in synthesizing antihypertensive model of Flordipine, 
contrary to the belief proposed by Triggle that N-substituted 1,4-dihydropyridine will 
not give good antihypertensive activity, probably the concept of prodrug would not 
have been predicted at that time and –NH was believed to be essential for calcium 
channel antagonism. 
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Earlier, Arthur P. Philips [122-124] reported Mannich bases derived from a Hantzsch 
pyridine synthesis products. Use of Mannich reaction on a phenolic Hantzsch 
synthesis product afforded an alternative type of compound containing a basic chain. 
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Where R= NH(CH3)2,NI(CH3)3, NH(C2H5)2, Piperidine & Morpholine
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4.4    AIM OF WORK 
 
Numerous Dihydropyridines and their derivatives have been reported for their various 
biological activities. These results promoted us to synthesize symmetric 
dihydropyridines and their mannich bases.  
 
4.5    REACTION SCHEME 
 
 
 Preparation of 4-(2-Hydroxy-3-(substitued-1-methyl) phenyl)-2,6-dimethyl-
1,4-dihydropyridine-3,5-dicarbonitrile 
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Where NR1R2= Secondary amines like piperidine, morpholine etc. 
 
 Preparation of 4-(3-Hydroxy-4-(substitued-1-methyl) phenyl)-2,6-dimethyl-
1,4-dihydropyridine-3,5-dicarbonitrile 
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Where NR1R2= Secondary amines like piperidine, morpholine etc. 
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4.6    PLAUSIBLE REACTION MEHCANISM 
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Where NR1R2 = Secondary amines like morpholine, piperidine 
            R3 & R4 = Phenyl ring  
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4.7    EXPERIMENTAL 
 
 Materials and Methods 
Melting points were determined in open capillary tubes and are uncorrected. 
Formation of the compounds was routinely checked by TLC on silica gel-G plates of 
0.5 mm thickness and spots were located by iodine and UV. IR spectra were recorded 
in Shimadzu FT-IR-8400 instrument using KBr Powder method. Mass spectra were 
recorded on Shimadzu GC-MS-QP-2010 model using Direct Injection Probe 
technique. 1H NMR was determined in DMSO-d6/CDCl3 solution on a Bruker 
Avance II 400 MHz NMR Spectrometer. Elemental analysis of the all the 
synthesized compounds was carried out on Elemental Vario EL III Carlo Erba 1108 
model. All the results are in agreements with the structures assigned. 
 
 Preparation of 4-(4-Hydroxy phenyl)-2,6-di-methyl-1,4-dihydropyridine-3,5-
dicarbonitrile 
A mixture of 4-hydroxy benzaldehyde (0.01 M) and 3-amino crotononitrile (0.02 M) 
were taken in glacial acetic acid in a stoppered flask and stirred for 1 hour at 10º-15º 
C. During the reaction, progress and the completion of reaction were checked by 
silica gel-G F254 thin layer chromatography using ethyl acetate: hexane (3:2) as a 
mobile phase. After the completion of the reaction, the crystalline product was 
separated out which was filtered and washed with diethyl ether. 
 
 Preparation of 4-(4-Hydroxy-3-(substitued-1-methyl) phenyl)-2,6-dimethyl-
1,4-dihydropyridine-3,5-dicarbonitrile (General Procedure) 
A mixture of 4-(4-hydroxy phenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-
dicarbonitrile (0.01 M), secondary amine (0.0135 M) and formaldehyde (0.02 M) 
were taken in absolute alcohol in 250 mL round bottom flask. The reaction mixture 
was refluxed for 1-4 hrs at reflux temperature till TLC completed. The progress and 
the completion of the reaction were checked by silica gel-G F254 thin layer 
chromatography using ethyl acetate: hexane (3:2) as a mobile phase. After completion 
of the reaction, the reaction mixture was allowed to cool at room temperature to 
obtain the product. When crystalline product was separated out, it was filtered and 
washed with cold ethanol. Similarly other compounds were also prepared. 
 
Chapter-4                                                                            Synthesis and Characterizatin of… 
 
114 
 
 
 Preparation of 4-(3,4-dihydroxy phenyl)-2,6-dimethyl-1,4-dihydropyridine-
3,5-dicarbonitrile 
A mixture of 3,4-dihydroxy benzaldehyde (0.01 M) and 3-amino crotononitrile (0.02 
M) was taken in glacial acetic acid in a stoppered flask and stirred for 1 hour at room 
temperature. During the reaction, progress and the completion of reaction were 
checked by silica gel-G F254 thin layer chromatography using ethyl acetate: hexane (3: 
2) as a mobile phase. After the completion of the reaction, the crystalline product was 
separated out which was filtered and washed with diethyl ether. 
 
 Preparation of 4-(3,4-dihydroxy-4-(substitued-1-methyl) phenyl)-2,6-
dimethyl-1,4-dihydropyridine-3,5-dicarbonitrile (General Procedure) 
A mixture of 4-(3,4-dihydroxy phenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-
dicarbonitrile (0.01 M), secondary amine (0.0135 M) and formaldehyde (0.02 M) 
were taken in absolute alcohol in 250 mL round bottom flask. The reaction mixture 
was refluxed for 1-4 hrs at reflux temperature till TLC complete. The progress and the 
completion of the reaction were checked by silica gel-G F254 thin layer 
chromatography using ethyl acetate: hexane (3:2) as a mobile phase. After completion 
of the reaction, the reaction mixture was allowed to cool at room temperature to 
obtain the product. When crystalline product was separated out, it was filtered and 
washed with cold ethanol. Similarly other compounds were also prepared. 
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4.8    PHYSICAL DATA 
 
 PHYSICAL DATA TABLE OF 4-(4-HYDROXY-3-(SUBSTITUED-1-
METHYL) PHENYL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE-3,5-
DICARBONITRILES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sr. 
No. 
Sample Code Substitution Molecular 
Formula 
M. Wt MP ºC Yield 
% NR1R2 
1 VMMB 101 N-methyl piperazine C21H25N5O 363.46 211-213 63 
2 VMMB 102 N-ethyl piperazine C22H27N5O 377.48 218-220 66 
3 VMMB 103 N-benzyl piperazine C27H29N5O 439.55 247-249 76 
4 VMMB 104 Morpholine C20H22N4O2 350.41 233-235 72 
5 VMMB 105 N-phenyl piperazine C26H27N5O 425.53 245-247 55 
6 VMMB 106 Piperidine C21H24N4O 348.44 252-254 62 
7 VMMB 107 Pyrollidine C20H22N4O 334.41 242-244 73 
8 VMMB 108 N,N diethyl amine C20H24N4O 336.43 256-258 75 
9 VMMB 111 2-methyl piperidine C22H26N4O 362.47 150-152 75 
10 VMMB 114 Piperazine C20H23N5O 349.43 236-238 78 
N
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NN
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 PHYSICAL DATA TABLE OF 4-(3,4-DIHYDROXY-5-(SUBSTITUED-1-
METHYL) PHENYL)-2,6-DIMETHYL-1,4-DIHYDROPYRIDINE-3,5-
DICARBONITRILES 
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CH3CH3
HO
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Sr. 
No. 
Sample Code Substitution Molecular 
Formula 
M. Wt MP ºC Yield % 
NR1R2 
1 VMMB 501 Piperazine C19H21N5O2 351.4 256-258 64 
2 VMMB 502 N-methyl piperazine C21H25N5O2 379.46 244-246 52 
3 VMMB 503 N-ethyl piperazine C22H27N5O2 393.48 212-214 55 
4 VMMB 504 N-phenyl piperazine C25H25N5O2 427.5 230-232 66 
5 VMMB 505 N-Benzyl piperazine C27H29N5O2 455.55 215-217 72 
6 VMMB 506 Morpholine C20H22N4O3 366.41 233-235 78 
7 VMMB 507 Piperidine C20H22N4O2 350.41 252-254 53 
8 VMMB 508 2-Methyl piperidine C21H24N4O2 364.44 247-249 69 
9 VMMB 511 Pyrolidine C19H20N4O2 336.39 223-225 71 
10 VMMB 514 N,N-diethyl amine C19H22N4O2 338.4 216-218 69 
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4.9    SPECTRAL STUDY 
 
 IR Spectra 
IR spectra of the synthesized compounds were recorded on Shimadzu FT-IR 8400 
model using KBr Powder method. Various functional groups present were identified 
by characteristic frequency obtained for them. 
The stretching frequency of OH group showed at 3650-3600 (O-H str.) cm-1and 
bending vibration at 1410-1310 cm-1. The characteristic band of secondary N-H group 
showed in the region of 3500-3200 cm-1 with a deformation due to in plane bending at 
1650-1550 cm-1. Aromatic C-H stretching and bending frequencies showed between 
3070-3030 cm-1 and 1600-1400 cm-1 respectively. C-H stretching and bending 
frequencies for methyl and methylene group were obtained near 2950-2850 cm-1 and 
1450-1375 cm-1. Characteristic frequency of C≡N showed at 2260-2200 cm-1. 
Characteristic frequency of C-N stretching showed near 1350-1280 cm-1. C-O 
stretching frequency showed at 1230-1140 cm-1. 
   
 Mass Spectra 
Mass spectra of the synthesized compounds were recorded on Shimadzu GC-MS-QP-
2010 model using Direct Injection Probe technique. The molecular ion peak was 
found in agreement with molecular weight of the respective compound. 
 
 1H NMR Spectra 
1H NMR spectra of the synthesized compounds were recorded on Bruker Avance II 
400 MHz NMR Spectrometer by making a solution of samples in DMSO-d6/CDCl3 
solvent using tetramethylsilane (TMS) as the internal standard unless otherwise 
mentioned. Number of protons identified from 1H NMR spectra and their chemical 
shift (δ ppm) were in the agreement of the structure of the molecule. J values were 
calculated to identify o, m and p coupling. In some cases, aromatic protons were 
obtained as multiplet. Interpretations of representative spectra are discussed as under. 
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 13C NMR Spectra 
13C NMR spectra of the synthesized compounds were recorded on Bruker Avance II 
400 MHz NMR Spectrometer by making a solution of samples in DMSO-d6/CDCl3 
solvent using tetramethylsilane (TMS) as the internal standard unless otherwise 
mentioned. Types of carbons identified from NMR spectrum and their chemical shifts 
(δ ppm) were in the agreement with the structure of the molecule.  
 
 Elemental Analysis 
Elemental analysis of the synthesized compounds was carried out on Vario EL Carlo 
Erba 1108 which showed calculated and found percentage values of Carbon, 
Hydrogen and Nitrogen in support of the structure of synthesized compounds.  
The analytical data for individual compounds synthesized in this chapter is mentioned 
below. 
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4.10    SPECTRAL CHARACTERIZATION 
 
1,4-dihydro-4-(4-hydroxy-3-((4-methylpiperazin-1-yl)methyl)phenyl)-2,6-
dimethylpyridine-3,5-dicarbonitrile (VMMB-101) 
Yield: 63%; IR (cm-1): 3550 (O-H str.), 3440 (N-H str.), 3124 (Ar C=C-H str.), 2980 
(Asym C-H str. -CH3), 2930 (Asym C-H str. -CH2), 2870 (Sym C-H str. -CH3), 2845 
(Sym C-H str. -CH2), 2198 (C≡N str.), 1698(N-H bend), 1529,1498, 1500 (Ar C=C 
str.), 1437 (C-H bend –CH2), 1375 (C-H bend –CH3), 1340 (C-N sec amine vib), 1261 
(C-O str.), 767(C-H oop def); 1H NMR 400 MHz: (CDCl3, δ ppm): 2.04 (s, 6H), 
2.30 (s, 3H), 2.57 (m, 8H), 3.71 (s, 2H), 4.21 (s, 1H), 6.84 (d, 1H), 7.05 (m, 2H). 13C 
NMR 400 MHz: (DMSO-d6, δ ppm): 11.5, 51.1, 51.5, 51.9, 52.0, 109.9, 111.4, 
122.1, 123.7, 126.7, 126.8, 140.0, 155.0, 157.7, 163.1 Mass: [m/z (%)], M. Wt.: 363; 
Elemental analysis, Calculated: C, 69.40; H, 6.93; N, 19.27; Found: C, 69.67; H, 
6.87; N, 19.12. 
 
4-(3-((4-ethylpiperazin-1-yl)methyl)-4-hydroxyphenyl)-1,4-dihydro-2,6-
dimethylpyridine-3,5-dicarbonitrile (VMMB-102) 
Yield: 66%; IR (cm-1): 3615 (O-H str.), 3425(N-H str.), 3090 (Ar C=C-H str.), 2972 
(Asym C-H str. -CH3), 2915 (Asym C-H str. -CH2), 2845 (Sym C-H str. -CH3), 2815 
(Sym C-H str. -CH2), 2232 (C≡N str.), 1632 (N-H bend), 1595, 1545, 1420 (Ar C=C 
str.), 1462 (C-H bend –CH2), 1370 (C-H bend –CH3), 1342 (C-N sec amine vib), 1080 
(C-O str.), 799 (C-H oop def); Mass: [m/z (%)], M. Wt.: 377 Elemental analysis, 
Calculated: C, 70.00; H, 7.21; N, 18.55; O, 4.24 Found: C, 70.36; H, 7.83; N, 18.17. 
 
4-(3-((4-benzylpiperazin-1-yl)methyl)-4-hydroxyphenyl)-1,4-dihydro-2,6-
dimethylpyridine-3,5-dicarbonitrile (VMMB-103) 
Yield: 76%; %; IR (cm-1): 3655 (O-H str.), 3546 (N-H str.), 3110 (Ar C=C-H str.), 
2972 (Asym C-H str. -CH3), 2933 (Asym C-H str. -CH2), 2840 (Sym C-H str. -CH3), 
2845 (Sym C-H str. -CH2), 2225 (C≡N str.), 1675 (N-H bend), 1480, 1498, 1500 (Ar 
C=C str.), 1460 (C-H bend –CH2), 1375 (C-H bend –CH3), 1340 (C-N sec amine vib), 
1180 (C-O str.), 810 (C-H oop def);  1H NMR 400 MHz: (CDCl3, δ ppm): 2.04 (s, 
6H), 2.57 (s, 8 H), 3.52 (s, 2H), 3.70 (s, 2H), 4.20 (s, 1H), 6.78 (m, 2H), 7.02 (d, 1H), 
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7.27 (m, 5H. 13C NMR 400 MHz: (DMSO-d6, δ ppm): 11.5, 51.1, 51.5, 51.9, 52.0, 
109.9, 111.4, 122.1, 123.7, 126.7, 126.8, 140.0, 155.0, 157.7, 163.1 Mass: [m/z (%)], 
M. Wt.:   439 ; Elemental analysis, Calculated: C, 73.78; H, 6.65; N, 15.93; Found: 
C, 73.11; H, 6.33; N, 15.40. 
 
1,4-dihydro-4-(4-hydroxy-3-(morpholinomethyl)phenyl)-2,6-dimethylpyridine-3,5-
dicarbonitrile (VMMB-104) 
Yield: 72%; IR (cm-1): 3620 (O-H str.), 3460 (N-H str.), 3017 (Ar C=C-H str.), 2966 
(Asym C-H str. -CH3), 2913 (Asym C-H str. -CH2), 2853 (Sym C-H str. -CH3), 2827 
(Sym C-H str. -CH2), 2201 (C≡N str.), 1663 (N-H bend), 1561, 1521, 1457 (Ar C=C 
str.), 1439 (C-H bend –CH2), 1384 (C-H bend –CH3), 1351-1329 (C-N sec amine 
vib), 1206 (C-O str.), 860-790 (C-H oop def); Mass: [m/z (%)], M. Wt.: 350 ; 
Elemental analysis, Calculated: C, 68.55; H, 6.33; N, 15.99; Found: C, 68.22; H, 
6.29; N, 15.59. 
 
1,4-dihydro-4-(4-hydroxy-3-((4-phenylpiperazin-1-yl)methyl)phenyl)-2,6-
dimethylpyridine-3,5-dicarbonitrile (VMMB-105) 
Yield: 55%; IR (cm-1): 3536 (O-H str.), 3249 (N-H str.), 3140 (Ar C=C-H str.), 
2991(Asym C-H str. -CH3), 2937 (Asym C-H str. -CH2), 2862 (Sym C-H str. -CH3), 
2855 (Sym C-H str. -CH2), 2245 (C≡N str.), 1594 (N-H bend), 1565, 1485, 1465(Ar 
C=C str.), 1474 (C-H bend –CH2), 1359 (C-H bend –CH3), 1340 (C-N sec amine vib), 
1151 (C-O str.), 802(C-H oop def);   Mass: [m/z (%)], M. Wt.: 425 ; Elemental 
analysis, Calculated: C, 73.39; H, 6.40; N, 16.46; Found: C, 73.74; H, 6.48; N, 
16.05. 
 
1,4-dihydro-4-(4-hydroxy-3-((piperidin-1-yl)methyl)phenyl)-2,6-dimethylpyridine-
3,5-dicarbonitrile (VMMB-106) 
Yield: 62%; IR (cm-1): 3586 (O-H str.), 3465 (N-H str.), 3140 (Ar C=C-H str.), 2965 
(Asym C-H str. -CH3), 2912(Asym C-H str. -CH2), 2865 (Sym C-H str. -CH3), 2855 
(Sym C-H str. -CH2), 2215 (C≡N str.), 1615(N-H bend), 1589, 1555, 1495 (Ar C=C 
str.), 1460 (C-H bend –CH2), 1375 (C-H bend –CH3), 1340 (C-N sec amine vib), 1180 
(C-O str.), 810 (C-H oop def); ); Mass: [m/z (%)], M. Wt.: 348 ; Elemental 
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analysis, Calculated: C, 72.39; H, 6.94; N, 16.08; Found: C, 72.63; H, 6.25; N, 
16.84. 
 
1,4-dihydro-4-(4-hydroxy-3-((pyrrolidin-1-yl)methyl)phenyl)-2,6-dimethylpyridine-
3,5-dicarbonitrile (VMMB-107) 
Yield: 73%; IR (cm-1): 3650-3600 (O-H str.), 3500-3200 (N-H str.), 3040 (Ar C=C-H 
str.), 2980 (Asym C-H str. -CH3), 2930 (Asym C-H str. -CH2), 2870 (Sym C-H str. -
CH3), 2845 (Sym C-H str. -CH2), 2260-2200 (C≡N str.), 1650-1580 (N-H bend), 
1580, 1545, 1500 (Ar C=C str.), 1460 (C-H bend –CH2), 1375 (C-H bend –CH3), 
1340 (C-N sec amine vib), 1180 (C-O str.), 810 (C-H oop def);Mass: [m/z (%)], M. 
Wt.: 334 ; Elemental analysis, Calculated:  C, 71.83; H, 6.63; N, 16.75; Found: C, 
71.43; H, 6.88; N, 16.21. 
 
4-(3-((diethylamino)methyl)-4-hydroxyphenyl)-1,4-dihydro-2,6-dimethylpyridine-
3,5-dicarbonitrile (VMMB-108) 
Yield: 75%; IR (cm-1): 3654 (O-H str.), 3280 (N-H str.), 3124 (Ar C=C-H str.), 2980 
(Asym C-H str. -CH3), 2930 (Asym C-H str. -CH2), 2870 (Sym C-H str. -CH3), 2845 
(Sym C-H str. -CH2), 2200 (C≡N str.), 1662 (N-H bend), 1580, 1516,1496 (Ar C=C 
str.), 1460 (C-H bend –CH2), 1375 (C-H bend –CH3), 1340 (C-N sec amine vib), 1180 
(C-O str.), 810 (C-H oop def);  1H NMR 400 MHz: (CDCl3, δ ppm): 1.10 (s, 6H), 
2.04 (s, 6 H), 2.62 (m, 4H), 3.77 (s, 2H), 4.20 (s, 1H), 6.82 (d, 1H), 7.02 (m, 1H), 
7.19 (s, 1H) 13C NMR 400 MHz: (DMSO-d6, δ ppm): 11.5, 51.1, 51.5, 51.9, 52.0, 
109.9, 111.4, 122.1, 123.7, 126.7, 126.8, 140.0, 155.0, 157.7, 163.1 Mass: [m/z (%)], 
M. Wt.:  336 ; Elemental analysis, Calculated: C, 71.40; H, 7.19; N, 16.65; Found: 
C, 71.19; H, 7.24; N, 16.55. 
 
1,4-dihydro-4-(4-hydroxy-3-((2-methylpiperidin-1-yl)methyl)phenyl)-2,6-
dimethylpyridine-3,5-dicarbonitrile (VMMB-111) 
Yield: 75%; IR (cm-1): 3645 (O-H str.), 3462(N-H str.), 3140 (Ar C=C-H str.), 2988 
(Asym C-H str. -CH3), 2939 (Asym C-H str. -CH2), 2850 (Sym C-H str. -CH3), 2835 
(Sym C-H str. -CH2), 2234 (C≡N str.), 1649 (N-H bend), 1650, 1565, 1555 (Ar C=C 
str.), 1467 (C-H bend –CH2), 1375 (C-H bend –CH3), 1349 (C-N sec amine vib), 1087 
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(C-O str.), 820 (C-H oop def);  Mass: [m/z (%)], M. Wt.: 362 ; Elemental analysis, 
Calculated:  C, 72.90; H, 7.23; N, 15.46; Found: C, 72.74; H, 7.72; N, 15.68. 
 
1,4-dihydro-4-(4-hydroxy-3-((piperazin-1-yl)methyl)phenyl)-2,6-dimethylpyridine-
3,5-dicarbonitrile (VMMB-114) 
Yield: 78%; IR (cm-1): 3652 (O-H str.), 3412 (N-H str.), 3140 (Ar C=C-H str.), 2972 
(Asym C-H str. -CH3), 2932 (Asym C-H str. -CH2), 2842 (Sym C-H str. -CH3), 2812 
(Sym C-H str. -CH2), 2260-2200 (C≡N str.), 1650-1580 (N-H bend), 1580, 1545, 
1500 (Ar C=C str.), 1460 (C-H bend –CH2), 1375 (C-H bend –CH3), 1340 (C-N sec 
amine vib), 1180 (C-O str.), 810 (C-H oop def); Mass: [m/z (%)], M. Wt.: 349 ; 
Elemental analysis, Calculated: C, 71.74; H, 7.63; N, 16.04; Found: C, 71.32; H, 
7.13; N, 16.58. 
 
1,4-dihydro-4-(3,4-dihydroxy-5-(piperazin-1-yl)phenyl)-2,6-dimethylpyridine-3,5-
dicarbonitrile (VMMB-501) 
Yield: 64%; IR (cm-1): 3596(O-H str.), 3514 (N-H str.), 3140 (Ar C=C-H str.), 2980 
(Asym C-H str. -CH3), 2930 (Asym C-H str. -CH2), 2870 (Sym C-H str. -CH3), 2845 
(Sym C-H str. -CH2), 2218 (C≡N str.), 1650-1580 (N-H bend), 1580, 1545, 1500 (Ar 
C=C str.), 1460 (C-H bend –CH2), 1375 (C-H bend –CH3), 1340 (C-N sec amine vib), 
1180 (C-O str.), 810 (C-H oop def); 1H NMR 400 MHz: (CDCl3, δ ppm): 2.05 (s, 
6H), 2.04 (s, 6 H), 2.62 (m, 4H), 3.77 (s, 2H), 4.20 (s, 1H), 6.82 (d, 1H), 7.02 (m, 1H), 
7.19 (s, 1H) 13C NMR 400 MHz: (DMSO-d6, δ ppm): 11.5, 51.1, 51.5, 51.9, 52.0, 
109.9, 111.4, 122.1, 123.7, 126.7, 126.8, 140.0, 155.0, 157.7, 163.1 Mass: [m/z (%)], 
M. Wt.: = 351; Elemental analysis, Calculated: C, 64.94; H, 6.02; N, 19.93; 
Found: C, 64.97; H, 6.57; N, 19.74. 
 
 
1,4-dihydro-4-(3,4-dihydroxy-5-((4-methylpiperazin-1-yl)methyl)phenyl)-2,6-
dimethylpyridine-3,5-dicarbonitrile (VMMB-502) 
Yield: 52%; IR (cm-1): 3645 (O-H str.), 3311 (N-H str.), 3124 (Ar C=C-H str.), 2984 
(Asym C-H str. -CH3), 2821 (Sym C-H str. -CH3), 2214 (C≡N str.), 1662 (N-H bend), 
1662, 1498 (Ar C=C str.), 1437 (C-H bend –CH2), 1346 (C-H bend –CH3), 1317 (C-N 
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sec amine vib), 1188 (C-O str.), 823 (C-H oop def); 1H NMR 400 MHz: (CDCl3, δ 
ppm): 2.07 (s, 6H), 2.14 (s, 3 H), 2.68 (m, 6H), 3.61 (m, 2H), 3.70 (s, 2H), 4.10 (s, 
1H), 6.39 (s, 1H), 6.67 (s, 1H), 7.63 (s, 1H), 9.00 (s, 1H)  13C NMR 400 MHz: 
(DMSO-d6, δ ppm): 11.5, 51.1, 51.5, 51.9, 52.0, 109.9, 111.4, 122.1, 123.7, 126.7, 
126.8, 140.0, 155.0, 157.7, 163.1  Mass: [m/z (%)], M. Wt.: 379; Elemental 
analysis, Calculated: C, 66.47; H, 6.64; N, 18.46; Found: C, 66.26; H, 6.75; N, 
18.22. 
 
4-(3-((4-ethylpiperazin-1-yl)methyl)-4,5-dihydroxyphenyl)-1,4-dihydro-2,6-
dimethylpyridine-3,5-dicarbonitrile (VMMB-503) 
Yield: 55%; IR (cm-1): 3621 (O-H str.), 3256 (N-H str.), 3035 (Ar C=C-H str.), 2965 
(Asym C-H str. -CH3), 2914 (Asym C-H str. -CH2), 2856 (Sym C-H str. -CH3), 2854 
(Sym C-H str. -CH2), 2231 (C≡N str.), 1615 (N-H bend), 1608, 1536, 1512 (Ar C=C 
str.), 1452 (C-H bend –CH2), 1381 (C-H bend –CH3), 1347 (C-N sec amine vib), 1179 
(C-O str.), 819 (C-H oop def); Mass: [m/z (%)], M. Wt.: 393; Elemental analysis, 
Calculated: C, 67.15; H, 6.92; N, 17.80; Found: C, 67.41; H, 6.13; N, 17.20. 
 
1,4-dihydro-4-(3,4-dihydroxy-5-(4-phenylpiperazin-1-yl)phenyl)-2,6-
dimethylpyridine-3,5-dicarbonitrile (VMMB-504) 
Yield: 66%; IR (cm-1): 3625 (O-H str.), 3229 (N-H str.), 3124 (Ar C=C-H str.), 3016 
(Asym C-H str. -CH3),  2833 (Sym C-H str. -CH3), 2198 (C≡N str.), 1660 (N-H bend), 
1660, 1599 (Ar C=C str.), 1496 (C-H bend –CH2), 1388 (C-H bend –CH3), 1346 (C-N 
sec amine vib), 1197 (C-O str.), 862 (C-H oop def);  H NMR 400 MHz: (CDCl3, δ 
ppm): 2.05 (s, 6H), 2.54 (s, 4H), 3.21 (s, 4H), 3.74 (s, 2H), 4.10 (d, 1H), 6.44 (d, 1H), 
6.63 (d, 1H), 6.80 (t, 1H), 6.91 (d, 2H), 7.21 (t, 2H), 9.26 (s, 1H)  13C NMR 400 
MHz: (DMSO-d6, δ ppm): 11.5, 51.1, 51.5, 51.9, 52.0, 109.9, 111.4, 122.1, 123.7, 
126.7, 126.8, 140.0, 155.0, 157.7, 163.1  Mass: [m/z (%)], M. Wt.: 427; Elemental 
analysis, Calculated: C, 70.24; H, 5.89; N, 16.38; Found: C, 70.35; H, 5.59; N, 
16.39. 
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4-(3-((4-benzylpiperazin-1-yl)methyl)-4,5-dihydroxyphenyl)-1,4-dihydro-2,6-
dimethylpyridine-3,5-dicarbonitrile (VMMB-505) 
Yield: 72%; IR (cm-1): 3650 (O-H str.), 3498 (N-H str.), 3150 (Ar C=C-H str.), 2960 
(Asym C-H str. -CH3), 2910 (Asym C-H str. -CH2), 2868 (Sym C-H str. -CH3), 2854 
(Sym C-H str. -CH2), 2215 (C≡N str.), 1614 (N-H bend), 1595, 1565, 1502 (Ar C=C 
str.), 1468 (C-H bend –CH2), 1355 (C-H bend –CH3), 1345 (C-N sec amine vib), 1180 
(C-O str.), 789 (C-H oop def); Mass: [m/z (%)], M. Wt.: 455; Elemental analysis, 
Calculated: C, 71.19; H, 6.42; N, 15.37; Found: C, 71.64; H, 6.58; N, 15.81. 
 
1,4-dihydro-4-(3,4-dihydroxy-5-(morpholinomethyl)phenyl)-2,6-dimethylpyridine-
3,5-dicarbonitrile (VMMB-506) 
Yield: 78%; IR (cm-1): 3622(O-H str.), 3468 (N-H str.), 3014 (Ar C=C-H str.), 2955 
(Asym C-H str. -CH3), 2913 (Asym C-H str. -CH2), 2876 (Sym C-H str. -CH3), 2860 
(Sym C-H str. -CH2), 2199 (C≡N str.), 1659 (N-H bend), 1560, 1523, 1508 (Ar C=C 
str.), 1465 (C-H bend –CH2), 1384 (C-H bend –CH3), 1348 (C-N sec amine vib), 1159 
(C-O str.), 870-795 (C-H oop def); Mass: [m/z (%)], M. Wt.: 366; Elemental 
analysis, Calculated: C, 65.56; H, 6.05; N, 15.29; Found: C, 65.50; H, 6.26; N, 
15.79. 
 
1,4-dihydro-4-(3,4-dihydroxy-5-(piperidin-1-yl)phenyl)-2,6-dimethylpyridine-3,5-
dicarbonitrile (VMMB-507) 
Yield: 53%; IR (cm-1): 3612 (O-H str.), 3514 (N-H str.), 3140 (Ar C=C-H str.), 2982 
(Asym C-H str. -CH3), 2930 (Asym C-H str. -CH2), 2870 (Sym C-H str. -CH3), 2845 
(Sym C-H str. -CH2), 2205 (C≡N str.), 1650-1580 (N-H bend), 1680, 1555, 1498 (Ar 
C=C str.), 1462 (C-H bend –CH2), 1378 (C-H bend –CH3), 1345 (C-N sec amine vib), 
1020 (C-O str.), 710 (C-H oop def); Mass: [m/z (%)], M. Wt.:  350; Elemental 
analysis, Calculated: C, 68.55; H, 6.33; N, 15.99; Found: C, 68.30; H, 6.98; N, 
15.10. 
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1,4-dihydro-4-(3,4-dihydroxy-5-(2-methylpiperidin-1-yl)phenyl)-2,6-
dimethylpyridine-3,5-dicarbonitrile (VMMB-508) 
Yield: 69%; IR (cm-1): 3642 (O-H str.), 3586 (N-H str.), 3015 (Ar C=C-H str.), 2994 
(Asym C-H str. -CH3), 2975 (Asym C-H str. -CH2), 2814 (Sym C-H str. -CH3), 2857 
(Sym C-H str. -CH2), 2197 (C≡N str.), 1652 (N-H bend), 1589, 1575, 1585 (Ar C=C 
str.), 1465 (C-H bend –CH2), 1378 (C-H bend –CH3), 1365 (C-N sec amine vib), 
1210(C-O str.), 815 (C-H oop def); Mass: [m/z (%)], M. Wt.: 364; Elemental 
analysis, Calculated: C, 69.21; H, 6.64; N, 15.37; Found: C, 69.95; H, 6.19; N, 
15.75. 
 
1,4-dihydro-4-(3,4-dihydroxy-5-(pyrrolidin-1-yl)phenyl)-2,6-dimethylpyridine-3,5-
dicarbonitrile (VMMB-509) 
Yield: 71%; IR (cm-1): 3575 (O-H str.), 3253 (N-H str.), 3007 (Ar C=C-H str.), 2970 
(Asym C-H str. -CH3), 2917 (Asym C-H str. -CH2), 2873 (Sym C-H str. -CH3), 2826 
(Sym C-H str. -CH2), 2196 (C≡N str.), 1663 (N-H bend), 1543, 1518, 1458 (Ar C=C 
str.), 1438 (C-H bend –CH2), 1385 (C-H bend –CH3), 1326 (C-N sec amine vib), 1176 
(C-O str.), 805 (C-H oop def);  Mass: [m/z (%)], M. Wt.: 336; Elemental analysis, 
Calculated: C, 67.84; H, 5.99; N, 16.66; Found: C, 67.64; H, 5.76; N, 16.62. 
 
4-(3-(diethylamino)-4,5-dihydroxyphenyl)-1,4-dihydro-2,6-dimethylpyridine-3,5-
dicarbonitrile (VMMB-510) 
Yield: 69%; IR (cm-1): 3501(O-H str.), 3595 (N-H str.), 3154 (Ar C=C-H str.), 2985 
(Asym C-H str. -CH3), 2925 (Asym C-H str. -CH2), 2845(Sym C-H str. -CH3), 2814 
(Sym C-H str. -CH2), 2248 (C≡N str.),1580 (N-H bend), 1548, 1535, 1487 (Ar C=C 
str.), 1465 (C-H bend –CH2), 1385 (C-H bend –CH3), 1345(C-N sec amine vib), 
1012(C-O str.), 805(C-H oop def); Mass: [m/z (%)], M. Wt.:  338; Elemental 
analysis, Calculated: C, 71.44; H, 7.55; N, 16.56; Found: C, 71.28; H, 7.33; N, 
16.55. 
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VMMB-108
4.11    REPRASENTATIVE SPECTRA 
IR Spectrum of 1,4-dihydro-4-(4-hydroxy-3-((4-methylpiperazin-1-
yl)methyl)phenyl)-2,6-dimethylpyridine-3,5-dicarbonitrile (VMMB-101) 
 
IR Spectrum of 4-(3-((diethylamino)methyl)-4-hydroxyphenyl)-1,4-dihydro-2,6-
dimethylpyridine-3,5-dicarbonitrile (VMMB-108) 
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Mass Spectrum of 1,4-dihydro-4-(4-hydroxy-3-((4-methylpiperazin-1-
yl)methyl)phenyl)-2,6-dimethylpyridine-3,5-dicarbonitrile (VMMB-101) 
 
Mass Spectrum of 4-(3-((diethylamino)methyl)-4-hydroxyphenyl)-1,4-dihydro-
2,6-dimethylpyridine-3,5-dicarbonitrile (VMMB-108) 
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1H NMR Spectrum of 1,4-dihydro-4-(4-hydroxy-3-((4-methylpiperazin-1-
yl)methyl)phenyl)-2,6-dimethylpyridine-3,5-dicarbonitrile (VMMB-101) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expanded 1H NMR Spectrum of 1,4-dihydro-4-(4-hydroxy-3-((4-
methylpiperazin-1-yl)methyl)phenyl)-2,6-dimethylpyridine-3,5-dicarbonitrile 
(VMMB-101) 
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1H NMR Spectrum of 4-(3-((diethylamino)methyl)-4-hydroxyphenyl)-1,4-
dihydro-2,6-dimethylpyridine-3,5-dicarbonitrile (VMMB-108) 
 
Expanded 1H NMR Spectrum of 4-(3-((diethylamino)methyl)-4-hydroxyphenyl)-
1,4-dihydro-2,6-dimethylpyridine-3,5-dicarbonitrile (VMMB-108) 
 
N
H
H3C
NC
CH3
CN
OH
N
N
H
H3C
NC
CH3
CN
OH
N
 
Chapter-4                                                                            Synthesis and Characterizatin of… 
 
130 
 
1H NMR Spectrum of 1,4-dihydro-4-(3,4-dihydroxy-5-((4-methylpiperazin-1-
yl)methyl)phenyl)-2,6-dimethylpyridine-3,5-dicarbonitrile (VMMB-502) 
 
Expanded 1H NMR Spectrum of 1,4-dihydro-4-(3,4-dihydroxy-5-((4-
methylpiperazin-1-yl)methyl)phenyl)-2,6-dimethylpyridine-3,5-dicarbonitrile 
(VMMB-502) 
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1H NMR Spectrum of 1,4-dihydro-4-(3,4-dihydroxy-5-(4-phenylpiperazin-1-
yl)phenyl)-2,6-dimethylpyridine-3,5-dicarbonitrile (VMMB-504) 
 
Expanded 1H NMR Spectrum of 1,4-dihydro-4-(3,4-dihydroxy-5-(4-
phenylpiperazin-1-yl)phenyl)-2,6-dimethylpyridine-3,5-dicarbonitrile (VMMB-
504) 
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13C NMR Spectrum of 1,4-dihydro-4-(3,4-dihydroxy-5-((4-methylpiperazin-1-
yl)methyl)phenyl)-2,6-dimethylpyridine-3,5-dicarbonitrile (VMMB-502) 
 
Expanded 13C NMR Spectrum of 1,4-dihydro-4-(3,4-dihydroxy-5-((4-
methylpiperazin-1-yl)methyl)phenyl)-2,6-dimethylpyridine-3,5-dicarbonitrile 
(VMMB-502) 
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13C NMR Spectrum of 1,4-dihydro-4-(3,4-dihydroxy-5-(4-phenylpiperazin-1-
yl)phenyl)-2,6-dimethylpyridine-3,5-dicarbonitrile (VMMB-504) 
 
Expanded 13C NMR Spectrum of 1,4-dihydro-4-(3,4-dihydroxy-5-(4-
phenylpiperazin-1-yl)phenyl)-2,6-dimethylpyridine-3,5-dicarbonitrile (VMMB-
504) 
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4.12    RESULT AND DISCUSSION 
 
 
Present work covers the synthesis of some novel Mannich base compounds using 
hydroxy substituted dihydropyridines and different secondary amines with 
formaldehyde. The main significance of the present work is the very rapid and easy 
reaction condition, facile work up method, excellent yield and high chemical purity of 
the desired compounds for biological as well as pharmacological interest. 
 
4.13    CONCLUSION 
 
Herein we reported a Mannich reaction of 1,4-dihydropyridines at C4 phenyl ring 
containing hydroxyl group, as an alternative of N-1 position of 1,4-dihydropyridines.  
The newly synthesized compounds are well characterized by IR, Mass, 1H NMR, 13C 
NMR and Elemental analysis. 
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5.1    INTRODUCTION 
 
Furanocoumarins or furocoumarins, are a class of organic chemical 
compounds produced by a variety of plants. They are biosynthesized partly through 
the phenylpropanoid pathway and the mevalonate pathway, which is biosynthesized 
by a coupling of dimethylallyl pyrophosphate(DMAPP) and 7-
hydroxycoumarin (umbelliferone). 
The chemical structure of furanocoumarins consists of a furan ring fused 
with coumarin. The furan may be fused in different ways producing several isomers. 
The compounds that form the core structure of the two most common isomers 
are psoralen and angelicin. Derivatives of these two core structures are referred to 
respectively as linear and angular furanocoumarins.[1] 
Many furanocoumarins are toxic and are produced by plants as a defense mechanism 
against various types of predators ranging from insects tomammals.[2] This class 
of phytochemical is responsible for the phytophotodermatitis seen in exposure to the 
juices of the wild parsnip and the Giant Hogweed. 
Furanocoumarins have other biological effects as well. For example, in 
humans, bergamottin and dihydroxybergamottin are responsible for the "grapefruit 
juice effect", in which these furanocoumarins affect the metabolism of certain 
drugs.[3] 
Furocoumarins, such as psoralene and the angelicine derivatives are naturally 
occurring compounds. They are known to possess a high photobiological activity [4]. 
Psoralene derivatives have been used for many years in the treatment of skin diseases 
[5]. Furocoumarin/ultraviolet therapy, known as photopheresis, has recently become an 
effective treatment of cutaneous T cell lymphoma, Sezary syndrome and related 
diseases [6,  7]. The photochemotherapeutic effects of furocoumarins are based on 
intercalation of the molecules between the pyrimidine bases of the microorganism’s 
DNA. The intercalation is then followed by the UV light activated cycloaddition 
reactions of furocoumarins with the pyrimidine bases. These [2+2] 
photocycloaddition reactions result in a cross-linking of DNA and prevent a 
microorganism’s reproduction. 
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Psoralens, which are linear furocoumarins, have the highest photosensitivity. Their 
molecules have two active sites in the [2+2] photocycloaddition reactions: the pyrone 
ring and furan ring double bonds. This kind of difunctionality of the psoralens (and of 
the angelicines in to a lesser extent) has been suggested to cause undesirable side 
effects in their medical use. Mutagenicity and carcinogenicity should be mentioned 
among these side effects of some psoralens [8‐14]. 
Even though some methods of furocoumarin synthesis have been known for a long 
time, the 
successful use of furocoumarins as effective medicines requires access to as many 
new derivatives as possible. For example, it has been found that furocoumarin analogs 
that contain other heteroatoms besides the oxygen atom in the lactone ring are free of 
some side effects [7]. Better intercalation properties and higher hydrophilicity should 
be also specific for new furocoumarins recommended for pharmaceutical testing. 
Therefore, the search for new synthetic approaches to the fucoumarins and their 
analogous heterocyclic compounds is a promising trend in photochemotherapy [15‐22]. 
 
Natural Furo coumarins: 
Linear Furo coumarins 
Psoralen[23] (also called psoralene) is the parent compound in a family of natural 
products known as furocoumarins. It is structurally related tocoumarin by the addition 
of a fused furan ring, and may be considered as a derivative of umbelliferone. 
Psoralen occurs naturally in the seeds of Psoralea corylifolia, as well as in 
the common fig, celery, parsley and West Indian satinwood. It is widely used 
in PUVA (=Psoralen +UVA) treatment for psoriasis, eczema, vitiligo, and cutaneous 
T-cell lymphoma. Many furocoumarins are extremely toxic to fish, and some are 
indeed used in streams in Indonesia to catch fish. 
OO O  
Bergamottin[24] is a natural furocoumarin found principally in grapefruit juice. It is 
also found in the oil of bergamot, from which it was first isolated and from which its 
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name is derived. To a lesser extent, bergamottin is also present in the essential oils of 
other citrus fruits. Along with the chemically related compound 6’,7’-
dihydroxybergamottin, it is believed to be responsible for the grapefruit juice effect in 
which the consumption of the juice affects the metabolism of a variety of 
pharmaceutical drugs. 
O OO
O
 
Bergapten [25]  (5-methoxypsoralen) is a psoralen (also known as furocoumarins) 
found in bergamot essential oil and many other citrus essential oils, and is the 
chemical in bergamot oil that causes phototoxicity. 
OO O
O
 
Imperatorin[26] is a furocoumarin and a phytochemical that has been isolated from 
Urena lobata L. (Malvaceae). It is biosynthesized from umbelliferone, a coumarin 
derivative.  Psoralen (also called psoralene) is the parent compound in a family of 
natural products known as furocoumarins. It is structurally related to coumarin by the 
addition of a fused furan ring, and may be considered as a derivative of umbelliferone. 
Psoralen occurs naturally in the seeds of Psoralea corylifolia, as well as in the 
common fig, celery, parsley and West Indian satinwood. It is widely used in PUVA 
(=Psoralen +UVA) treatment for psoriasis, eczema, vitiligo, and Cutaneous T-cell 
Lymphoma.  
OO O
O
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Although safe to mammals, it should be used with care since many furocoumarins are 
extremely toxic to fish, and some are indeed used in streams in Indonesia to catch 
fish. 
Xanthotoxin[27], also known as Methoxsalen (marketed under the trade name 
Oxsoralen) is a drug used to treat psoriasis, eczema, vitiligo, and some cutaneous 
Lymphomas in conjunction with exposing the skin to sunlight. Methoxsalen modifies 
the way skin cells receive the UVA radiation, allegedly clearing up the disease. The 
dosage comes in 10mg tablets, which are taken in the amount of 30mg 75 minutes 
before a PUVA light treatment. The substance is also present in bergamot oil which is 
used in many perfumes and aromatherapy oils. 
OO O
O
 
 
Angular Furo coumarins: 
Angelicin[28] is an angular furocoumarin, a DNA intercalator and crosslinker with 
diverse photobiological effects. Upon long wavelength UV irradiation, forms 
monoadduct with double-stranded DNA and react with unsaturated fatty acids. 
Inhibits DNA and RNA synthesis and cell replication in Ehrlich ascites tumor cells. 
Angelicin is used as tranquilliser, sedative, or anticonvulsant. 
O OO
 
5,6-Dihydroxyangelicin[29] is a natural angular furocoumarin isolated from the root of 
Angelica glabra Makino and from the fruits of Ligusticum acutilobum. 
O OO
OHOH
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Lanatin[30] is a natural furocoumarin extracted from Heracleum thomsoni. 
O OO
O
 
Heratomin[31] is a furocoumarin extracted from Heracleum Thomsoni. Inhibitor of 
insect cytochromes P450. 
O OO
O
 
 
 
Synthesis of some Naturally occurring furo coumarins: 
O
OH
NH2
Phenylalanine
O OHO
OO O
OO O
OO O
OO O
OO O
OCH3
OCH3
O
Bergapton
XanthotoxinImperatorin
OO
H3CO
O
Sphondin
Angelicin
7-hydroxy coumarin
Psoralen
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5.2 SYNTHETIC ASPECT 
 
Acylhydroxyheteroarenes are convenient intermediates in furoheteroarene synthesis. 
The key reaction for preparation of these intermediates is the Fries rearrangement of 
acyloxyheteroarenes. 
Nevertheless, this reaction with heteroarene derivatives has not been studied much 
when compared with that of benzene derivatives. 
 
Condensation of α-haloketones, as shown in Scheme 14 for the preparation of 
angelicine derivative[32]. 
 
O
O
HO O X
R1
O
R2 K2CO3
CH3CN O OO
R1
O
R1=CH3, C6H5, p-CH3OC6H4, p-ClC6H4, OC2H5
R2= H, CO2C2H5
X=Cl, Br
 
 
Base-catalyzed condensation of acylhydroxycoumarins with ethyl chloroacetate is 
also a useful reaction for preparation of psoralen derivatives, as exemplified in 
Scheme 15 by the synthesis of a substituted psoralen[32] . 
 
O O
O
HO
Cl
OC2H5
O
K2CO3
CH3CN O OOO
C2H5O
 
 
The microwave promoted tandem Claisen rearrangement-cyclization reaction of 
allyloxycoumarins in the presence of BF3 / ether directly produces the 
dihydrofuranocoumarins in good yields, the products obtained by microwave 
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irradiation in N-methylformamide, NMF, can be purified with more ease, since NMF 
is soluble in water. The results clearly show that the rearrangement of 
allyloxycoumarins to allylcoumarins and preparation of 
dihydrofuranocoumarins via tandem Claisen rearrangement-cyclization reaction of 
allyloxycoumarins in the presence of BF3 / ether using microwave irradiation are the 
best alternative for preparation of these compounds[33]. 
OO O OHO O
OHO O O OO
H2SO4
N,N-DEA
Reflux, 24 h
 
 
New derivatives of coumarin and angelicin, 8-acetyl-7-cyanomethoxy-4-methyl-
chromen-2-one, 8-acetyl-7-ethoxycarbonylmethoxy-4-methyl-chromen-2-one, 8-
cyano-4,9-dimethyl-2H-furo[2,3-h]-1-chromen-2-one, and 8-ethoxycarbonyl-4,9-
dimethyl-(2H-furo[2,3-h]-1-chromen-2-one) were obtained by conventional synthesis 
and by efficient and high-yielding microwave-assisted synthesis[34].  
OR1O
O
O
chloroacetonitrile or
ethyl chloro acetate
K2CO3
Acetone
OHO
O
O
chloroacetonitrile or
ethyl chloroacetate
O OO
R2
K2CO3
1-methyl-2-pyrrolidone
R1= -CH2CN, CH2COOC2H5 R2= CN, COOC2H5
 
 
7-Chloroacetoxycoumarins 1a-d undergo unusual  Fries rearrangement with 
dihydrofuro[2,3-h]coumarin-9-ones 2a-d formation (Scheme 1)[35] 
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O O
R1
R2
O
O
Cl
AlCl3
O O
R1
R2
O O O
R1
O
O
O
2 a-d 3 a-b
a: R1=R2=H; b: R1=Me, R2=H; c: R1=Me, R2=Cl; d: R1=Me, R2=Et
 
Propargyloxycoumarins with BF3/Et2O and DMF resulted to pyranocoumarins, while 
with NMF gave furocoumarins.  
The treatment of 8-propargyloxy-benzo[f]coumarin with boron trifluoride diethyl 
etherate in N,N-dimethylformamide under reflux or MW irradiation resulted in 
pyrano[3,2-h]benzo[f] coumarin , while the furo[3,2-h]benzo[f]coumarin is received 
from the treatment with N-methylformamide under MW irradiation[36].  
O
O
O O
O
OO
O
O
NMF
BF3/Et2O
DMF
 
Regioselective synthesis of dihydrofurocoumarins and dihydropyranocoumarins in 
excellent yields from 4-prop-2-ynyloxy coumarin via a thiol mediated radical reaction 
is described. Alkenyl radicals are generated from easily available terminal alkynes 
and thiophenol. Thiophenol catalyzed the Claisen rearrangement of the 4-prop-2-
ynyloxycoumarin ethers[37].  
O O
O
SPh
H
R
O O
O
R
O O
R
O
SPh
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A simple and efficient synthesis of furo[3,2-c]coumarin derivatives from 4-
hydroxycoumarin and α-haloketones via a tandem O-alkylation/cyclisation protocol is 
described[38]. 
O O
OH
X R
R1 O
AcOH/AcONH4 
or piperidine
Toluene
O O
O
R
R1
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5.3    AIM OF CURRENT WORK 
 
Even though some methods of furocoumarin synthesis have been known for a long 
time, the successful use of furocoumarins having effective biological activity requires 
access to as many new derivatives as possible. With this aim several furo coumarins, 
having substituted aromatics attached to furan ring of furo coumarins were 
synthesized. 
 
5.4    REACTION SCHEME 
 
O
OH
Br O
OO
OOH
HCHO
EtOHR1
R1
R1
O
R1 = -CH3, -diCH3  
 
O
OH
Br
O
R2
O
O
O
O
OH
O
R2
R2 = -OH, -OCH3, -Cl, -F etc.
EtOH
Reflux
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5.5    EXPERIMENTAL 
Preparation of 2,3-dihydro-2-[2-hydroxybenzoyl]-4H-furo[3,2-c][1]benzopyran-
4-one. (General Method) 
3-bromo 4-hydroxy coumarin (0.01 mmol) was dissolved in ethanol (40 ml) and 
further water was added (40 ml). To this formaldehyde (0.004 mmol) was added and 
the solution heated on boiling water-bath for 15 min. The yellowish mass which 
separated was filtered, washed with water, dried and crystallized from methanol to 
give 2,3-dihydro-2-[2-hydroxybenzoyl]-4H-furo[3,2-c][1]benzopyran-4-one as 
feathery needles. The purity of the compound is checked by TLC. (Chloroform: 
Methanol :: 9:1).  [39] 
 
Preparation of 2,3-dihydro-2-(2-hydroxybenzoyl)-3-phenyl-4H-furo[3,2-
c][1]benzopyran-4-one. (General Method) 
To 3-bromo 4-hydroxy coumarin (0.01 mmol) in ethanol (25 ml) was added 
substituted benzaldehyde (0.012 mmol) and the mixture refluxed for 10-18 hr. Work-
up and crystallization from ethanol yielded 2,3-dihydro-2-(2-hydroxybenzoyl)-3-
phenyl-4H-furo[3,2-c][1]benzopyran-4-one. The purity of the compound is checked 
by TLC. (Chloroform: Methanol :: 9:1). [39] 
Similarly other derivatives were also synthesized on basis of above two general 
methods. 
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5.6    PHYSICAL DATA  
 PHYSICAL DATA TABLE OF 3-((12E)-(SUBSTITUTED 4-HYDROXY-2-
OXO-2H-CHROMEN-3-YLIMINO)METHYL)-4-HYDROXY-2H-
CHROMEN-2-ONES 
 
Sr. 
No Code Structure 
Molecular 
formula 
Molec
u-lar 
weight 
M. P. 
(oC) 
% 
Yield 
1 VNRFC-101 
O
O
O
OH
O
OMe
OMe
C26H20O7 444.12 
148-
150 35% 
2 VNRFC-102 O
O
O
OH
O
OH
 
C24H16O6 400.38 
190-
192 18% 
3 VNRFC-103 
O
O
O
OH
O
OMe
C25H18O6 414.41 
135-
137 35% 
4 VNRFC-104 O
O
O
OH
O
C28H18O5 434.44 
188-
190 27% 
5 VNRFC-105 O
O
O
OH
O
C24H16O5 384.38 
125-
127 55% 
6 VNRFC-106 
O
O
O
OH
O
F
C24H15FO5 402.37 
187-
189 26% 
7 VNRFC-107 O
O
O
OH
O
Cl
C24H15ClO5 418.83 
122-
124 28% 
8 VNRFC-108 
O
O
O
OH
O
C21H18O5 350.36 
110-
112 30% 
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9 VNRFC-109 O
O
O
OH
OS
C22H18O5S 394.44 
152-
154 15% 
10 VNRFC-110 
O
O
O
OH
O
Me
C25H18O5 398.41 
170-
172 38% 
11 VNRFC-115 
O
O
O
OH
O
C18H12O5 308.28 
212-
214[39] 67% 
12 VNRFC-116 
O
O
O
OH
O
C20H16O5 336.34 
198-
200 62% 
13 VNRFC-117 
O
O
O
OH
O
C22H20O5 364.39 
208-
210 55% 
14 VNRFC-118 
O
O
O
OH
O
C22H20O5 364.39 
192-
194 57% 
15 VNRFC-119 
O
O
O
OH
O
C22H20O5 364.39 
180-
182 55% 
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5.7  SPECTRAL STUDY 
 IR spectra 
Infra Red spectra were taken on Shimadzu FT-IR-8400 spectrometer using KBr 
pellet method. The characteristic aromatic group in furocoumarin moiety is observed 
at 3010-3090 cm-1. Methylene (-CH2) observed at 1375 cm-1.  
 1H NMR spectra 
1H NMR spectra were recorded on a Bruker AC 400 MHz NMR spectrometer using 
TMS (Tetramethyl Silane) as an internal standard and DMSO-d6 as a solvent. In the 
NMR spectra of 2-(2-hydroxy benzoyl) 3-(substituted phenyl) 2,3-dihydrofuro[3,2-
c]chromen-4-one derivatives various proton values of methylene (-CH2), methyl (-
CH3) and aromatic protons (Ar-H) etc. were observed. 
 Mass spectra 
The mass spectrum of compounds were recorded by Shimadzu GC-MS-QP-2010  
spectrometer. The mass spectrum of compounds was obtained by positive chemical 
ionization mass spectrometry. The molecular ion peak and the base peak in all 
compounds were clearly obtained in mass spectral study. The molecular ion peak 
(M+) values are in good agreement with molecular formula of all the compounds 
synthesized.  
 Elemental analysis 
Elemental analysis of the synthesized compounds was carried out on Vario EL-III 
Carlo Erba 1108 model at Saurashtra University, Rajkot which showed calculated 
and found percentage values of Carbon, Hydrogen and Nitrogen in support of the 
structure of synthesized compounds. The elemental analysis data are given for 
individual compounds. 
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5.8  SPECTRAL CHARACTERIZATION 
2-(2-hydroxy benzoyl) 3-(3,4-dimethoxy phenyl) 2,3-dihydrofuro[3,2-c]chromen-4-
one (VNRFC-101) 
Yield: 35%; IR (cm-1): 3535 (O-H str.), 3052 (Ar C=C-H str.), 2980 (Asym C-H str. -
CH3), 2950 (Asym C-H str. -CH2), 2885 (Sym C-H str. -CH3), 2825 (Sym C-H str. -
CH2), 1740 (-C=O str.), 1632, 1617, 1575 (Ar C=C str.), 1458 (C-H bend –CH2), 
1371 (C-H bend –CH3), 1176 (C-O str.) , 965 (-C-Cl str.), 715 (C-H oop def); Mass: 
[m/z (%)], M. Wt.: 444; Elemental analysis, Calculated: C, 70.26; H, 4.54; O, 
25.20 Found: C, 70.27; H, 4.12; O, 25.67. 
 
2-(2-hydroxy benzoyl) 3-(2-hydroxy phenyl) 2,3-dihydrofuro[3,2-c]chromen-4-one 
(VNRFC-102) 
Yield: 18%; IR (cm-1): 3547 (O-H str.), 3053 (Ar C=C-H str.), 2948 (Asym C-H str. -
CH2), 2833 (Sym C-H str. -CH2), 1727 (-C=O str.), 1648, 1619, 1568 (Ar C=C str.), 
1477 (C-H bend –CH2), 1164 (C-O str.), 958 (-C-Cl str.), 721 (C-H oop def); Mass: 
[m/z (%)], M. Wt.: 400 Elemental analysis, Calculated: C, 72.00; H, 4.03; O, 23.98 
Found: C, 72.09; H, 4.15; O, 23.53. 
 
2-(2-hydroxy benzoyl) 3-(4-methoxy phenyl) 2,3-dihydrofuro[3,2-c]chromen-4-one 
(VNRFC-103) 
Yield: 35%; %; IR (cm-1): 3547 (O-H str.), 3070 (Ar C=C-H str.), 2970 (Asym C-H 
str. -CH3), 2938 (Asym C-H str. -CH2), 2882 (Sym C-H str. -CH3), 2833 (Sym C-H 
str. -CH2), 1735 (-C=O str.), 1643, 1624, 1562 (Ar C=C str.), 1475 (C-H bend –CH2), 
1369 (C-H bend –CH3), 1177 (C-O str.), 722 (C-H oop def); Mass: [m/z (%)], M. 
Wt.:   414 ; Elemental analysis, Calculated: C, 72.46; H, 4.38; O, 23.16; Found: C, 
72.61; H, 4.33; O, 23.26. 
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2-(2-hydroxy benzoyl) 3-(naphthalene) 2,3-dihydrofuro[3,2-c]chromen-4-one 
(VNRFC -104) 
Yield: 27%; IR (cm-1): 3544 (O-H str.), 3068 (Ar C=C-H str.), 2946 (Asym C-H str. -
CH2), 2837 (Sym C-H str. -CH2), 1724 (-C=O str.), 1631, 1609, 1565 (Ar C=C str.), 
1456 (C-H bend –CH2), 1176 (C-O str.), 712 (C-H oop def); Mass: [m/z (%)], M. 
Wt.: 434 ; Elemental analysis, Calculated: C, 77.41; H, 4.18; O, 18.41; Found: C, 
77.21; H, 4.28; O, 18.51. 
 
2-(2-hydroxy benzoyl) 3-(phenyl) 2,3-dihydrofuro[3,2-c]chromen-4-one (VNRFC -
105) 
Yield: 55%; IR (cm-1):3556 (O-H str.), 3073 (Ar C=C-H str.), 2949 (Asym C-H str. -
CH2), 2838 (Sym C-H str. -CH2), 1725 (-C=O str.), 1643, 1618, 1577 (Ar C=C str.), 
1465 (C-H bend –CH2), 1182 (C-O str.), 724 (C-H oop def); Mass: [m/z (%)], M. 
Wt.: 384 ; Elemental analysis, Calculated: C, 74.99; H, 4.20; O, 20.81; Found: C, 
74.15; H, 4.27; O, 20.05. 
 
2-(2-hydroxy benzoyl) 3-(4-fluoro phenyl) 2,3-dihydrofuro[3,2-c]chromen-4-one 
(VNRFC -106) 
Yield: 26%; IR (cm-1): 3546 (O-H str.), 3072 (Ar C=C-H str.), 2942 (Asym C-H str. -
CH2), 2841 (Sym C-H str. -CH2), 1723 (-C=O str.), 1642, 1614, 1574 (Ar C=C str.), 
1464 (C-H bend –CH2), 1177 (C-O str.), 720 (C-H oop def), 668 (C-F str.); Mass: 
[m/z (%)], M. Wt.: 402 ; Elemental analysis, Calculated: C, 71.64; H, 3.76; O, 
19.88; Found: C, 71.65; H, 3.44; O, 19.78. 
 
2-(2-hydroxy benzoyl) 3-(2-chloro phenyl) 2,3-dihydrofuro[3,2-c]chromen-4-one 
(VNRFC-107) 
Yield: 28%; IR (cm-1): 3550 (O-H str.), 3068 (Ar C=C-H str.), 2941 (Asym C-H str. -
CH2), 2835 (Sym C-H str. -CH2), 1730 (-C=O str.), 1639, 1612, 1572 (Ar C=C str.), 
1469 (C-H bend –CH2), 1176 (C-O str.), 962 (-C-Cl str.), 719 (C-H oop def); 1H 
NMR 400 MHz: (CDCl3, δ ppm): 4.22 (s, 1H), 6.33 (s, 1H), 7.39 (m, 8H), 7.53 (s, 
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1H), 4.20 (s, 1H), 6.82 (d, 1H), 7.02 (m, 1H), 7.19 (s, 1H); Mass: [m/z (%)], M. Wt.: 
334(M+), 336(M+2) ; Elemental analysis, Calculated:  C, 68.82; H, 3.61; O, 19.10 
Found: C, 68.73; H, 3.58; O, 19.05. 
 
2-(2-hydroxy benzoyl) 3-(isopropyl) 2,3-dihydrofuro[3,2-c]chromen-4-one (VNRFC 
-108) 
Yield: 30%; IR (cm-1): 3538 (O-H str.), 3077 (Ar C=C-H str.), 2934 (Asym C-H str. -
CH2), 2857 (Sym C-H str. -CH3), 2833 (Sym C-H str. -CH2), 1738 (-C=O str.), 1642, 
1619, 1574 (Ar C=C str.), 1463 (C-H bend –CH2), 1362, 1380 (isopropyl bend.), 1374 
(C-H bend –CH3), 1174 (C-O str.), 718 (C-H oop def); Mass: [m/z (%)], M. Wt.:  
350 ; Elemental analysis, Calculated: C, 71.99; H, 5.18; O, 22.83; Found: C, 71.89; 
H, 5.22; O, 22.67. 
 
2-(2-hydroxy benzoyl) 3-(tetrahydrothiophen-2-yl) 2,3-dihydrofuro[3,2-c]chromen-
4-one (VNRFC -109) 
Yield: 15%; IR (cm-1): 3553 (O-H str.), 3069 (Ar C=C-H str.), 2937 (Asym C-H str. -
CH2), 2831 (Sym C-H str. -CH2), 1733 (-C=O str.), 1642, 1617, 1576 (Ar C=C str.), 
1466 (C-H bend –CH2), 1178 (C-O str.), 732 (C-H oop def);  Mass: [m/z (%)], M. 
Wt.: 394 ; Elemental analysis, Calculated:  C, 66.99; H, 4.60; O, 20.28; Found: C, 
66.83; H, 4.62; N, 20.31. 
 
2-(2-hydroxy benzoyl) 3-(tetrahydrothiophen-2-yl) 2,3-dihydrofuro[3,2-c]chromen-
4-one (VNRFC -110) 
Yield: 38%; IR (cm-1): 3554 (O-H str.), 3078 (Ar C=C-H str.), 2968 (Asym C-H str. -
CH3), 2942 (Asym C-H str. -CH2), 2875 (Sym C-H str. -CH3), 2836 (Sym C-H str. -
CH2), 1742 (-C=O str.), 1644, 1626, 1567 (Ar C=C str.), 1481 (C-H bend –CH2), 
1372 (C-H bend –CH3), 1173 (C-O str.), 719 (C-H oop def); Mass: [m/z (%)], M. 
Wt.: 398 ; Elemental analysis, Calculated: C, 75.37; H, 4.55; O, 20.08; Found: C, 
75.33; H, 4.17; O, 20.12. 
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2-(2-hydroxy benzoyl) 2,3-dihydrofuro[3,2-c]chromen-4-one (VNRFC -115) 
Yield: 67%; IR (cm-1): 3565 (O-H str.), 3082, 3049 (Ar C=C-H str.), 2906 (Asym C-
H str. -CH2), 2880 (Sym C-H str. -CH2), 1743 (-C=O str.), 1624, 1595, 1546 (Ar C=C 
str.), 1450 (C-H bend –CH2), 1153 (C-O str.), 962 (-C-Cl str.), 719 (C-H oop def); 1H 
NMR 400 MHz: (CDCl3, δ ppm): 3.11 (m, 1H), 3.65 (m, 1H), 6.97 (t, 1H), 7.04 (d, 
1H), 7.41 (m, 2H), 7.53 (t, 1H), 7.67 (m, 1H), 7.74 (m, 1H), 7.85 (m, 1H) Mass: [m/z 
(%)], M. Wt.: = 308; Elemental analysis, Calculated: C, 70.13; H, 3.92; O, 25.95; 
Found: C, 70.08; H, 3.85; O, 25.78. 
 
2-(2-hydroxy 6-methyl benzoyl) 2,3-dihydrofuro[3,2-c]chromen-4-one (VNRFC -
116) 
Yield: 62%; IR (cm-1): 3552 (O-H str.), 3068 (Ar C=C-H str.), 2971 (Asym C-H str. -
CH3), 2935 (Asym C-H str. -CH2), 2883 (Sym C-H str. -CH3), 2829 (Sym C-H str. -
CH2), 1732 (-C=O str.), 1645, 1627, 1559 (Ar C=C str.), 1477 (C-H bend –CH2), 
1371 (C-H bend –CH3), 1175 (C-O str.), 721 (C-H oop def); Mass: [m/z (%)], M. 
Wt.: 336; Elemental analysis, Calculated: C, 71.42; H, 4.79; O, 23.78 Found: C, 
71.35; H, 4.74; O, 23.82. 
 
2-(2-hydroxy 3,4-dimethyl benzoyl) 2,3-dihydrofuro[3,2-c]chromen-4-one (VNRFC 
-117) 
Yield: 55%; IR (cm-1): 3546 (O-H str.), 3073 (Ar C=C-H str.), 2975 (Asym C-H str. -
CH3), 2942 (Asym C-H str. -CH2), 2884 (Sym C-H str. -CH3), 2836 (Sym C-H str. -
CH2), 1732 (-C=O str.), 1641, 1628, 1566 (Ar C=C str.), 1471 (C-H bend –CH2), 
1371 (C-H bend –CH3), 1174 (C-O str.), 722 (C-H oop def); Mass: [m/z (%)], M. 
Wt.: 364; Elemental analysis, Calculated: C, 72.51; H, 5.53; O, 21.95; Found: C, 
72.38; H, 5.85; O, 21.77. 
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2-(2-hydroxy 3,5-dimethyl benzoyl) 2,3-dihydrofuro[3,2-c]chromen-4-one (VNRFC 
-118) 
Yield: 57%; IR (cm-1): 3550 (O-H str.), 3074(Ar C=C-H str.), 2968 (Asym C-H str. -
CH3), 2935 (Asym C-H str. -CH2), 2883 (Sym C-H str. -CH3), 2835 (Sym C-H str. -
CH2), 1732 (-C=O str.), 1644, 1627, 1561 (Ar C=C str.), 1476 (C-H bend –CH2), 
1373 (C-H bend –CH3), 1174 (C-O str.), 720 (C-H oop def); Mass: [m/z (%)], M. 
Wt.: 364; Elemental analysis, Calculated: C, 72.51; H, 5.53; O, 21.95; Found: C, 
72.63; H, 5.59; O, 21.44. 
 
2-(2-hydroxy 4,6-dimethyl benzoyl) 2,3-dihydrofuro[3,2-c]chromen-4-one (VNRFC 
-119) 
Yield: 55%; IR (cm-1): 3545 (O-H str.), 3068 (Ar C=C-H str.), 2971 (Asym C-H str. -
CH3), 2942 (Asym C-H str. -CH2), 2885 (Sym C-H str. -CH3), 2837 (Sym C-H str. -
CH2), 1732 (-C=O str.), 1638, 1614, 1557 (Ar C=C str.), 1478 (C-H bend –CH2), 
1374 (C-H bend –CH3), 1175 (C-O str.), 719 (C-H oop def); Mass: [m/z (%)], M. 
Wt.: 364; Elemental analysis, Calculated: C, 72.51; H, 5.53; O, 21.95; Found: C, 
72.45; H, 5.59; O, 21.88. 
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5.9  REPRESENTATIVE SPECTRA 
IR spectrum of 2-(2-hydroxy benzoyl) 3-(2-chloro phenyl) 2,3-dihydrofuro[3,2-
c]chromen-4-one (VNRFC-107) 
 
IR spectrum of 2-(2-hydroxy benzoyl) 2,3-dihydrofuro[3,2-c]chromen-4-one 
(VNRFC-115) 
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Mass spectrum of 2-(2-hydroxy benzoyl) 3-(2-chloro phenyl) 2,3-
dihydrofuro[3,2-c]chromen-4-one (VNRFC-101) 
 
Mass spectrum of 2-(2-hydroxy benzoyl) 2,3-dihydrofuro[3,2-c]chromen-4-one 
(VNRFC -115) 
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1H NMR spectrum of 2-(2-hydroxy benzoyl) 3-(2-chloro phenyl) 2,3-
dihydrofuro[3,2-c]chromen-4-one (VNRFC-107) 
 
Expanded 1H NMR spectrum of 2-(2-hydroxy benzoyl) 3-(2-chloro phenyl) 2,3-
dihydrofuro[3,2-c]chromen-4-one (VNRFC-107) 
 
 
 
O
O
O
OH
O
Cl
O
O
O
OH
O
Cl
 
Chapter-5                                                                               Facile Synthesis of some novel… 
 
165 
 
1H NMR spectrum of 2-(2-hydroxy benzoyl) 2,3-dihydrofuro[3,2-c]chromen-4-
one (VNRFC -115) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expanded 1H NMR spectrum of 2-(2-hydroxy benzoyl) 2,3-dihydrofuro[3,2-
c]chromen-4-one (VNRFC -115) 
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5.10  RESULT & DISCUSSION 
 
Present work covers the synthesis of some novel furocoumarin compounds. The main 
significance of the present work is that the said molecules are synthesized in a one pot 
synthetic process with reaction time ranging from 10 hr to 18 hr. It was found that 
VNRFC-102 and VNRFC-109 were obtained in extremely less yields.  
 
5.11  CONCLUSION 
 
 
Total 15 derivatives of 2-(substituted 2-hydroxy benzoyl) 2,3-dihydrofuro[3,2-
c]chromen-4-one  and 2-(2-hydroxy benzoyl) 3-(substituted phenyl) 2,3-
dihydrofuro[3,2-c]chromen-4-one were synthesized. All the newly synthesized 
compounds were characterized by IR, 1H NMR, 13C NMR, Mass spectral data and 
elemental analysis.  
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6.1   INTRODUCTION 
 
Pyrimidine is a heterocyclic aromatic organic compound similar 
to benzene and pyridine, containing two nitrogen atoms at positions 1 and 3 of the six-
member ring.[1] It is isomeric with two other forms of diazine: Pyridazine, with the 
nitrogen atoms in positions 1 and 2; and Pyrazine, with the nitrogen atoms in 
positions 1 and 4. 
 
N
N
pyrimidine
 
 
A pyrimidine has many properties in common with pyridine, as the number of 
nitrogen atoms in the ring increases the ring pi electronsbecome less energetic 
and electrophilic aromatic substitution gets more difficult while nucleophilic aromatic 
substitution gets easier. An example of the last reaction type is the displacement of 
the amino group in 2-aminopyrimidine by chlorine[2] and its reverse.[3] Reduction 
inresonance stabilization of pyrimidines may lead to addition and ring cleavage 
reactions rather than substitutions. One such manifestation is observed in the Dimroth 
rearrangement. 
Compared to pyridine, N-alkylation and N-oxidation is more difficult, and 
pyrimidines are also less basic: The pKa value for protonated pyrimidine is 1.23 
compared to 5.30 for pyridine. Pyrimidine also is found in meteorites, although 
scientists still do not know its origin. Pyrimidine also photolytically decomposes into 
Uracil under UV light.[4] 
 
Heterocyclic rings have played an important  role in medicinal chemistry, serving as 
key templates central to the development of numerous  important therapeutic agents 
[5]. Pyrimidine derivatives have found application in a wide range of medicinal 
chemistry because of their diverse biological activities, such as antimicrobial [6], 
antitumor and antifungal activities [7], also these compounds are considered to be 
important for drugs and agricultural chemicals [8-10]. These chemotherapeutic 
applications of pyrimidine derivatives prompted us to the synthesis of some 
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substituted pyrimidines in a facil pathway. Recently, several methods have been 
reported for the synthesis of pyrimidine derivatives. In one method aldehydes,  β-
dicarbonyl compounds, and urea/thiourea were reacted in the presence of a catalytic 
amount of tetrachlorosilane in DMF at normal ambient temperature [11]. The synthesis 
of 2-thiopyrimido benzimidazole derivatives under condensation of 4-isothiocyanato-
4-methyl-2-pentanone and 3,3-diaminobenzidine in absolute methanol under refluxing 
conditions is the other method [12]. Pyrimidine derivatives also can be prepared by 
reaction of certain amides with  carbonitriles under electrophilic activation of the 
amide with 2-chloro-pyridine and  trifluoromethanesulfonic anhydride [13]. However, 
these methods suffer from drawbacks, such as longer reaction time, complicated 
workup, and low yield.  
 
 
In recent years, dihydropyrimidine-2(1H)one derivatives have gained much interest 
for their biological and pharmaceuticals Properties  such as  HIV gp-120-CD4 
inhibitors[14], calcium channel blockers[15],  α-adrenergic and neuropeptide Y 
antagonists[16], as well as antihypertensive, antitumor, antibacterial, anti-
inflammatory[17] agent. The scope of this pharmacophore has been further increased 
by the identification of the Monostrol as a novel as a cell-permeable lead compound 
for the development of the new anticancer drugs[18] bearing the dihydropyrimidones 
core. Thus the development of facile and environmental friendly synthetic method 
towards dihydropyrimidines constitute active area of investigation of in organic 
synthesis, the first synthetic method for the preparation of dihydropyrimidine-2(1H) 
ones (DHPMs) was recorded by Biginelli [19], that involves the one pot three 
component condensation of aldehyde, 1, 3-dicarbonyl compounds and urea or 
thiourea in ethanol under strongly acidic conditions producing DHPMs, albeit in low 
yields. In the view of the pharmaceuticals importance of these compounds many 
improved catalytic methods have been developed [20-24]. Although these methods have 
their long reaction time, harsh reaction conditions, unsatisfactory yield and use of 
large quantity of catalyst. Therefore improvements with respect to the above have 
been continuously sought. In this paper we wish to report an efficient environment 
friendly procedure for the synthesis of DHPMs for aryl aldehyde using 5-
sulphosalicyclic acid   catalyst in microwave irradiation system. 
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Several catalysts like PPA, AlCl3, H3BO3, conc., BF3OEt, NH4Cl, CAN, NBS, 
triflates of lanthanide compounds and In, Bi, Cu, along with microwave irradiation 
etc. have been tried [25-29] to improve yields and conditions of Biginelli reaction. 
However, all these several methods involving these various catalyst suffer from one 
or the other drawback like, expensive reagents i.e., triflates of Bi, Cu, lanthanides etc., 
prolonged reaction time, and strongly acidic conditions, unsatisfactory yields and 
tedious workup procedures (e.g. acidic alumina) for the isolation of the pure product 
in good yields. Catalysts like, ferric oxide nano composites is effective and give good 
result, but the preparation procedure of this catalyst is very difficult. This requires the 
development of a new catalyst for high yield and the lack of inexpensive reagent, 
which requires shorter reaction time and with easier workup procedure. In this paper 
we wish to report an efficient environment friendly procedure for the synthesis of 
DHPMs for aryl aldehyde using 5- 
sulphosalicyclic acid  catalyst in microwave irradiation system.   
 
Three nucleobases found in nucleic acids, cytosine (C), thymine (T), and uracil (U), 
are pyrimidine -2-ones: 
 
N
H
N
O
NH2
N
H
NH
O
O
N
H
NH
O
O
Cytosine Thymine Uracil
 
 
P. Biginelli reported the synthesis of functionalized 3,4-dihydropyrimidin-2(1H)-ones 
(DHPMs) via three-component condensation reaction of an aromatic aldehyde, urea, 
and ethyl acetoacetate. In the past decade, this multicomponent reaction has 
experienced a remarkable revival, mainly due to the interesting pharmacological 
properties associated with this dihydropyrimidine scaffold.  
HO
R
H2N
NH2
OH3C O
O
O +
H+
EtOH/Heat
N
H
NH
H3C
O
O
O
R
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HN
H
NO O
F
a
HN
H
NO O
O
b
HN
H
NO O
SH
c
 
Gielen-Haertwig, et. al., have reported diaryl-dihydropyrimidin-2-ones as human 
neutrophil elastase inhibitors[30]. 
N
NH
O
CF3  
 
Coskun et. al.,  has reported N-Substituted pyrimidines - quinazolin-1-oxides[31] 
 
 
N
N
O
R
 
 
 
 
 
Ozaki, et. al., has reported pyrimidine derivative having potential anti-inflammatory 
activity[32]. 
N
N
O
R
 
Lowe, et. al., have reported quinazolinedione inhibitors of calcium independent 
phosphodiesterase[33] 
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N
N
O
COOMe
OH
 
Tuan P.  has reported A facile synthesis of substituted 3-amino-1H quinazoline-2,4-
diones[34] 
 
N
N
O
OHMe
F
F
R
 
 
Baraka, et. al., have reported 2,4(1H,3H)-quinaolinedione derivatives with analgesic 
and antiinflammatory activities[35] 
 
N
NH
O
O
 
Kashima, et. al., have reported Antiinflammatory activity of 2(1H)-pyrimidinones and 
their salts[36] 
 
 
 
 
 
N
NH
O
OEt
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6.2    SYNTHETIC ASPECT 
 
Synthesis of functionalized 3,4-dihydropyrimidin-2(1H)-ones (DHPMs) via three-component 
condensation reaction of an aromatic aldehyde, urea, and ethyl acetoacetate[37]. 
 
R1
O
H
O
R2
O
O R3
H2N
O
NH2
N
O
N
O O
R3
H
R2R1
H
H
EtOH
 
Pyrimidine-2-one reacted with all three alkylating agents furnishing the respective N1-
alkylated products (a), (b) and (c) in 60, 95, and 60% yields, respectively[38]. 
 
N
N
CCl3
O
H
N
N
CCl3
O
O
H2N
N
N
CCl3
O
O
EtO OEt
O
N
N
CCl3
O
OMe
Cl3C
O
60%
95%
60%
(i)
(ii)
(iii)
(a)
(b)
(c)
 
(i) 2-chloroacetamide 
(ii) Diethyl 2-bromomalonate 
(iii) 5-bromo-1,1,1-trichloro-4-methoxypent-3-en-2one 
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S. Balalaie reported reaction with 1,3-dicarbonyl compound, phenylglyoxal 
monohydrate, urea and zinc chloride by heating in ethanol under reflux condition to 
obtain dihydropyrimidine-2-ones[39]. 
 
 
O
Ph
H
O H2N NH2
O
R
O O
N
H
NH
O
PhO
O
R
A
B
A:ZnCl2, EtOH, Reflux
B:ZnCl2;AlCl3(1:3), Silica gel, M.W
 
 
 
J. Ghomi, showed approach to synthesis of pyrimidine-2-ones under ultrasound 
irradiation by reacting chalcone derivatives with urea  in the presence of potassium 
hydroxide in ethanol to produce the pyrimidine-2-one  derivatives[40]. 
 
 
O
R H2N NH2
O KOH
EtOH HN NH
O
R
R= H,2-CH3,3 -CH3, 4 -CH3, 2 -OCH3, 4 -OCH3, 2,4 -OCH3, N(Me)2  
 
The facile preparation of 3,4-dihydropyrimidine-2-one derivatives with traceless 
solid-phase sulfone linker strategy is described. Key steps involved in the solid-phase 
synthetic procedure include (i) sulfinate acidification, (ii) condensation of urea or 
thiourea with aldehydes and sulfinic acid, and (iii) traceless product release via a one-
pot cyclization−dehydration process. A library of 18 compounds was synthesized[41]. 
SO2-Na+
HN
N
H
O R3
R1
R2steps(i) - (iii)
 
 
 
4-Alkyl and 4-cycloalkyl substituted 1H-pyrimidin- 2-ones were prepared from the 
corresponding b-keto acetals by reaction with urea. 4-Ph derivative 3 was prepared 
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from 2,4-dichloro-pyrimidine by selective Suzuki coupling and subsequent hydrolysis 
of the remaining chloride[42]. 
 
R
O
H OMe
O
NaOMe, DEE
H2SO4, MeOH
aq. KOH
R OMe
OMeO
Urea, HCl
EtOH N NH
O
R= (a) Me, (b) cyclopr. (c) cyclobut. (d) cyclohex.
 
N N
Cl
Cl
PhB(OH)2, Pd(PPh3)4
K2CO3, PhCH3, MeOH N N
Cl
Ph
conc. HCl
N NH
O
Ph
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6.3    AIM OF CURRENT WORK 
The aim of current work was to synthesize fused Pyrido[4,3-d] pyrimidine-2-ones having 
methyl sulfonyl group. These compounds are not reported in literature and therefore, it was 
aimed develop methyl sulfonyl bearing compounds. 
 
6.4    REACTION SCHEME 
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6.5    EXPERIMENTAL 
 Preparation of N-(mathanesulphonyl) 3-ene 4-(4-methyl piperidyl) 
piperidine. 
 
Take 1-methane sulfonyl-piperidin-4-one (0.01 mole) and catalytic amount of p-
toluene sulfonic acid (PTSA) monohydrade (0.5 g) in 9 ml toluene at room 
temperature and add 4-methyl pyridine (0.011 mole) at room temperature. Raise temp 
to 55-60 oC for 90 minutes. Maintain it for 1 hrs with azeotropic distillation and then 
maintain for 6 hrs at 80-85 oC. Cool it at 60 oC and then distill toluene under vacuum. 
Cool it at 0-5 oC. Add 60 ml Methyl tert-butyl ether (MTBE) and stir for 20 min, filter 
and wash with 20 ml MTBE.[43] 
 
 Preparation of 1-methanesulfonyl 3-(4-(trifluoromethyl)benzoyl) piperidin-4-
one. 
 
N-(mathanesulphonyl) 3-ene 4-(4-methyl piperidyl) piperidine (0.01 mole) is 
reacted with a 4-(trifluoromethyl) benzoyl chloride (0.011 mole) in presence of tri 
ethyl amine (0.015 mole) in 10 ml toluene. The reaction was kept under stirring at 15-
20 oC for 4-5 hours. Completion of reaction was checked with TLC. The slurry 
obtained was filtered to obtain 1-methanesulfonyl-piperidin-4-one 3-(4-
(trifluoromethyl)phenyl)methanone. M.P: 122.[43] 
 
 Preparation of 4-(4-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-6-
(methylsulfonyl)-1-(substituted phenyl)pyrido[4,3-d]pyrimidin-2(1H)-one 
Take 30 ml ethanol into RBF, charge 1-methanesulfonyl-piperidin-4-one 3-(4-
(trifluoromethyl)phenyl)methanone (0.005) and substituted urea (0.011 mole). 
Dissolve reaction mass under stirring. Slowly add 1 ml HCl into RBF. Heat to reflux 
for 20 hrs. Check TLC for completion of reaction. RBF put under cool condition over 
night. Precipitated product was filtered and washed with ethanol to obtain 4-(4-
(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-6-(methylsulfonyl)-1-(substituted 
phenyl)pyrido[4,3-d]pyrimidin-2(1H)-one. TLC solvent system: Toluene:Ethyl 
acetate - 7:3. M.P: 146.[43] 
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6.6    PHYSICAL DATA  
 
 
 
 
 
 
 
 
 
 
 
 
Sr. 
No Code Structure 
Molecular 
formula 
Molecular 
weight 
M. P. 
(oC) 
% 
Yield 
1 VNRUR-101 H C15H14F3N3O3S 373 210-212 70 
2 VNRUR-102 C6H5 C21H18F3N3O3S 449 142-144 68 
3 VNRUR-103 4-Cl C6H4 C21H17ClF3N3O3S 483 152-154 66 
4 VNRUR-104 3- NO2 C6H5 C21H17F3N4O5S 494 178-180 71 
5 VNRUR-105 4-F C6H5 C21H17F4N3O3S 467 158-160 70 
6 VNRUR-106 3-Cl C6H5 C21H17ClF3N3O3S 483 162-164 66 
7 VNRUR-107 3,4Cl C6H5 C21H16Cl2F3N3O3S 517 176-178 58 
8 VNRUR-108 2,4 Me C6H5 C23H22F3N3O3S 477 156-158 49 
9 VNRUR-109 2-F C6H5 C21H17F4N3O3S 467 172-174 45 
10 VNRUR-110 3-Cl C6H5 C21H17ClF3N3O3S 483 204-206 66 
N
NN
R'
O
SO2CH3
CF3
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6.7  SPECTRAL STUDY 
 IR spectra 
Infra Red spectra were taken on Shimadzu FT-IR-8400 spectrometer using KBr 
pellet method. The characteristic aromatic group in furocoumarin moiety is observed 
at 3010-3090 cm-1. Methylene (-CH2) observed at 1375 cm-1.  
1H NMR spectra 
1H NMR spectra were recorded on a Bruker AC 400 MHz NMR spectrometer using 
TMS (Tetramethyl Silane) as an internal standard and DMSO-d6 as a solvent. In the 
NMR spectra of 4-(4-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-6-(methylsulfonyl)-
pyrido[4,3-d]pyrimidin-2(1H)-one derivatives various proton values of methylene (-
CH2), methyl (-CH3) and aromatic protons (Ar-H) etc. were observed. 
 Mass spectra 
The mass spectrum of compounds were recorded by Shimadzu GC-MS-QP-2010  
spectrometer. The mass spectrum of compounds was obtained by positive chemical 
ionization mass spectrometry. The molecular ion peak and the base peak in all 
compounds were clearly obtained in mass spectral study. The molecular ion peak 
(M+) values are in good agreement with molecular formula of all the compounds 
synthesized.  
 Elemental analysis 
Elemental analysis of the synthesized compounds was carried out on Vario EL-III 
Carlo Erba 1108 model at Saurashtra University, Rajkot which showed calculated 
and found percentage values of Carbon, Hydrogen and Nitrogen in support of the 
structure of synthesized compounds. The elemental analysis data are given for 
individual compounds. 
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6.8  SPECTRAL CHARACTERIZATION 
4-(4-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-6-(methylsulfonyl)-pyrido[4,3-
d]pyrimidin-2(1H)-one (VNRUR-101) 
Yield: 70%; IR (cm-1): 3529, 3412 (N-H str.), 3010 (Ar C=C-H str.), 2933 (Asym C-
H str. -CH3), 2933 (Asym C-H str. -CH2), 2872 (Sym C-H str. -CH3), 1730 (-C=O 
str.), 1643, 1633 (Ar C=C str.), 1404 (C-H bend –CH2), 1329 (C-H bend –CH3), 1165 
(C-O str.) , 719 (C-H oop def), 586 (C-F str.);  1H NMR 400 MHz: (CDCl3, δ ppm): 
2.04 (s, 6H), 2.30 (s, 3H), 2.57 (m, 8H), 3.71 (s, 2H), 4.21 (s, 1H), 6.84 (d, 1H), 7.05 
(m, 2H); Mass: [m/z (%)], M. Wt.: 444; Elemental analysis, Calculated: C, 70.26; 
H, 4.54; O, 25.20 Found: C, 70.27; H, 4.12; O, 25.67. 
 
4-(4-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-6-(methylsulfonyl)-1-
phenylpyrido[4,3-d]pyrimidin-2(1H)-one (VNRUR -102) 
Yield: 68%; IR (cm-1): 3583, 3412 (N-H str.), 3072 (Ar C=C-H str.), 2902 (Asym C-
H str. -CH3), 2925 (Asym C-H str. -CH2), 2872 (Sym C-H str. -CH3), 1747 (-C=O 
str.), 1568, 1539, 1496 (Ar C=C str.), 1408 (C-H bend –CH2), 1329 (C-H bend –CH3), 
1159 (C-O str.) , 707 (C-H oop def), 561 (C-F str.); 1H NMR 400 MHz: (CDCl3, δ 
ppm): 2.93 (s, 1H), 2.95 (s, 3H), 3.14 (s, 1H), 3.48 (s, 2H), 3.84 (s, 2H), 7.07 (d, 1H), 
7.27 (s, 1H), 7.35 (d, 1H), 7.51 (m, 3H), 7.66 (d, 2H); Mass: [m/z (%)], M. Wt.: 400 
Elemental analysis, Calculated: C, 72.00; H, 4.03; O, 23.98 Found: C, 72.09; H, 
4.15; O, 23.53. 
 
4-(4-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-6-(methylsulfonyl)-1-(4-chloro 
phenyl)pyrido[4,3-d]pyrimidin-2(1H)-one (VNRUR -103) 
Yield: 66%; %; IR (cm-1): 3577, 3423 (N-H str.), 3081 (Ar C=C-H str.), 2915 (Asym 
C-H str. -CH3), 2931 (Asym C-H str. -CH2), 2874 (Sym C-H str. -CH3), 1752 (-C=O 
str.), 1648, 1635, 1582 (Ar C=C str.), 1414 (C-H bend –CH2), 1326 (C-H bend –CH3), 
1149 (C-O str.) , 705 (C-H oop def), 564 (C-F str.); Mass: [m/z (%)], M. Wt.:   
414(M+), 416(M+2) ; Elemental analysis, Calculated: C, 72.46; H, 4.38; O, 23.16; 
Found: C, 72.61; H, 4.33; O, 23.26. 
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4-(4-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-6-(methylsulfonyl)-1-(3-nitro 
phenyl)pyrido[4,3-d]pyrimidin-2(1H)-one (VNRUR -104) 
Yield: 71%; IR (cm-1): 3565, 3418 (N-H str.), 3086 (Ar C=C-H str.), 2906 (Asym C-
H str. -CH3), 2924 (Asym C-H str. -CH2), 2868 (Sym C-H str. -CH3), 1754 (-C=O 
str.), 1668, 1643, 1585 (Ar C=C str.), 1415 (C-H bend –CH2), 1332 (C-H bend –CH3), 
1145 (C-O str.) , 714 (C-H oop def), 566 (C-F str.); Mass: [m/z (%)], M. Wt.: 434 ; 
Elemental analysis, Calculated: C, 77.41; H, 4.18; O, 18.41; Found: C, 77.21; H, 
4.28; O, 18.51. 
 
4-(4-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-6-(methylsulfonyl)-1-(4-fluoro 
phenyl)pyrido[4,3-d]pyrimidin-2(1H)-one (VNRUR -105) 
Yield: 70%; IR (cm-1): 3575, 3411 (N-H str.), 3076 (Ar C=C-H str.), 2914 (Asym C-
H str. -CH3), 2935 (Asym C-H str. -CH2), 2881 (Sym C-H str. -CH3), 1752 (-C=O 
str.), 1681, 1665, 1572 (Ar C=C str.), 1417 (C-H bend –CH2), 1326 (C-H bend –CH3), 
1148 (C-O str.) , 712 (C-H oop def), 567 (C-F str.); Mass: [m/z (%)], M. Wt.: 384 ; 
Elemental analysis, Calculated: C, 74.99; H, 4.20; O, 20.81; Found: C, 74.15; H, 
4.27; O, 20.05. 
 
4-(4-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-6-(methylsulfonyl)-1-(2-chloro 
phenyl)pyrido[4,3-d]pyrimidin-2(1H)-one (VNRUR -106) 
Yield: 66%; IR (cm-1): 3575, 3424 (N-H str.), 3055 (Ar C=C-H str.), 2917 (Asym C-
H str. -CH3), 2934 (Asym C-H str. -CH2), 2878 (Sym C-H str. -CH3), 1751 (-C=O 
str.), 1571, 1545, 1484 (Ar C=C str.), 1418 (C-H bend –CH2), 1325 (C-H bend –CH3), 
1162 (C-O str.) , 717 (C-H oop def), 567 (C-F str.); Mass: [m/z (%)], M. Wt.: 
402(M+), 404(M+2) ; Elemental analysis, Calculated: C, 71.64; H, 3.76; O, 19.88; 
Found: C, 71.65; H, 3.44; O, 19.78. 
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4-(4-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-6-(methylsulfonyl)-1-(3,4-dichloro 
phenyl)pyrido[4,3-d]pyrimidin-2(1H)-one (VNRUR -107) 
Yield: 58%; IR (cm-1): 3584, 3414 (N-H str.), 3076 (Ar C=C-H str.), 2908 (Asym C-
H str. -CH3), 2926 (Asym C-H str. -CH2), 2874 (Sym C-H str. -CH3), 1750 (-C=O 
str.), 1578, 1547, 1492 (Ar C=C str.), 1404 (C-H bend –CH2), 1324 (C-H bend –CH3), 
1159 (C-O str.) , 705 (C-H oop def), 562 (C-F str.); Mass: [m/z (%)], M. Wt.: 
334(M+), 336(M+2), 338(M+4) ; Elemental analysis, Calculated:  C, 68.82; H, 
3.61; O, 19.10 Found: C, 68.73; H, 3.58; O, 19.05. 
 
4-(4-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-6-(methylsulfonyl)-1-(2,4-dimethyl 
phenyl)pyrido[4,3-d]pyrimidin-2(1H)-one (VNRUR -108) 
Yield: 49%; IR (cm-1): 3574, 3413 (N-H str.), 3074 (Ar C=C-H str.), 2913 (Asym C-
H str. -CH3), 2932 (Asym C-H str. -CH2), 2874 (Sym C-H str. -CH3), 1747 (-C=O 
str.), 1617, 1586, 1474 (Ar C=C str.), 1412 (C-H bend –CH2), 1324 (C-H bend –CH3), 
1154 (C-O str.) , 704 (C-H oop def), 562 (C-F str.); Mass: [m/z (%)], M. Wt.:  350 ; 
Elemental analysis, Calculated: C, 71.99; H, 5.18; O, 22.83; Found: C, 71.89; H, 
5.22; O, 22.67. 
 
4-(4-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-6-(methylsulfonyl)-1-(2-fluoro 
phenyl)pyrido[4,3-d]pyrimidin-2(1H)-one (VNRUR -109) 
Yield: 45%; IR (cm-1): 3581, 3415 (N-H str.), 3078 (Ar C=C-H str.), 2907 (Asym C-
H str. -CH3), 2924 (Asym C-H str. -CH2), 2877 (Sym C-H str. -CH3), 1752 (-C=O 
str.), 1668, 1664, 1497 (Ar C=C str.), 1413 (C-H bend –CH2), 1332 (C-H bend –CH3), 
1155 (C-O str.) , 716 (C-H oop def), 567 (C-F str.); Mass: [m/z (%)], M. Wt.: 394 ; 
Elemental analysis, Calculated:  C, 66.99; H, 4.60; O, 20.28; Found: C, 66.83; H, 
4.62; N, 20.31. 
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4-(4-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-6-(methylsulfonyl)-1-(3-chloro 
phenyl)pyrido[4,3-d]pyrimidin-2(1H)-one (VNRUR -110) 
Yield: 66%; IR (cm-1): 3583, 3420 (N-H str.), 3081 (Ar C=C-H str.), 2916 (Asym C-
H str. -CH3), 2922 (Asym C-H str. -CH2), 2885 (Sym C-H str. -CH3), 1751 (-C=O 
str.), 1667, 1634, 1504 (Ar C=C str.), 1418 (C-H bend –CH2), 1392 (C-H bend –CH3), 
1157 (C-O str.) , 704 (C-H oop def), 565 (C-F str.); Mass: [m/z (%)], M. Wt.: 
398(M+), 400(M+2) ; Elemental analysis, Calculated: C, 75.37; H, 4.55; O, 20.08; 
Found: C, 75.33; H, 4.17; O, 20.12. 
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6.9  REPRESENTATIVE SPECTRA 
 IR spectrum of 4-(4-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-6-
(methylsulfonyl)-pyrido[4,3-d]pyrimidin-2(1H)-one (VNRUR-101)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR spectrum of 4-(4-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-6-
(methylsulfonyl)-1-phenylpyrido[4,3-d]pyrimidin-2(1H)-one (VNRUR -102)  
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Mass spectrum of 4-(4-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-6-
(methylsulfonyl)-pyrido[4,3-d]pyrimidin-2(1H)-one (VNRUR-101) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of 4-(4-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-6-
(methylsulfonyl)-1-phenylpyrido[4,3-d]pyrimidin-2(1H)-one (VNRUR -102) 
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1H NMR spectrum of 4-(4-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-6-
(methylsulfonyl)-pyrido[4,3-d]pyrimidin-2(1H)-one (VNRUR-101) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expanded 1H NMR spectrum of 4-(4-(trifluoromethyl)phenyl)-5,6,7,8-
tetrahydro-6-(methylsulfonyl)-pyrido[4,3-d]pyrimidin-2(1H)-one (VNRUR-101) 
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1H NMR spectrum of 4-(4-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-6-
(methylsulfonyl)-1-phenylpyrido[4,3-d]pyrimidin-2(1H)-one (VNRUR -102) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expanded 1H NMR spectrum of 4-(4-(trifluoromethyl)phenyl)-5,6,7,8-
tetrahydro-6-(methylsulfonyl)-1-phenylpyrido[4,3-d]pyrimidin-2(1H)-one 
(VNRUR -102) 
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6.10  RESULT AND DISCUSSION 
 
In the current work, synthesis of some novel pyrimidine-2-one derivatives by reaction 
of substituted urea with a diketone was carried out. The main significance of the 
present work is that the process for synthesis of pyrimidine-2-one derivatives is novel, 
with facile work up method, and high chemical purity. It is for biological as well as 
pharmacological screening for further study. 
 
6.11  CONCLUSION 
 
A convenient method for preparation of 4-(4-(trifluoromethyl)phenyl)-5,6,7,8-
tetrahydro-6-(methylsulfonyl)-1-(substituted phenyl)pyrido[4,3-d]pyrimidin-2(1H)-
one was developed. After three step reaction, the final product obtained was pure 
along with good yields. 
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7.1    INTRODUCTION 
 
Heterocycles containing Oxygen and Nitrogen possess many biological and 
pharmacological properties. Besides, these they are also known to exhibit properties 
and application such as anti-oxidant, heat stabilizers, photo sensitizers, indicator, 
lubricants and many more. 
 
Six membered oxygen heterocycles constitute a group of compounds, which occur 
widely throughout the plant kingdom. Coumarin (2H-1-benzopyran-2-one) is one of 
the naturally occurring heterocycles in many natural products. It is widely distributed 
in Plant world either in free state or in combined state. It was first isolated from tonka 
beans (Dipteryx odorata). It also occurs in sweet clover (Melilotus Officinalis and 
Melilotus Alba) and woodruff (Aperula odorata) 
 
It is the parent substance of a very large group of derivatives, many of which occur 
naturally and are of economic importance for example Umbelliferone, Aesculetin, 
Herniarin etc. 
 
 
 
 
 
 
 
 
 
 
Coumarin chemistry has become important because of the discovery of varied 
biochemical properties, industrial uses and analytical applications. Coumarins have 
been found to be physiologically a ctive for animals as well as humans. It acts as 
narcotic for rabbits, frogs and many other animals. 3-Chlorocoumarin have proved to 
be sedative as well as hypnotic for mice and humans. However, it is toxic to dogs and 
humans[1]. Werder synthesized over hundred derivatives of coumarin-3-carboxylic 
O O O O
O O O O
HO
HO
HO
MeO
Coumarin Umbelliferone
Aesculetin Herniarin
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acids – they were found to be sedative in small doses and hypnotic in large doses[2] 
Coumarin also shows various other biological activities such as antifungal[3], 
anticoagulants [4], anti-psorasis [5], carcinogen [6], antibacterial [7] and insecticidal [8]. 
 
Some of the commercial drugs having an application as vasodialators are Chromonar 
and Visnadin, Haloxon antihelminthics, diuretics like mercumallylic acid, and 
systemic insecticidehymecromone. Antibiotic novobiocin produced by streptomyces 
spheroids and niveus has been marketed as antibacterial or antimicrobial preparation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Coumarin is also used as synthetic intermediates for preparation of many heterocyclic 
compounds of biological and pharmacological importance [9-12]. Some biological 
activities such antiHIV [13] and Antitumor agents [14] are also reported. 
 
4-hydroxy coumarins - a metabolite of coumarin are oxygen heterocycles, which are 
studied for their tautomeric structures [15]. It can exist in 2 forms as shown below. 
 
O O
CH3
NEt2O
(OEt)2
O OO
H3C
H3C
O O Et
Me
O O
ch3
ClO
P
O
(ClCH2CH2O)2
O O
OH
OMe
HgOH
Chromonar
Visnadin
Haloxan
Mercumallylic Acid
OHO O
CH3
OO O
CH3
O
CH2CH(CH3)2
OH
O
OH
O O
NH2
OMe
Novobiocin
Hymercromone
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Chemically, it is acidic in nature and therefore reacts easily at 3rd position. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O O
OH
O OH
O
4-hydroxy-2H-chromen-2-one 2-hydroxy-4H-chromen-4-one
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7.2     SYNTHETIC ASPECT 
 
 Preparation of Coumarin:   
 
1) The biosynthesis of coumarin in plants is via hydroxylation, glycolysis and 
cyclization of cinnamic acid. Coumarin can be prepared in a laboratory in a Perkin 
reaction between salicylaldehyde and acetic anhydride [16]  
CHO
OH
O
O
CH3H3C
O
2-hydroxybenzaldehyde Acetic anhydride
O O
+
CH3COOH
CH3COONa
 
 
2) One of the most  reliable method for preparation of coumarin and it’s derivatives is  
Pechmann condensation. It is a condensation starting from a phenol and a carboxylic 
acid or ester containing a β-carbonyl group under under acidic conditions. It was 
discovered by the German chemist Hans von Pechmann [17] 
 
 
 
 
 
 
 
3) Cyclization of 3-amino-3-phenyl propanoic acid in presence of HBr results in 58% 
of coumarin. [18] 
 
 
 
 
 
 
4) O-demethylation and lactonisation of E-Cinnamic acid in presence of Pyridine and 
HCl gives 55% of coumarin [19] 
OH OH
CH3
O
O
O
CH3
H2SO4
RT
O O
CH3
OH
NH2
COOH O O
HBr
3-amino-3-phenylpropanoic acid Coumarin
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COOH O O
Coumarin
O
CH3
E-Cinnamic Acid
C6H5N, HCl
20 min,
 
 
5) Malonic acid diethyl ester condenses with salicylaldehyde to give coumarin [20] 
 
 
 
 
 
 
6) Manimaran et al synthesized coumarins, thiocoumarins and carbostyrils in presence 
of AlCl3 [21] 
O O
OH
Cl
O
Ph
cinnamoyl chloride
O
Ph
Phenyl Cinnamate
Phenol
OH
HO
O
Ph
Phenol
cinnamic acid
+
AlCl3
AlCl3
AlCl3
 
 
7) Substituted coumarins and benzocoumarins were prepared by esterification of 2-
furanacrylic acid with substituted phenols in presence of POCl3 and Pyridine. Further, 
cyclisation of furanacrylates were effected in presence of AlCl3 to yield 73% of 
coumarin [22] 
EtO OEt
O O OH
CHO
+
O O
diethyl malonate
2-hydroxybenzaldehyde Coumarin
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O
O
OH Phenol
POCl3
O
O
O Ph
AlCl3
O O
2-furanacrylic acid
Furanacrylate
Coumarin
73%
 
 
8) Coumarin was also prepared via cyclization-elimination followed by 
cyclocondensation reaction between 2-hydroxybenzaldehyde and trimethylsilylketene 
in presence of NaH [23] 
 
 
 
 
 
 
9) 3-Ethoxy acrolyl chloride with phenol in presence of triethyl amine and diethyl 
ether yielded phenyl ester which on treatment with H2SO4 and SO3 cyclised to give 
coumarins in good yields (69%) [24] 
 
 
 
 
 
 
 
 
 
 
 
Si HC C O
H3C
H3C
H3C
NaH
O O
92%
+
OH
Cl OEt
O
N-Et3
Et2O
PhO
O
O
OEt
H2SO4
SO3
O O
69%
(E)-3-ethoxyacryloyl chloride
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10) Koepp Erich et al used Cs (OAc)2 instead of NaOAc in Perkin synthesis of 
cinnamic acid to yield coumarin 79%  [25] 
OH
CHO
O O
Ac2O
Cs(OAc)2
 
 
Some another coworkers discussed a new approach of using aromatic metallation 
reaction of aldehydes such as 1 with LiCH2-CO-NMe2 and deblocking and cyclisation 
of the adducts with AcOH [26] 
 
 
 
 
 
11) European patent disclosed preparation of coumarin catalytically by 
dehydrogenation followed by cyclization of the cyclohexanoyl propionic acid esters at 
100-300 oC in presence of catalyst comprising of a carrier having Pd supported either 
on CrO3 or Cr(OH)3. [27] 
 
 
 
 
 
 
 
12) Zhou, Chengdong et al described an improved synthesis of coumarin by using 
salicylaldehyde. Salicyaldehyde was heated with Ac2O and PEG at 185 oC for 1 hour 
to give 2-acetoxy-benzaldehyde. It was further heated with Ac2O and KF at 180-190 
oC for 4-5 hours to give 76% of coumarin [28] 
 
OH
CHO
+ Ac2O
OAc
OH
O O
180
Polymer
Ac2O
 
O
OMe
O
Pd
O OO O
42% 26%methyl 3-(2-oxocyclohexyl)propanoate
CHO
O OMe
N CH2
O
H3C
H3C
Li
O O
THF
AcOH+
2-(methoxymethoxy)benzaldehyde
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13) Flash Vacuum Pyrolysis of Salicylaldehyde and triphenyl phosphine adduct in 
presence of methylendichloride gave coumarin in 87% yields [29] 
 
OH
CHO
MeO
P
Ph3
O
CHO
CH2Cl2 OMe
O
O O
87%
+
 
 
 Preparation of 4-hydroxycoumarin 
 
1) Zeigler and coworkers  cyclised malonic acid diphenyl ester in presence of AlCl3 
using Friedal Craft’s alkylation to give 4-hydroxycoumarin in 85% yield [30] 
 
PhO OPh
O O
AlCl3
180-185
O O
OH85%
Diphenyl Malonate
 
 
2) Shah et al synthesized 4-hydroxy coumarin by fusion of equimolar malonic acid 
and phenol in 2-3, moles of POCl3 and ZnCl2 – which gave 64% yield [31] 
HO OH
O O
O O
OH
+
OH
Malonic Acid
Phenol
ZnCl2
POCl3
64%
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3) Sheikh et al synthesized trimethoxy and tetramethoxy substituted 4-
hydroxycoumarins by Friedal Craft’s acylation [32] 
4) Selenium catalysed carbonylation of 4-hydroxy acetophenone in THF containing 
PhNO2 under Carbon Monoxide atomosphere at 90 oC for 30 hours giving 68% yield  
[33] 
 
 
 
 
 
5) A facile synthesis of 4-Hydroxycoumarin in presence of sulfur from 2-
hydroxyacetophenone with carbon monoxide in presence of triethylamine and THF 
yielded 96% of 4-hydroxycoumarin [34] 
 
O O
OH
OH
THF
Ac
+ CO
96%
N-Et3  , S
 
 
6) Coumarins were also prepared by treating malonic acid diesters with MgCl2 and 
acetylsalicylic chloride (II) and further cyclisation of resulting dialkyl2-(2-
acetoxybenzoyl)malonate by alkali. Di ethylmalonate, MgCl2 and acetylsalicylic 
chloride were treated with acetonitrile and triethylamine mixture at 0 oC for one 
hour.The product obtained was heated with KOH in MeOH at 50 oC for 3 hours to 
give 77.4% target compound [35] 
 
O O
OH
Ac
96%
N-Et3
MeCN, KOH in MeOH
MgCl2
O
Cl
EtO OEt
O O
+
diethyl malonate 2-acetylbenzoyl chloride
 
 
O O
OH
OH
Se , THF
C
+ CO
O
 
Chapter-7                                                                                   Rapid Synthesis and Process… 
203 
 
7) Intramolecular Claisen Condensation of methylacetylsalicylate with NaOMe in 
liquid paraffin at 160-260 oC for 5 hours gave 20% of 4-hydroxycoumarin [36] 
 
OAc
OMe
O
O O
OH
NaOMe
HCl/H2O
methyl 2-acetoxybenzoate 20%
 
 
8) Substituted 4-hydroxycoumarin was synthesized via new Baker-Venkatraman 
rearrangement [37] 
 
N OPh
Et
Et
O
+ AcCl
BuLi  , THF
ZnCl2
Ac
O
O
Et
2-acetylphenyl butyrate
O O
OH
NaH, THF
CF3-COOH, PhMe
phenyl diethylcarbamate
 
 
9) One-pot synthesis of coumarin, 4-hydroxythiocoumarin and 2-quinolones by 
acylation followed by internal ring closure [38] 
 
OH
OAc
O O
OH
+ Et2CO3
2-hydroxyphenyl acetate
NaH, PhMe
 
 
10) Salicylic Acid was esterified and acetylated. It was further cyclised with metallic 
sodium in dry Toluene [39] 
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OH
COOH
O O
OH
+ Ac2O MeOH
Na / Toluene
2-hydroxybenzoic acid
 
 
E) Further reactions of 4-hydroxycoumarins: 
 
4-hydroxycoumarins frequently reaction with aromatic aldehydes to give 3-
benzylidene-2,4-chromandiones [41-44] 
 
 
 
 
 
 
 
 
However, reactions using Salicyaldehyde or it’s analogues multicyclic compounds as 
shown below was obtained either solely or in addition to salicylidene derivatives of 
type as shown. [45] 
 
 
 
 
 
 
 
 
 
 
 
 
O O
O
O O
OH
CHO
R2
+
R2
4-Hydroxycoumarin
Substituted Benzaldehyde
3-benzylidene-2,4-chromanediones
O O
OH
CHO
OH
2-hydroxybenzaldehyde
+
4-Hydroxycoumarin
O O
O O
OOH
O
O
O
OH
+
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The proportions of the products were dependent on reaction conditions used – for 
example when salicylaldehyde and 4-hydroxycoumarin was refluxed in ethanol were 
dimeric type of structure in addition to benzylidene derivative was obtained [46] 
 
Of two moles of salicylaldehyde was reacted with 4-hydroxy-6-iodocoumarins, it 
gave appropriate benzylidene derivative only. However, one mole of salicylaldehyde 
with two moles of 4-hydroxycoumarin gave the dicoumaryl structure. [47] 
 
 
 
 
 
 
 
 
 
 
 
Similarly, reaction of 4-hydroxycoumarin with acetylated aldehydohexoses in ethanol 
for 24 hours gave substance of type below [48] 
 
 
 
 
 
 
Reaction between 4-hydroxycoumarin and hydroxylamine hydrochloride gave 
corresponding 2,4-chromadione-4-oximes. [49] 
O O
OH
4-Hydroxycoumarin
+ NH2OH
O
O
N
O
OH
(Z)-3-(hydroxyimino)-3H-chromene-2,4-dione
 
 
O O
OH
CHO
OH
2-hydroxybenzaldehyde
4-Hydroxycoumarin
+2
O
O
O
OH
O O
OH
CHO
OH
2-hydroxybenzaldehyde
4-Hydroxycoumarin
+ 2
O O
O O
OOH
O O
OH
CH(CHOAc)4CH2OAc
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Reaction of Chlorine with 4-hydroxycoumarins in suitable solvent or sulfuryl chloride 
led to formation 3,3-dichloro-2,4-dichromandiones. [50-54] Halogenations of 3-
substituted 4-hydroxycoumarin afforded 3-chloro-2,4-chromandiones. When 3,3’ 
methylenebis (4-hydroxycoumarin) was treated with sufuryl chloride, 3,3’ 
methylenebis (3-chloro-2,4-chromandione) was isolated. 
 
O O
OH
Cl2+
SO2Cl2
O O
OH
Cl
Cl
O O
OH
Cl2+
SO2Cl2
O O
OH
R
Cl
R
O
O
OH
O
OH
O
Cl2
O
O
OH
O
OH
O
Cl
Cl
 
 
When 3-amino-4-hydroxycoumarin was reacted with nitrous acid gave 3-diazo-2,4-
chromandiones. The same product was also obtained in 72% yield when sodium 
nitrite in dilute hydrochloric acid was added to 3-amino-4-hydroxycoumarin. [55] 
 
 
 
 
 
 
However, reaction of 4-hydroxycoumarin with aqueous sodium nitrite afforded 2,3,4-
chromantrione-3-oxime which forms a silver salt. [56]  
 
 
 
 
O O
OH
N2
O O
OH
N
OH
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7.3    AIM OF CURRENT WORK 
 
Our aim was to exploit the 3rd position on 4-hydroxy coumarin skeleton and also their 
substituted derivatives in the benzenoid part using substitution of various functional 
groups i.e –Br, –CHO, -NO2, -NH2, -CN, thereby developing and optimizing the 
process, yield and purification techniques for the same. 
 
7.4  REACTION SCHEME 
 
 Preparation of various 3-substituted 4-hydroxy coumarins: 
 
 
Scheme-1 
 
 
 
 
 
Scheme-2 
 
 
 
 
 
 
 
 
 
 
 
 
O O
OH
O O
OH
CHO
Triethyl ortho formate
M.W.
180 W
PTSA
O O
OH
OH
OH
OH
O
O
malonic acidsubstituted phenol
R R
ZnCl2
POCl3
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Scheme-3 
O O
OH
O O
OH
NO2Acetic Acid
HNO3
Na2S2O4
NaHCO3
H2O
O O
OH
NH2.HCl
HCl
NaOH
H2O
E.A.
O O
OH
NH2
HNO3
HCl
NaCN CuCN
H2OO O
OH
CN
 
 
Scheme-4 
O O
OH
O O
OH
BrBr2
MeOH
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7.5  EXPERIMENTAL 
 
Step 1 –Procedure for synthesizing 4-hydroxycoumarin: 
 
4-hydroxycoumarin was prepared according to the method of Shah and co-workers. 
Phenol (0.1 mole) and malonic acid (10.4 gm; 0.1 moles) were added to a mixture of 
phosphorous oxychloride (40 ml) and anhydrous zinc chloride (30 gms) which was 
preheated to get rid of any moisture. The reaction mixture was heated on a water bath 
at 70 oC for 8-10 hours. It was cooled and decomposed with ice and water to afford 
buff-yellow coloured solid. 
 
The solid was then filtered and washed thoroughly with water. It was then triturated 
with 10% sodium carbonate solution and filtered. The filterate was slowly acidified 
with dilute HCl till the effervescence ceased. The product was filtered and dried and 
recrystallised with methanol.[31]  
 
Step 2 –Procedure for synthesizing 3-substituted 4-hydroxycoumarins: 
 
 3-formyl 4-hydroxy coumarin using microwave irradiation: 
4-hydroxy coumarin 1.0 g (0.01 mole) was taken in a 50 ml RBF to which was added 
triethyl ortho formate 7 ml (4.21 mol) and 0.02 g p-toluene sulphonic acid. The 
reaction mass was then put under microwave irradiation having 180 Watts for 5 
minutes. As a result, solid slurry obtained, which was then filtered. This solid slurry 
was dissolved in 15 ml saturated solution of sodium bicarbonate and filtered. To the 
filtrate was added conc. HCl dropwise until pH 4.0 is achieved. The resulted slurry 
was filtered u/v and dried at 50 oC for 3 – 4 hrs. M.P.: 138-140 oC. [57] 
 
 3-nitro 4-hydroxy coumarin: 
4-hydroxy coumarin 1.62 g (0.01 mole) was taken into a conical flask 50 ml to which 
was added 10 ml acetic acid and 1.5 ml nitric acid. The reaction mass was heated  to 
60 oC on water bath with constant stirring under a fume hood. The reaction mass was 
heated for 15-20 minutes until the solids obtained. Completion of reaction was 
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checked using TLC. Slurry filtered u/v and washed with acetic acid followed by 
petroleum ether. It was then dried at 50 oC for 2-3 hrs. M.P.: 176-178 oC. [58] 
 
 3-amino 4-hydroxy coumarin: 
3-nitro 4-hydroxy coumarin (0.01 mol) was dissolved in 100 ml saturated solution of 
sodium bicarbonate. Reaction mass was taken in a 500 ml beaker with constant 
mechanical stirring under fume hood. To which sodium dithionite 10 g was added in 
portions with constant stirring. As a result, solution colour changes from yellow to sea 
green to clear. Completion of reaction is checked using TLC. Reation mixture was 
then cooled to 0 oC and brought to pH-1 with conc. HCl dropwise. The resulting 
precipitates were filtered u/v, dried at 50 oC for 5-6 hours. M.P.: 226-228. [59] 
 
 Diazonium salt of 3-amino 4-hydroxy coumarin: 
To a stirred reaction of 1:1 (1.61 ml HCl and 1.61 ml H2O) was added 1.0 g 3-amino 
4-hydroxy coumarin at 0-5oC. To this was added sat. solution of NaNO2 dropwise 
until starch paper turned blue. Preparation of diazonium salt was tested with B-
naphthol by doing dye test. 
 
 3-cyano 4-hydroxy coumarin: 
1.68 g CuCN and 0.68 g NaNO2 in 2 ml H2O were taken in RBF with condenser, 
which was heated at 60 oC with continuous stirring. To which was added diazonium 
salt of 3-amino 4-hydroxy coumarin portion wise. After completion of addition the 
reaction mass was heated to reflux for 30 minutes. Completion of reaction was 
checked using TLC.  To the reaction mass was added ethyl acetate. Organic layer was 
extracted and concentrated u/v to give solid 3-cyano 4-hydroxy coumarin. M.P: 265-
269. [60] 
 
 3-bromo 4-hydroxy coumarin: 
In a round bottom flask was taken 4-hydroxy coumarin (0.01 mmol) which was 
dissolved in 20 ml methanol. The reaction mass was kept under stirring at room 
temperature. Bromine (0.02 mmol) was added dropwise from addition funnel in 15-20 
minutes. The reaction mass after addition was stirred for 2-3 hours. Completion of 
reaction was checked with help of TLC. After completion, reaction mass was poured 
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in water 50ml. Reaction was further stirred for 10-15 minutes. Slurry obtained was 
filtered and dried at room temperature to obtain 3-bromo 4-hydroxy coumarin. M.P.: 
194-195. [61] 
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O O
OH
R
R = -Br, -CHO, -NO2, -NH2, -CN
7.6  PHYSICAL DATA  
 
 
 
 PHYSICAL DATA OF 3-SUBSTITUTED 4-HYDROXY COUMARINS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sr. 
No
. 
Sample 
Code 
Substitution Molecular 
Formula M. Wt 
 
M.P oC 
(Reported) 
 
Yield 
% R 
1 VMINT 101 -Br C9H5BrO3 241.04 194-195 94% 
2 VMINT 102 -CHO C10H6O4 190.15 138-140 90% 
3 VMINT 103 -NO2 C9H5NO5 207.14 176-178 92% 
4 VMINT 104 -NH2 C9H7NO3 177.16 226-228 90% 
5 VMINT 105 -CN C10H5NO3 187.15 265-269 85% 
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7.7    RESULT AND DISCUSSION 
 
Present work covers the synthesis of some 3-substituted 4-hydroxy coumarins. Sole 
purpose for synthesizing these molecules was to explore set of different unreported 4-
hydroxy coumarin derivatives. For this, all the intermediates were prepared by 
altering classical methods or developing altogether new process, to get intermediates 
with very less reaction time, of high chemical purity and better yields. 
 
 
 
7.8    CONCLUSION 
 
Total 5 intermediates, 3-bromo 4-hydroxy coumarin, 3-formyl 4-hydroxy coumarin, 
3-nitro 4-hydroxy coumarin, 3-amino 4-hydroxy coumarin and 3-cyano 4-hydroxy 
coumarin were synthesized. All 5 intermediates were confirmed with their reported 
melting points from literature and were used as starting material for synthesizing 4-
hydroxy coumarin derivatives. 
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8.1    INTRODUCTION 
 
Alexander Fleming discovered penicillin and set in motion a medical revolution. In 
1943, penicillin was mass produced and saved many wounded soldiers from death by 
bacterial infection. Yet as we enjoy the benefits of antibiotics, their use promotes 
antibiotic resistance in bacteria. By confronting bacteria with antibiotics, we select for 
those that are resistant and change the course of their evolution. Microbes are 
mutating and evolving in their ways that make them resistant in commonly occurring 
microbial infections. Knowledge of Antimicrobial activity of newly synthesized 
organic compounds is necessary for combating resistance of resistant and virulent 
strains. Day by day resistance of commensals and pathogenic strains grow higher and 
higher. However, our knowledge is restricted to less than 1% of the facts about causes 
of resistant strains and their sensitivity. In present era many antimicrobial drugs have 
been rendered ineffective due to the microbial resistance to the then efficient drugs. 
This warrants a search for an effective antimicrobial drug against the resistant clinical 
strains. 
 
Organic compounds with antimicrobial potential are being synthesized in laboratory and 
referred as “Novel Compounds”. The synthetic organic compounds are synthesized and 
purified through analytical techniques to get the fine powder. New organic synthetic 
compounds synthesized in laboratory are likely to be new on this earth and hence, their 
characteristics and activities are never evaluated and analyzed. However, they must be 
investigated properly before used as an alternative medicine for in vitro and in vivo anti-
microbial activity. 
 
An anti-microbial is a substance that kills or inhibits the growth of microorganisms 
such as bacteria, fungi, or protozoans. Antimicrobial drugs either kill microbes 
(microbicidal) or prevent the growth of microbes (microbistatic). Disinfectants are 
antimicrobial substances used on non-living objects. [1] 
 
 Antibiotic resistance is a serious concern worldwide as it would result in 
strains against which currently available antibacterial agents will be ineffective. In 
general, bacterial pathogens may be classified as either gram-positive or gram-
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negative pathogens. Antibiotics compounds with effective activity against both gram-
positive and gram-negative pathogens are generally regarded as having a broad 
spectrum of activity. The synthesized compounds were preliminary screened gram-
positive and gram-negative pathogens. For evaluation of antibacterial activity in our 
case, we have used Staphylococcus aureus and Bacillus cereus from gram positive 
group of bacteria and Escherichia coli and Salmonella Typhimurium from gram 
negative Group of bacteria. 
 
BACTERIA:- 
  
In 1928, a German scientist C.E. Chrenberg first used the term “Bacterium” to denote 
small microscopic organism with a relatively simple and primitive form of the cellular 
organization known as “Prokaryotic”.  
                            
Bacteria are generally unicellular e.g. Cocci, Bacilli, etc… Filamentous, Eg. 
Actinomycetes, some being sheathed having certain cells specialized for reproduction. 
The microorganisms are capable of producing diseases in host are known as 
‘Pathogenic’. Most of the microorganisms present on the skin and mucous membrane 
are non pathogenic and are often referred to as “Commensals” or if they live on food 
residues as in intestine, they may be called “Saprophytes”. Generally, the pathogenic 
Cocci and Bacilli are gram positive and the pathogenic coco bacilli are gram negative. 
                            
STAPHYLOCOCCUS AUREUS : - 
 
Genus: Staphylococcus [Microccaceae] 
Staphylococci are differentiated from micrococcus, a genus of the same family 
by its ability to utilize glucose, mannitol and pyruvate anaerobically. Cells of 
staphylococci are usually to be found on the skin or mucous membranes of the animal 
body, especially of the nose and mouth where they occur in large numbers even under 
normal conditions. 
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Species: Staphylococcus Aureus 
The individual cells of S.Aureus are 0.8 to 0.9 micro in diameter. They are 
ovoid or spherical, non motile, non capsulated, non sporing stain with ordinary aniline 
dyes and gram positive, typically arranged in groups of irregular clusters like 
branches of groups found in pus, singly or in pairs. The optimum temperature for the 
growth is 370 C, optimum pH is 7.4 to 7.6. They produce golden yellow pigment, 
which develops best at room temperature. They cause pyoregenic of pus forming 
[Suppurative] conditions, mastitis of women and cows, boils, carbuncles infantile 
impetigo, internal abscess and food poisoning. In recent years, there has been a 
dramatic increase in the incidence of hospital associated nosocomial infections caused 
by strains of Staphylococcus aureus that are resistant to multiple antibiotics. [2]  
 
ESCHERICHIA COLI : - 
 
Genus: Escherichia [Enterobacteriaceae] 
  This genus comprises escherichia and several variants and are of particular 
interest to the sanitarian since they occur commonly in the formal intestinal tract of 
man and animals. Their presence in foods or in drinking water may indicate faecal 
pollution. E.Coli is the most distinctively recognized feacal species. [3]  
 
Species: Escherichia coli 
E.Coli is the most important type in this species, which contains a number of 
other types. Escherichia in 1885 discovered in from the faces of the newborn and 
showed the organisms in the infesting within three days after birth. It is a commensals 
of the human intestine and found in the intestinal tract of men and animals and is also 
found in the sewage water, land, soil contaminated by feacal matters. The gram 
negative rods are 2 to 4 micro by 0.4 micro in size, commonly seen in coccobacillary 
form and rarely in filamentous form. They are facultative anaerobes and grow in all 
laboratory media. Colonies are circular, raised, and smooth and emit a faecal odour. 
E.Coli are generally non pathogenic and are incriminated as pathogens because in 
certain instances some strains have been found to produce septicemia, inflammations 
of liver and gall bladder, appendix, meningitis, pneumonia and other infections and 
this species is a recognized pathogen in the veterinary field. [4]  
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SALMONELLA TYPHI:- 
 
Salmonella  is a genus of rod-shaped, Gram-negative, non-spore-forming, 
predominantly motile enterobacteria with diameters around 0.7 to 1.5 µm, lengths 
from 2 to 5 µm, and flagella which grade in all directions (i.e. peritrichous). They 
are chemoorganotrophs, obtaining their energy from oxidation and reduction reactions 
using organic sources, and are facultative anaerobes. Salmonella are found worldwide 
in cold- and warm-blooded animals (including humans), and in the environment. They 
cause illnesses like typhoid fever, paratyphoid fever, and foodborne illness.  [5]  
Serovar Typhimurium has considerable diversity and may be very old. The majority 
of the isolates belong to a single clonal complex. Isolates are divided into phage types, 
but some phage types do not have a single origin as determined using mutational 
changes. Phage type DT104 is heterogeneous and represented in multiple sequence 
types, with its multidrug-resistant variant being the most successful and causing 
epidemics in many parts of the world. [6]  
 
BACILLUS CEREUS:- 
 
Bacillus cereus is an endemic, soil-dwelling, Gram-positive, rod-shaped, beta 
hemolyticbacterium. Some strains are harmful to humans and cause foodborne illness, 
while other strains can be beneficial as probiotics for animals. B. cereus bacteria 
are aerobes, and like other members of the genus Bacillus can produce 
protective endospores. Its virulence factors include cereolysin and phospholipase C. [7]  
 
B. cereus is responsible for a minority of foodborne illnesses (2–5%), causing 
severe nausea,vomiting and diarrhea. [8] Bacillus foodborne illnesses occur due to 
survival of the bacterial endospores when food is improperly cooked. [9]   B. cereus is 
also known to cause chronic skin infections that are difficult to eradicate though less 
aggressive than necrotizing fasciitis. B. cereus can also cause keratitis. [10]  
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8.2    METHODS USED FOR SCREENING: 
 
The antimicrobial activity was assayed by Cup plate agar diffusion method by 
measuring inhibition zones in mm. In vitro antimicrobial activity of all synthesized 
compounds and standard drug have been evaluated against four strains of bacteria 
which include two Gram +ve bacteria namely Staphylococcus aureus, Bacillus cereus 
and two Gram-ve bacteria such as Escherichia coli, S.typhi. These strains were 
selected for their known pathogenesis of Human diseases. 
 
The antibacterial activity was compared with standard drug Ampicillin. It is a beta-
lactam antibiotic that has been used extensively to treat bacterial infections since 
1961. Ampicillin is able to penetrate Gram-positive and some Gram-negative bacteria. 
Ampicillin acts as a competitive inhibitor of the enzyme transpeptidase, which is 
needed by bacteria to make their cell walls.[11] It inhibits the third and final stage of 
bacterial cell wall synthesis in binary fission, which ultimately leads to cell lysis. 
Ampicillin has received FDA approval for its mechanism of action. 
 
Antibacterial activity 
 
The purified products were screened for their antibacterial activity by using cup-plate 
agar diffusion method. The nutrient agar broth prepared by the usual method, was 
inoculated aseptically with 0.5 mL of 18 h old actively growing subculture of S. 
aureus, B. cereus, E. coli and S.typhi in separate conical flasks at 40-50° C and mixed 
well by gentle shaking. About 25 mL of the contents of the flask were poured and 
evenly spread in petridish (90 mm in diameter) and allowed to set for two h. The cups 
(6 mm in diameter) were formed by the help of sterile borer in agar medium and filled 
with 0.04 mL (400μg/mL) solution of sample in DMSO. The compounds were 
allowed to diffuse into the plate for 2 h at 2-8˚ C. 
 
The plates were then incubated at 37° C for 24 h.  The control was maintained with 
0.04 mL of DMSO and Standard drug 0.04 mL (400μg/mL) was prepared in similar 
manner.  The zone of inhibition of the bacterial growth were measured in millimeter 
and recorded in Table. 
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Table 8.2 
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8.3     RESULTS & DISCUSSION 
 
Clinical isolates of opportunist and pathogenic cultures of Gram Positive and 
Negative bacteria were obtained which were resistant to several antibiotics.  
 
The compounds VMMB 104 and VMMB 110 shown antibacterial activity against 
S.typhi.  Many compounds of the VMMB series have shown good antibacterial 
activity against B. cereus and S. aureus. None of the compounds from the VMMB 
Series have been active against E.coli.  
  
All the compounds of VMMB Series have shown good activity against S.aureus. 
Compounds have shown high activity equivalent to the standard drug. The 
compounds VMMB 501, VMMB 503 and VMMB 507 showed activity against 
S.typhi.  Many compounds of the VMMB series have shown good antibacterial 
activity against B. cereus as compared to Standard drug. None of the compounds from 
the VMMB Series have been active against E.coli.  
 
All microbial cultures showed characteristic pattern of their sensitivity for all 
synthetic compounds.  
 
The antimicrobial activities of Gram Negative, Gram Positive bacteria which can 
grow under normal laboratory conditions were analyzed. Still many other problematic 
resistant strains are to be screened for large number of synthetic compounds being 
synthesized every day. Among them, several synthetic series and biological extracts 
have attracted considerable attention during the last several years. Loss of sensitivity 
of microorganism against antimicrobials may be due to many factors including 
change in their genetic makeup. The antimicrobial activity of any antimicrobial 
depends on many external and internal influences. The major part of their capacity to 
inhibit Prokaryotes depends on the major ring structure skeleton of the synthetic 
compound and the external moieties – additional groups attached to main skeleton. 
The physical and chemical properties of synthetic compound are also detrimental 
factor in exhibiting their activity. 
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The results were recorded at the end of 24 hours to give complete growth cycle for a 
bacterium so that uniformity of growth could be maintained for all bacterial cultures. 
Upon further incubation of the Nutrient Agar  plates, not a single cell of the bacterial 
culture could grow if once proved to be sensitive. The possible reason for no growth 
might be the damages to vital cellular parts by the synthetic compounds. 
 
Detailed account of physic-chemical properties of the organic compounds could be 
correlated with high antimicrobial activities. Further studies on these aspects could 
focus on the DNA profiles of microorganisms. Understanding the genetic and 
biochemical basis of sensitivity and resistance of microbes would also be quite 
interesting to explore. 
 
Each of the organic compounds under study has generated a typical 
antimicrobiogram, reflecting a significant diversity amongst them. Majority of the 
synthetic organic compounds were dispersed into the medium when added into Petri 
dishes and killed the target organisms and shown no growth at the site of inoculation. 
Interestingly, in case of few organic compounds, they could not show inhibition of 
microbes and organisms could grow in the form of small colonies which could then be 
further investigated for the number of cells present.  
 
Further studies such as finding their physicochemical basis at macromolecular level of 
the detection of the cause of their success and failure as antimicrobials, would be 
quite interesting. 
  
From the table it can be inferred that most of the compounds from VMMB Series are 
active against Gram positive bacteria. The compounds can be studied further for their 
activity against other Gram positive organisms and for their mode of action. The 
compounds however are less effective against Gram negative bacteria. Coumarin 
bearing DHPs, Diazepines and Cyano pyridine are good scaffold for anti 
microbial activity. On the basis of the above interesting results, new synthetic 
programmes can be planned to develop more active compounds. 
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Summary 
 
SUMMARY 
 
 The work represented in the thesis entitled “Studies On Nitrogen And Oxygen 
Containing Heterocyclic Compounds” is divided into seven chapters which can be 
summarized as under. 
 
Chapter-1 deals with Microwave protocols for the synthesis of Benzofuran 
derivatives linked with 1,3,4 oxadiazoles. Ethyl benzofuran 2-carboxylate was 
synthesized via condensation of ethyl bromo acetate and salicaldehyde which was 
then reacted with hydrazine hydrate to yield benzofuran-2-carbohydrazide. 
Furthermore, reaction of benzofuran-2-carbohydrazide with substituted benzoic acids 
in presence of phosphorous oxychloride in microwave gave 2-(benzofuran-2-yl)-5-
substituted phenyl - 1,3,4-oxadiazoles in good to excellent yields. The compounds 
were well characterized by IR, 1H and 13C NMR and Mass spectrometry. 
 
Chapter-2 is related to preparation of various substituted 3-amino 4-hydroxy 
coumarins and their reaction with 1-adamantane carboxylic acid chloride in presence 
of triethyl amine to give 3-(1-amido adamantyl) 4-hydroxy coumarins. The 
synthesized compounds were well characterized by IR, 1H NMR and Mass 
spectrometry. 
 
Chapter-3 deals with grindstone technique used for the synthesis of titled 
compounds. This method is superior since it is eco-friendly, high yielding, requires no 
special apparatus, non-hazardous, simple and convenient. A series of some new Schiff 
bases have been prepared. The synthesized compounds were well characterized by IR, 
1H NMR and Mass spectrometry.   The major benefit of this approach is solvent free 
conditions, easy work up process and shorter reaction time. 
 
Summary 
 
Chapter-4 encompasses the cyclization reaction of 3-aminocrotononitrile with 
substituted benzaldehydes to give 4-substituted 2,6-dimethyl 3,5-dicarbonitrile 1,4-
dihydropyridines. Futhermore, their reaction with formaldehyde and various 
secondary amines yielded various mannich bases. The synthesized compounds were 
well characterized by IR, 1H and 13C NMR and Mass spectrometry. 
 
Chapter-5 covers the synthesis of some novel furocoumarin compounds. The main 
significance of the present work is that the said molecules are synthesized in a one pot 
synthetic process with reaction time ranging from 10 hr to 18 hr. Total 15 derivatives 
of 2-(substituted 2-hydroxy benzoyl) 2,3-dihydrofuro[3,2-c]chromen-4-one  and 2-(2-
hydroxy benzoyl) 3-(substituted phenyl) 2,3-dihydrofuro[3,2-c]chromen-4-one were 
synthesized. All the newly synthesized compounds were characterized by IR, 1H 
NMR, Mass spectral data and elemental analysis.  
 
Chapter-6 represents some novel pyrimidine-2-one derivatives synthesized by 
reaction of substituted urea with a diketone. The main significance of the present 
work is that the process for synthesis of pyrimidine-2-one derivatives is novel, with 
facile work up method, and high chemical purity for biological as well as 
pharmacological interest. A convenient method for preparation of 4-(4-
(trifluoromethyl)phenyl)-5,6,7,8-tetrahydro-6-(methylsulfonyl)-1-(substituted 
phenyl)pyrido[4,3-d]pyrimidin-2(1H)-one was developed. After three step reaction, 
the final product obtained was pure along with good yields. 
 
Chapter-7 is related to substitution of various functional groups i.e –Br, –CHO, -
NO2,    -NH2, -CN, -COOH at 3rd position of 4-hydroxy coumarin skeletal, thereby 
developing and optimizing the process, yield and purification techniques for the same. 
The synthesized compounds were well characterized by IR, 1H and 13C NMR and 
Mass spectrometry. 
 
Chapter-8 covers Biological Activity part, wherein the  antimicrobial activity of 
VMMB series was assayed by Cup plate agar diffusion method by measuring 
Summary 
 
inhibition zones in mm. In vitro antimicrobial activity of all synthesized compounds 
and standard drug have been evaluated against four strains of bacteria which include 
two Gram +ve bacteria namely Staphylococcus aureus, Bacillus cereus and two 
Gram-ve bacteria such as Escherichia coli, S.typhi. These strains were selected for 
their known pathogenesis of Human diseases. 
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Conference on Selected Topics in Spectroscopy and Stereochemistry” 
organized by the Department of Chemistry, Saurashtra University, Rajkot, 
dated March, 18-20, 2009.  
 “A National Workshop On Updates In Process and Medicinal Chemistry” 
jointly organized by National Facility for Drug Discovery through New 
Chemicals Entities Development & Instrumentation support to Small 
Manufacturing Pharma Enterprises and DST FIST, UGC-SAP & DST-DPRP 
Funded Department of Chemistry, Saurashtra University, Rajkot dated March, 
3-4, 2009. 
 
  DST-FIST, UGC (SAP) supported and GUJCOST Sponsored “National 
Workshop on Management and Use of Chemistry Database and Patent 
Literature” organized by GUJCOST & Dept. of Chemistry of Saurashtra 
University, Rajkot, (Gujarat), dated February, 27-29, 2008. 
 
 PAPER/POSTER PRESENTED AT THE INTERNATIONAL 
CONFERENCE: 
 
 “Synthesis and antimicrobial screening of some substituted (3E) – 3 –    
benzylidene – 2 H – chromene 2,4 (3H) – diones.” 
 
Vaibhav Ramani, Chetna Rajyaguru and Anamik Shah* 
 
Poster presented at 13th ISCB International Conference was organized on 
“Interplay of Chemical and Biological Sciences: Impact on Health and 
Environment” at Delhi University, Delhi on 26th February - 1st March 2009  
 “Synthesis and anti-bacterial activity of poly-substituted pyrrole derivatives” 
Vaibhav Ramani, Chintan Dholakiya and Anamik Shah* 
Poster presented at 14th ISCB International conference on chemical biology for 
discovery: perspectives and challenges, CDRI, Lucknow, 15-18 Jan., 2010. 
 
